cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
SKCM	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	12.5	2.59e-20	3.69e-14	0.95	0.82	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	12.24	7.61e-20	1e-13	1.06	0.81	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	12.2	9.32e-20	1.14e-13	0.88	0.81	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	12.2	9.32e-20	1.14e-13	0.88	0.81	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	12.1	1.43e-19	1.54e-13	0.88	0.81	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	12.07	1.56e-19	1.57e-13	0.88	0.81	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	12.07	1.56e-19	1.57e-13	0.88	0.81	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	11.96	2.51e-19	1.97e-13	0.88	0.8	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	11.96	2.51e-19	1.97e-13	0.88	0.8	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	11.93	2.93e-19	1.97e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-11.93	2.93e-19	1.97e-13	-0.87	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	11.93	2.93e-19	1.97e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	11.93	2.93e-19	1.97e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	11.84	4.17e-19	2.44e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	11.84	4.17e-19	2.44e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	11.84	4.17e-19	2.44e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	11.75	6.07e-19	3.09e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	11.75	6.07e-19	3.09e-13	0.87	0.8	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
SKCM	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	11.73	6.76e-19	3.35e-13	0.92	0.8	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	11.55	1.47e-18	5.44e-13	0.93	0.79	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	11.55	1.47e-18	5.44e-13	0.93	0.79	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	11.46	2.18e-18	7.74e-13	0.87	0.79	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	11.42	2.52e-18	8.87e-13	0.87	0.79	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	11.39	2.86e-18	9.15e-13	0.86	0.79	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
SKCM	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-11.38	3e-18	9.4e-13	-0.92	-0.79	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
SKCM	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-11.38	3e-18	9.4e-13	-0.92	-0.79	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	11.29	4.52e-18	1.35e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	11.29	4.52e-18	1.35e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-11.29	4.52e-18	1.35e-12	-1.02	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-11.28	4.76e-18	1.41e-12	-0.86	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	11.25	5.4e-18	1.56e-12	1.14	0.79	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	11.25	5.4e-18	1.56e-12	1.14	0.79	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	11.21	6.19e-18	1.63e-12	0.86	0.79	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	11.21	6.19e-18	1.63e-12	0.86	0.79	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	11.21	6.19e-18	1.63e-12	0.86	0.79	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	11.21	6.19e-18	1.63e-12	0.86	0.79	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	11.21	6.31e-18	1.63e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	11.21	6.31e-18	1.63e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	11.21	6.31e-18	1.63e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	11.21	6.31e-18	1.63e-12	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-11.21	6.31e-18	1.63e-12	-1.02	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-11.21	6.31e-18	1.63e-12	-1.02	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	11.12	9.32e-18	2.08e-12	0.86	0.78	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.512	rs55788996	ENSG00000230658.1	KLHL7-AS1	11.09	1.05e-17	2.33e-12	0.86	0.78	Cerebrospinal fluid biomarker levels;	chr7:23153230	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	11.07	1.15e-17	2.5e-12	0.86	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	11.07	1.16e-17	2.5e-12	1.13	0.78	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	11.07	1.16e-17	2.5e-12	1.13	0.78	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
SKCM	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-11.07	1.18e-17	2.5e-12	-0.9	-0.78	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
SKCM	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	11.03	1.38e-17	2.5e-12	1.13	0.78	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	11.03	1.38e-17	2.5e-12	1.13	0.78	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	11.03	1.38e-17	2.5e-12	1.13	0.78	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	10.99	1.64e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	10.99	1.65e-17	2.5e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
SKCM	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-10.98	1.7e-17	2.5e-12	-1.02	-0.78	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	10.95	1.96e-17	2.52e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	10.93	2.14e-17	2.73e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	10.91	2.36e-17	3e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	10.9	2.39e-17	3.03e-12	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
SKCM	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-10.9	2.42e-17	3.04e-12	-0.92	-0.78	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	10.88	2.66e-17	3.19e-12	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	10.84	3.19e-17	3.76e-12	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	10.81	3.57e-17	4e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	10.76	4.48e-17	4.86e-12	1.12	0.77	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	10.7	5.72e-17	6.18e-12	1.07	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	10.68	6.23e-17	6.69e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.793	rs6723185	ENSG00000217702.2	RP11-287D1.4	10.66	6.8e-17	7.03e-12	1.12	0.77	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	10.65	7.07e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
SKCM	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	10.65	7.08e-17	7.03e-12	0.84	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
SKCM	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-10.63	7.76e-17	7.68e-12	-1	-0.77	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	10.61	8.62e-17	8.51e-12	0.82	0.77	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	10.59	9.49e-17	9.3e-12	1.03	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
SKCM	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	10.58	9.72e-17	9.44e-12	1.11	0.77	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	10.58	9.72e-17	9.44e-12	1.11	0.77	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-10.5	1.38e-16	1.29e-11	-0.98	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-10.5	1.41e-16	1.3e-11	-0.84	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	10.49	1.43e-16	1.31e-11	1.11	0.77	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	10.49	1.43e-16	1.31e-11	1.11	0.77	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
SKCM	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	10.49	1.43e-16	1.32e-11	0.92	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-10.47	1.59e-16	1.45e-11	-0.97	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	10.44	1.83e-16	1.63e-11	0.84	0.76	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-10.44	1.85e-16	1.63e-11	-0.98	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-10.44	1.85e-16	1.63e-11	-0.98	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-10.44	1.85e-16	1.63e-11	-0.98	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-10.44	1.85e-16	1.63e-11	-0.98	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-10.44	1.85e-16	1.63e-11	-0.98	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	10.42	1.95e-16	1.72e-11	1.01	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	10.42	1.95e-16	1.72e-11	1.01	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-10.41	2.1e-16	1.84e-11	-0.97	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
SKCM	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	10.4	2.19e-16	1.91e-11	1.21	0.76	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-10.39	2.24e-16	1.95e-11	-0.83	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	10.37	2.48e-16	2.14e-11	1.22	0.76	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	10.36	2.57e-16	2.2e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	10.35	2.71e-16	2.3e-11	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	10.35	2.71e-16	2.3e-11	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
SKCM	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.82	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.82	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.82	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	10.3	3.34e-16	2.62e-11	0.82	0.76	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
SKCM	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-10.28	3.6e-16	2.8e-11	-0.99	-0.76	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	10.28	3.61e-16	2.8e-11	0.84	0.76	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	10.28	3.61e-16	2.8e-11	0.84	0.76	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	10.27	3.89e-16	3e-11	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	10.24	4.35e-16	3.32e-11	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
SKCM	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	10.19	5.54e-16	3.93e-11	1.09	0.76	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-10.15	6.42e-16	4.36e-11	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
SKCM	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-10.14	6.84e-16	4.63e-11	-0.89	-0.75	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
SKCM	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	10.1	7.94e-16	5.32e-11	0.9	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	10.1	7.94e-16	5.32e-11	0.9	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
SKCM	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-10.08	8.69e-16	5.79e-11	-0.99	-0.75	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-10.08	8.92e-16	5.93e-11	-0.96	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-10.04	1.04e-15	6.87e-11	-0.87	-0.75	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-10.04	1.08e-15	7.07e-11	-0.97	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-10.04	1.08e-15	7.07e-11	-0.97	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
SKCM	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	10.03	1.09e-15	7.09e-11	1.18	0.75	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	10.03	1.11e-15	7.15e-11	0.95	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	10.03	1.11e-15	7.17e-11	0.9	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
SKCM	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-10.02	1.17e-15	7.54e-11	-0.9	-0.75	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
SKCM	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	10.01	1.19e-15	7.59e-11	1.12	0.75	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-10.01	1.19e-15	7.59e-11	-1	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	10.01	1.21e-15	7.71e-11	0.82	0.75	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	10	1.26e-15	7.97e-11	1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	10	1.26e-15	7.97e-11	1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	10	1.26e-15	7.97e-11	1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	10	1.26e-15	7.97e-11	1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	10	1.29e-15	8.07e-11	1.01	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	10	1.29e-15	8.07e-11	1.01	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	9.99	1.31e-15	8.22e-11	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	9.98	1.35e-15	8.46e-11	0.83	0.75	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	9.98	1.35e-15	8.46e-11	0.83	0.75	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
SKCM	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	9.98	1.37e-15	8.54e-11	1.11	0.75	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	9.98	1.37e-15	8.54e-11	1.11	0.75	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	9.97	1.45e-15	8.93e-11	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	9.96	1.53e-15	9.31e-11	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	9.95	1.56e-15	9.4e-11	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	9.95	1.56e-15	9.4e-11	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	9.95	1.56e-15	9.4e-11	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	9.94	1.61e-15	9.7e-11	1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-9.92	1.77e-15	1.06e-10	-0.9	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
SKCM	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	9.91	1.92e-15	1.14e-10	0.82	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	9.91	1.92e-15	1.14e-10	0.82	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
SKCM	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-9.9	1.93e-15	1.14e-10	-0.89	-0.75	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
SKCM	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	9.9	2e-15	1.18e-10	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
SKCM	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	9.89	2.04e-15	1.2e-10	1.2	0.75	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	9.89	2.1e-15	1.23e-10	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-9.88	2.12e-15	1.24e-10	-0.97	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
SKCM	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	9.88	2.14e-15	1.25e-10	1.09	0.75	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
SKCM	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-9.83	2.66e-15	1.55e-10	-0.8	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
SKCM	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	9.82	2.83e-15	1.64e-10	0.94	0.74	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	9.82	2.84e-15	1.64e-10	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-9.81	2.86e-15	1.65e-10	-0.96	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-9.8	3.03e-15	1.74e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-9.8	3.03e-15	1.74e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-9.8	3.03e-15	1.74e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-9.8	3.03e-15	1.74e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	9.76	3.59e-15	2.05e-10	0.98	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	9.75	3.85e-15	2.17e-10	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	9.75	3.85e-15	2.17e-10	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	9.75	3.85e-15	2.17e-10	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	9.75	3.85e-15	2.17e-10	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-9.75	3.85e-15	2.17e-10	-0.96	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	9.74	4.08e-15	2.29e-10	1.04	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	9.72	4.35e-15	2.43e-10	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
SKCM	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	9.72	4.45e-15	2.48e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	9.7	4.84e-15	2.64e-10	1.13	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-9.68	5.16e-15	2.81e-10	-0.97	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-9.67	5.51e-15	2.99e-10	-0.89	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	9.66	5.74e-15	3.08e-10	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-9.65	5.88e-15	3.12e-10	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-9.65	5.88e-15	3.12e-10	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-9.65	5.88e-15	3.12e-10	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-9.65	5.88e-15	3.12e-10	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-9.65	5.88e-15	3.12e-10	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-9.64	6.24e-15	3.21e-10	-0.97	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	9.64	6.34e-15	3.22e-10	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	9.63	6.55e-15	3.28e-10	0.97	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	9.63	6.6e-15	3.28e-10	1.11	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-9.63	6.6e-15	3.28e-10	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
SKCM	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-9.62	6.93e-15	3.44e-10	-0.8	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-9.6	7.34e-15	3.54e-10	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	9.58	7.96e-15	3.83e-10	0.95	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	9.58	7.99e-15	3.83e-10	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
SKCM	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-9.58	8.06e-15	3.86e-10	-0.88	-0.74	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-9.58	8.29e-15	3.97e-10	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	9.57	8.51e-15	4.06e-10	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	9.57	8.51e-15	4.06e-10	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
SKCM	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	9.57	8.59e-15	4.09e-10	0.8	0.73	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	9.56	8.75e-15	4.16e-10	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-9.55	9.11e-15	4.32e-10	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
SKCM	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	9.55	9.34e-15	4.41e-10	1.22	0.73	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
SKCM	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	9.55	9.34e-15	4.41e-10	1.22	0.73	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-9.55	9.38e-15	4.42e-10	-1.01	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-9.53	1.03e-14	4.65e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	9.53	1.03e-14	4.67e-10	0.87	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-9.52	1.08e-14	4.85e-10	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-9.52	1.08e-14	4.85e-10	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-9.52	1.08e-14	4.85e-10	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-9.52	1.08e-14	4.85e-10	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-9.52	1.08e-14	4.85e-10	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-9.51	1.11e-14	4.95e-10	-1.01	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-9.51	1.11e-14	4.95e-10	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-9.51	1.12e-14	5.01e-10	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-9.48	1.28e-14	5.68e-10	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	9.4	1.8e-14	7.88e-10	0.99	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-9.39	1.9e-14	8.31e-10	-0.87	-0.73	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	9.37	2.03e-14	8.82e-10	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	9.37	2.03e-14	8.82e-10	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
SKCM	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-9.37	2.12e-14	9.17e-10	-0.84	-0.73	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	9.34	2.32e-14	1e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-9.34	2.41e-14	1.04e-09	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-9.34	2.41e-14	1.04e-09	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-9.33	2.44e-14	1.05e-09	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	9.33	2.47e-14	1.06e-09	0.99	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-9.33	2.5e-14	1.07e-09	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-9.33	2.5e-14	1.07e-09	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	9.33	2.53e-14	1.07e-09	0.96	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	9.32	2.6e-14	1.09e-09	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	9.32	2.6e-14	1.09e-09	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	9.32	2.6e-14	1.09e-09	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
SKCM	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-9.31	2.71e-14	1.14e-09	-1.02	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
SKCM	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Depression;	chr6:28301886	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Depression;	chr6:28303421	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Depression;	chr6:28317705	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Depression;	chr6:28323463	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.29	2.92e-14	1.21e-09	0.82	0.72	Depression;	chr6:28327262	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	9.28	3.05e-14	1.26e-09	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-9.28	3.05e-14	1.26e-09	-0.87	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
SKCM	cis	rs858239	0.601	rs7809661	ENSG00000230658.1	KLHL7-AS1	9.28	3.1e-14	1.28e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23142130	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	9.27	3.24e-14	1.33e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	9.27	3.24e-14	1.33e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	9.27	3.24e-14	1.33e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	9.23	3.82e-14	1.56e-09	1.3	0.72	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
SKCM	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	9.22	3.98e-14	1.61e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	9.22	3.98e-14	1.61e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	9.22	3.98e-14	1.61e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	9.22	3.98e-14	1.61e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-9.2	4.33e-14	1.75e-09	-0.98	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-9.2	4.33e-14	1.75e-09	-0.98	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	9.19	4.53e-14	1.81e-09	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	9.19	4.53e-14	1.81e-09	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	9.19	4.53e-14	1.81e-09	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	9.19	4.58e-14	1.83e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	9.19	4.58e-14	1.83e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	9.16	5.18e-14	2.03e-09	0.87	0.72	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	9.15	5.55e-14	2.18e-09	0.85	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-9.14	5.68e-14	2.22e-09	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-9.14	5.68e-14	2.22e-09	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	9.13	5.93e-14	2.25e-09	1.29	0.72	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
SKCM	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-9.11	6.65e-14	2.52e-09	-1.08	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	9.09	7.29e-14	2.75e-09	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-9.08	7.45e-14	2.81e-09	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	9.07	7.73e-14	2.91e-09	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
SKCM	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-9.06	8.15e-14	3.06e-09	-0.89	-0.72	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	9.05	8.52e-14	3.2e-09	1.18	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	9.03	9.24e-14	3.46e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	9.03	9.24e-14	3.46e-09	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-9.03	9.44e-14	3.53e-09	-0.97	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	9.01	1.04e-13	3.88e-09	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	9.01	1.04e-13	3.88e-09	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	8.98	1.17e-13	4.35e-09	0.9	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	8.97	1.22e-13	4.51e-09	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	8.97	1.23e-13	4.53e-09	0.98	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	8.97	1.23e-13	4.53e-09	0.98	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	8.97	1.23e-13	4.53e-09	0.98	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	8.92	1.51e-13	5.47e-09	1.2	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
SKCM	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	8.92	1.55e-13	5.57e-09	1.28	0.71	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	8.92	1.55e-13	5.57e-09	1.28	0.71	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	8.92	1.55e-13	5.57e-09	1.28	0.71	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
SKCM	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	8.91	1.61e-13	5.77e-09	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
SKCM	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	8.91	1.64e-13	5.88e-09	1.35	0.71	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-8.91	1.65e-13	5.9e-09	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	8.9	1.67e-13	5.98e-09	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	8.87	1.89e-13	6.68e-09	1.28	0.71	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
SKCM	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-8.87	1.96e-13	6.91e-09	-0.83	-0.71	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
SKCM	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	8.86	2.01e-13	7.04e-09	0.9	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
SKCM	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-8.85	2.15e-13	7.49e-09	-0.85	-0.71	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	8.84	2.23e-13	7.74e-09	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-8.83	2.3e-13	7.9e-09	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	8.79	2.77e-13	9.28e-09	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	8.76	3.19e-13	1.06e-08	1.21	0.7	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
SKCM	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-8.74	3.44e-13	1.14e-08	-0.87	-0.7	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	8.73	3.58e-13	1.19e-08	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	8.73	3.58e-13	1.19e-08	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	8.73	3.65e-13	1.21e-08	0.87	0.7	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	8.73	3.68e-13	1.22e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	8.72	3.74e-13	1.23e-08	0.96	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	8.72	3.77e-13	1.24e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	8.71	4.02e-13	1.3e-08	1.27	0.7	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-8.7	4.19e-13	1.34e-08	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	8.69	4.36e-13	1.39e-08	0.79	0.7	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	8.66	4.86e-13	1.53e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	8.66	4.86e-13	1.53e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	8.66	4.86e-13	1.53e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	8.66	4.86e-13	1.53e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	8.66	5e-13	1.54e-08	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
SKCM	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	8.65	5.13e-13	1.56e-08	0.82	0.7	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	8.65	5.2e-13	1.56e-08	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	8.65	5.25e-13	1.57e-08	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	8.64	5.39e-13	1.61e-08	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	8.61	6.14e-13	1.78e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	8.61	6.25e-13	1.78e-08	0.82	0.7	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	8.61	6.25e-13	1.78e-08	0.82	0.7	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	8.61	6.25e-13	1.78e-08	0.82	0.7	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	8.61	6.25e-13	1.78e-08	0.82	0.7	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	8.6	6.57e-13	1.85e-08	0.91	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	8.6	6.57e-13	1.85e-08	0.91	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	8.6	6.59e-13	1.85e-08	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	8.59	6.72e-13	1.89e-08	0.95	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-8.59	6.85e-13	1.92e-08	-0.9	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	8.57	7.25e-13	2.02e-08	0.81	0.7	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	8.57	7.26e-13	2.02e-08	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
SKCM	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	8.57	7.39e-13	2.05e-08	0.75	0.7	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	8.57	7.39e-13	2.05e-08	0.75	0.7	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	8.57	7.39e-13	2.05e-08	0.75	0.7	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
SKCM	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	8.57	7.39e-13	2.05e-08	0.75	0.7	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
SKCM	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-8.57	7.4e-13	2.05e-08	-1.13	-0.7	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
SKCM	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	8.57	7.52e-13	2.08e-08	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	8.56	7.83e-13	2.15e-08	0.82	0.7	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	8.56	7.83e-13	2.15e-08	0.82	0.7	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	8.55	8.1e-13	2.21e-08	0.97	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	8.55	8.1e-13	2.21e-08	0.97	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	8.55	8.1e-13	2.21e-08	0.97	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	8.53	8.79e-13	2.36e-08	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	8.53	8.79e-13	2.36e-08	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-8.51	9.71e-13	2.58e-08	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	8.49	1.07e-12	2.8e-08	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	8.48	1.1e-12	2.81e-08	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
SKCM	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	8.48	1.12e-12	2.83e-08	1.26	0.69	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-8.45	1.27e-12	3.17e-08	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-8.45	1.28e-12	3.21e-08	-0.86	-0.69	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
SKCM	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-8.44	1.31e-12	3.28e-08	-0.77	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-8.44	1.32e-12	3.29e-08	-0.88	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-8.43	1.36e-12	3.4e-08	-0.96	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
SKCM	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	8.43	1.41e-12	3.5e-08	0.76	0.69	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	8.43	1.41e-12	3.5e-08	0.76	0.69	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	8.43	1.41e-12	3.5e-08	0.76	0.69	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	8.43	1.41e-12	3.5e-08	0.76	0.69	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
SKCM	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	8.42	1.46e-12	3.61e-08	0.86	0.69	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
SKCM	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	8.41	1.48e-12	3.61e-08	0.87	0.69	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	8.4	1.6e-12	3.87e-08	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	8.38	1.69e-12	4.1e-08	0.95	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	8.37	1.78e-12	4.29e-08	1.15	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	8.37	1.82e-12	4.36e-08	1.17	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	8.36	1.86e-12	4.45e-08	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	8.36	1.89e-12	4.53e-08	0.82	0.69	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	8.35	1.93e-12	4.63e-08	0.81	0.69	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	8.35	1.93e-12	4.63e-08	0.81	0.69	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	8.35	1.94e-12	4.64e-08	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
SKCM	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	8.34	2.03e-12	4.81e-08	1.22	0.69	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
SKCM	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	8.34	2.09e-12	4.9e-08	0.86	0.69	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	8.34	2.09e-12	4.9e-08	0.86	0.69	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	8.34	2.09e-12	4.9e-08	0.86	0.69	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	8.34	2.09e-12	4.9e-08	0.86	0.69	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
SKCM	cis	rs16828019	0.777	rs35080169	ENSG00000235358.1	RP11-399E6.1	8.34	2.1e-12	4.91e-08	1.25	0.69	Intelligence (multi-trait analysis);	chr1:40989287	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-8.34	2.1e-12	4.91e-08	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-8.34	2.1e-12	4.91e-08	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-8.34	2.1e-12	4.91e-08	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	8.33	2.11e-12	4.91e-08	0.84	0.69	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	8.33	2.15e-12	4.98e-08	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-8.32	2.22e-12	5.14e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-8.31	2.34e-12	5.34e-08	-1.15	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-8.31	2.34e-12	5.34e-08	-1.15	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
SKCM	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
SKCM	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	8.31	2.34e-12	5.34e-08	0.77	0.69	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	8.31	2.39e-12	5.4e-08	1.1	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	8.31	2.39e-12	5.4e-08	1.1	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	8.31	2.4e-12	5.4e-08	1.13	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-8.31	2.4e-12	5.4e-08	-1.13	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
SKCM	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	8.3	2.41e-12	5.4e-08	0.81	0.69	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	8.3	2.41e-12	5.4e-08	0.81	0.69	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	8.3	2.41e-12	5.4e-08	0.81	0.69	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	8.3	2.41e-12	5.4e-08	0.81	0.69	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	8.3	2.41e-12	5.4e-08	0.81	0.69	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-8.3	2.46e-12	5.46e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	8.3	2.52e-12	5.53e-08	0.77	0.68	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
SKCM	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	8.29	2.54e-12	5.53e-08	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
SKCM	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	8.29	2.6e-12	5.65e-08	0.8	0.68	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	8.29	2.63e-12	5.71e-08	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
SKCM	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-8.27	2.78e-12	6e-08	-0.72	-0.68	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	8.27	2.85e-12	6.05e-08	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-8.27	2.86e-12	6.05e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	8.26	2.92e-12	6.18e-08	1.17	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
SKCM	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	8.25	3.05e-12	6.4e-08	0.85	0.68	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	8.24	3.18e-12	6.57e-08	0.81	0.68	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
SKCM	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	8.22	3.49e-12	7.05e-08	1.22	0.68	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-8.22	3.6e-12	7.19e-08	-0.92	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
SKCM	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	8.21	3.67e-12	7.19e-08	0.77	0.68	Depression;	chr6:28240757	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	8.21	3.68e-12	7.19e-08	0.86	0.68	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
SKCM	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	8.21	3.74e-12	7.3e-08	0.84	0.68	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
SKCM	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	8.2	3.78e-12	7.34e-08	1.23	0.68	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	8.2	3.78e-12	7.34e-08	1.23	0.68	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	8.2	3.78e-12	7.34e-08	1.23	0.68	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	8.2	3.78e-12	7.34e-08	1.23	0.68	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	8.2	3.78e-12	7.34e-08	1.23	0.68	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	8.2	3.87e-12	7.53e-08	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	8.2	3.89e-12	7.55e-08	0.81	0.68	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
SKCM	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	8.2	3.94e-12	7.61e-08	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-8.19	4.07e-12	7.86e-08	-0.83	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
SKCM	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	8.19	4.1e-12	7.91e-08	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
SKCM	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-8.18	4.24e-12	8.12e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-8.18	4.24e-12	8.12e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-8.18	4.24e-12	8.12e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-8.18	4.24e-12	8.12e-08	-0.8	-0.68	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	8.18	4.31e-12	8.24e-08	0.73	0.68	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	8.18	4.31e-12	8.24e-08	0.73	0.68	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
SKCM	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	8.17	4.33e-12	8.28e-08	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	8.17	4.38e-12	8.36e-08	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	8.17	4.38e-12	8.36e-08	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
SKCM	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.17	4.4e-12	8.39e-08	0.83	0.68	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	8.17	4.46e-12	8.46e-08	0.86	0.68	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	8.17	4.46e-12	8.46e-08	0.86	0.68	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	8.17	4.46e-12	8.46e-08	0.86	0.68	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	8.17	4.46e-12	8.46e-08	0.86	0.68	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	8.17	4.46e-12	8.46e-08	0.86	0.68	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
SKCM	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	8.16	4.53e-12	8.6e-08	1.21	0.68	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	8.16	4.53e-12	8.6e-08	1.21	0.68	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
SKCM	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	8.16	4.68e-12	8.86e-08	0.85	0.68	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-8.14	5.05e-12	9.42e-08	-0.91	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	8.13	5.21e-12	9.71e-08	0.8	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	8.12	5.4e-12	1e-07	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	8.12	5.4e-12	1e-07	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	8.12	5.58e-12	1.02e-07	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	8.12	5.62e-12	1.02e-07	0.81	0.68	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
SKCM	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	8.12	5.63e-12	1.03e-07	0.85	0.68	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
SKCM	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	8.1	5.9e-12	1.07e-07	1.21	0.68	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	8.1	5.9e-12	1.07e-07	1.21	0.68	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	8.1	5.9e-12	1.07e-07	1.21	0.68	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
SKCM	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	8.1	5.98e-12	1.08e-07	0.84	0.68	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-8.09	6.19e-12	1.12e-07	-0.85	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
SKCM	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	8.09	6.29e-12	1.13e-07	0.81	0.68	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	8.09	6.29e-12	1.13e-07	0.81	0.68	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	8.09	6.29e-12	1.13e-07	0.81	0.68	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	8.09	6.29e-12	1.13e-07	0.81	0.68	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
SKCM	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-8.09	6.35e-12	1.14e-07	-0.74	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
SKCM	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
SKCM	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
SKCM	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	8.08	6.57e-12	1.17e-07	0.84	0.68	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	8.08	6.72e-12	1.19e-07	1.17	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	8.08	6.72e-12	1.19e-07	1.17	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
SKCM	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	8.07	6.82e-12	1.21e-07	0.76	0.67	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
SKCM	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	8.07	6.84e-12	1.21e-07	0.74	0.67	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	8.05	7.39e-12	1.3e-07	0.84	0.67	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	8.05	7.39e-12	1.3e-07	0.84	0.67	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	8.05	7.39e-12	1.3e-07	0.84	0.67	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	8.05	7.39e-12	1.3e-07	0.84	0.67	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	8.05	7.39e-12	1.3e-07	0.84	0.67	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
SKCM	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.05	7.4e-12	1.31e-07	-0.81	-0.67	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
SKCM	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-8.04	7.76e-12	1.31e-07	-0.76	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
SKCM	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	8.04	7.78e-12	1.32e-07	1.22	0.67	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
SKCM	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	8.04	7.79e-12	1.32e-07	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
SKCM	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	8.03	8.26e-12	1.39e-07	0.79	0.67	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
SKCM	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	8.02	8.7e-12	1.46e-07	0.86	0.67	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	8.02	8.76e-12	1.47e-07	0.83	0.67	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	8.02	8.78e-12	1.48e-07	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	8.02	8.78e-12	1.48e-07	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
SKCM	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	8.01	8.88e-12	1.49e-07	0.73	0.67	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	8.01	8.95e-12	1.5e-07	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
SKCM	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	8	9.21e-12	1.54e-07	0.74	0.67	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	8	9.21e-12	1.54e-07	0.74	0.67	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	8	9.21e-12	1.54e-07	0.74	0.67	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	8	9.21e-12	1.54e-07	0.74	0.67	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
SKCM	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	8	9.47e-12	1.57e-07	0.81	0.67	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
SKCM	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	7.99	9.78e-12	1.62e-07	0.82	0.67	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
SKCM	cis	rs916888	0.647	rs199520	ENSG00000262539.1	RP11-259G18.3	-7.99	9.89e-12	1.63e-07	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.647	rs199519	ENSG00000262539.1	RP11-259G18.3	-7.99	9.89e-12	1.63e-07	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:46259551~46260606:-
SKCM	cis	rs7224296	0.709	rs199518	ENSG00000262539.1	RP11-259G18.3	-7.99	9.89e-12	1.63e-07	-0.84	-0.67	Intelligence (multi-trait analysis);	chr17:46777214	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.647	rs199517	ENSG00000262539.1	RP11-259G18.3	-7.99	9.89e-12	1.63e-07	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	7.99	9.95e-12	1.64e-07	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	7.98	1.04e-11	1.71e-07	0.76	0.67	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
SKCM	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	7.98	1.05e-11	1.72e-07	0.83	0.67	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	7.98	1.05e-11	1.72e-07	0.83	0.67	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	7.98	1.05e-11	1.72e-07	0.83	0.67	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	7.98	1.05e-11	1.72e-07	0.83	0.67	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
SKCM	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	7.97	1.05e-11	1.72e-07	0.84	0.67	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	7.97	1.05e-11	1.72e-07	0.84	0.67	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	7.97	1.05e-11	1.72e-07	0.84	0.67	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	7.97	1.05e-11	1.72e-07	0.84	0.67	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
SKCM	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	7.97	1.09e-11	1.79e-07	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	7.96	1.13e-11	1.84e-07	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
SKCM	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	7.95	1.15e-11	1.88e-07	1.18	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	7.95	1.15e-11	1.88e-07	1.18	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
SKCM	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-7.95	1.17e-11	1.9e-07	-0.79	-0.67	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.686	rs199501	ENSG00000262539.1	RP11-259G18.3	-7.95	1.18e-11	1.92e-07	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46785247	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-7.95	1.19e-11	1.92e-07	-0.92	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-7.95	1.19e-11	1.92e-07	-0.82	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
SKCM	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	7.94	1.23e-11	1.98e-07	0.79	0.67	Depression;	chr6:28363475	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.821	rs199499	ENSG00000262539.1	RP11-259G18.3	7.93	1.28e-11	2.07e-07	1.04	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46259551~46260606:-
SKCM	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-7.91	1.41e-11	2.26e-07	-0.72	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-7.91	1.41e-11	2.26e-07	-0.72	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
SKCM	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	7.91	1.42e-11	2.27e-07	0.84	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	7.91	1.42e-11	2.27e-07	0.84	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
SKCM	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	7.9	1.5e-11	2.37e-07	0.97	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
SKCM	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	7.89	1.51e-11	2.38e-07	0.84	0.67	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
SKCM	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	7.89	1.51e-11	2.38e-07	0.84	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
SKCM	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	7.89	1.51e-11	2.39e-07	0.82	0.67	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	7.89	1.53e-11	2.41e-07	0.81	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
SKCM	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-7.89	1.56e-11	2.46e-07	-0.92	-0.67	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-7.88	1.6e-11	2.51e-07	-0.9	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	7.87	1.69e-11	2.64e-07	0.8	0.67	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	7.87	1.69e-11	2.64e-07	0.8	0.67	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	7.87	1.69e-11	2.64e-07	0.8	0.67	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	7.87	1.69e-11	2.64e-07	0.8	0.67	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	7.87	1.69e-11	2.64e-07	0.8	0.67	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
SKCM	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	7.87	1.7e-11	2.65e-07	0.83	0.67	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
SKCM	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	7.86	1.78e-11	2.78e-07	0.83	0.66	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
SKCM	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	7.86	1.78e-11	2.78e-07	0.83	0.66	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
SKCM	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-7.84	1.89e-11	2.94e-07	-0.92	-0.66	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
SKCM	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	7.84	1.93e-11	2.99e-07	0.77	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	7.84	1.93e-11	2.99e-07	0.77	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
SKCM	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	7.83	1.98e-11	3.06e-07	0.72	0.66	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
SKCM	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	7.83	2.02e-11	3.12e-07	0.76	0.66	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
SKCM	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	7.83	2.05e-11	3.15e-07	0.77	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
SKCM	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	7.82	2.08e-11	3.2e-07	0.83	0.66	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
SKCM	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-7.82	2.11e-11	3.23e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
SKCM	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.81	0.66	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	7.81	2.2e-11	3.33e-07	0.83	0.66	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	7.81	2.21e-11	3.34e-07	0.83	0.66	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	7.8	2.26e-11	3.42e-07	0.82	0.66	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	7.8	2.26e-11	3.42e-07	0.82	0.66	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-7.8	2.33e-11	3.51e-07	-0.81	-0.66	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
SKCM	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-7.79	2.35e-11	3.54e-07	-0.75	-0.66	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
SKCM	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	7.79	2.37e-11	3.56e-07	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	7.79	2.37e-11	3.56e-07	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
SKCM	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	7.79	2.4e-11	3.59e-07	0.82	0.66	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
SKCM	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-7.78	2.51e-11	3.73e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
SKCM	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	7.77	2.6e-11	3.84e-07	0.8	0.66	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	7.76	2.74e-11	4.03e-07	0.83	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
SKCM	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	7.76	2.76e-11	4.05e-07	0.8	0.66	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-7.76	2.77e-11	4.05e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	7.75	2.81e-11	4.1e-07	1.1	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
SKCM	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-7.74	2.97e-11	4.31e-07	-0.82	-0.66	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	7.74	3.02e-11	4.38e-07	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
SKCM	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	7.74	3.03e-11	4.4e-07	0.82	0.66	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	7.74	3.03e-11	4.4e-07	0.82	0.66	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	7.74	3.03e-11	4.4e-07	0.82	0.66	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
SKCM	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-7.74	3.04e-11	4.4e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	7.73	3.11e-11	4.49e-07	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	7.73	3.11e-11	4.49e-07	0.8	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
SKCM	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	7.73	3.11e-11	4.5e-07	0.83	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-7.72	3.3e-11	4.76e-07	-0.8	-0.66	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-7.7	3.53e-11	5.08e-07	-0.79	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
SKCM	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	7.7	3.66e-11	5.25e-07	0.82	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	7.69	3.78e-11	5.42e-07	1.17	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	7.69	3.8e-11	5.44e-07	1.22	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
SKCM	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	7.69	3.81e-11	5.45e-07	0.71	0.66	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	7.69	3.81e-11	5.45e-07	0.71	0.66	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	7.69	3.81e-11	5.45e-07	0.71	0.66	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-7.69	3.81e-11	5.45e-07	-0.71	-0.66	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	7.68	3.85e-11	5.51e-07	0.81	0.66	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-7.68	3.88e-11	5.53e-07	-0.8	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
SKCM	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	7.68	3.89e-11	5.53e-07	0.81	0.66	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	7.68	3.89e-11	5.53e-07	0.81	0.66	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-7.68	3.9e-11	5.53e-07	-0.91	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-7.68	3.92e-11	5.53e-07	-0.77	-0.66	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
SKCM	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	7.68	3.99e-11	5.63e-07	1.21	0.66	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
SKCM	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	7.67	4.11e-11	5.77e-07	0.79	0.66	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
SKCM	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-7.66	4.2e-11	5.85e-07	-0.78	-0.66	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	7.66	4.22e-11	5.88e-07	0.79	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
SKCM	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	7.66	4.23e-11	5.89e-07	0.87	0.66	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	7.66	4.26e-11	5.93e-07	0.77	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
SKCM	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	7.66	4.32e-11	6e-07	0.74	0.66	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
SKCM	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	7.66	4.32e-11	6e-07	0.72	0.66	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	7.66	4.32e-11	6e-07	0.72	0.66	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-7.65	4.49e-11	6.21e-07	-0.84	-0.65	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	7.64	4.64e-11	6.4e-07	0.79	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
SKCM	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-7.64	4.68e-11	6.45e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-7.64	4.68e-11	6.45e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-7.64	4.71e-11	6.49e-07	-1	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
SKCM	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-7.64	4.77e-11	6.57e-07	-0.8	-0.65	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-7.64	4.78e-11	6.57e-07	-0.82	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-7.64	4.78e-11	6.57e-07	-0.82	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
SKCM	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-7.63	4.85e-11	6.65e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-7.62	5e-11	6.73e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
SKCM	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	7.62	5e-11	6.73e-07	0.7	0.65	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	7.62	5.08e-11	6.83e-07	0.79	0.65	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
SKCM	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	7.61	5.23e-11	7.02e-07	0.76	0.65	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	7.61	5.23e-11	7.02e-07	0.76	0.65	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	7.61	5.23e-11	7.02e-07	0.76	0.65	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
SKCM	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	7.61	5.27e-11	7.08e-07	0.74	0.65	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	7.6	5.48e-11	7.34e-07	0.7	0.65	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	7.6	5.52e-11	7.39e-07	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	7.6	5.52e-11	7.39e-07	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
SKCM	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-7.6	5.53e-11	7.4e-07	-0.9	-0.65	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
SKCM	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	7.6	5.54e-11	7.4e-07	0.84	0.65	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
SKCM	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	7.6	5.54e-11	7.4e-07	0.84	0.65	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
SKCM	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	7.6	5.54e-11	7.4e-07	0.84	0.65	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
SKCM	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	7.6	5.6e-11	7.45e-07	0.9	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	7.6	5.62e-11	7.45e-07	0.75	0.65	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	7.59	5.71e-11	7.57e-07	0.75	0.65	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
SKCM	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	7.59	5.74e-11	7.61e-07	0.81	0.65	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	7.59	5.89e-11	7.79e-07	0.78	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	7.59	5.91e-11	7.82e-07	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
SKCM	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	7.58	6.05e-11	7.99e-07	0.79	0.65	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	7.58	6.05e-11	7.99e-07	0.79	0.65	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	7.58	6.05e-11	7.99e-07	0.79	0.65	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	7.58	6.17e-11	8.13e-07	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
SKCM	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	7.57	6.35e-11	8.36e-07	0.76	0.65	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
SKCM	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	7.56	6.65e-11	8.75e-07	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	7.56	6.65e-11	8.75e-07	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
SKCM	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	7.56	6.74e-11	8.87e-07	0.71	0.65	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
SKCM	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	7.56	6.76e-11	8.89e-07	0.71	0.65	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	7.56	6.76e-11	8.89e-07	0.71	0.65	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
SKCM	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	7.55	6.87e-11	9.01e-07	0.79	0.65	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-7.55	7.02e-11	9.21e-07	-0.83	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	7.54	7.13e-11	9.35e-07	0.82	0.65	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
SKCM	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	7.54	7.15e-11	9.37e-07	0.7	0.65	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-7.54	7.43e-11	9.71e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-7.54	7.43e-11	9.71e-07	-0.77	-0.65	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
SKCM	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	7.54	7.44e-11	9.72e-07	0.75	0.65	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	7.54	7.44e-11	9.72e-07	0.75	0.65	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
SKCM	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	7.53	7.51e-11	9.79e-07	1.18	0.65	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	7.53	7.51e-11	9.79e-07	1.18	0.65	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	7.53	7.51e-11	9.79e-07	1.18	0.65	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
SKCM	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	7.53	7.65e-11	9.97e-07	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	7.53	7.76e-11	1.01e-06	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	7.53	7.76e-11	1.01e-06	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	7.53	7.78e-11	1.01e-06	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
SKCM	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	7.52	7.98e-11	1.03e-06	0.8	0.65	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	7.52	7.98e-11	1.03e-06	0.8	0.65	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	7.52	7.98e-11	1.03e-06	0.8	0.65	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	7.52	7.98e-11	1.03e-06	0.8	0.65	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	7.52	8.06e-11	1.04e-06	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	7.52	8.06e-11	1.04e-06	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
SKCM	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	7.52	8.07e-11	1.04e-06	0.79	0.65	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
SKCM	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Depression;	chr6:28399886	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	7.51	8.15e-11	1.04e-06	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
SKCM	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-7.51	8.25e-11	1.05e-06	-0.9	-0.65	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
SKCM	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-7.51	8.25e-11	1.05e-06	-0.9	-0.65	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
SKCM	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	7.51	8.32e-11	1.06e-06	0.77	0.65	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	7.51	8.32e-11	1.06e-06	0.77	0.65	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
SKCM	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-7.51	8.32e-11	1.06e-06	-0.89	-0.65	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
SKCM	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	7.5	8.64e-11	1.1e-06	0.8	0.65	Myopia;	chr6:28302807	chr6:28176188~28176674:+
SKCM	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	7.5	8.69e-11	1.1e-06	0.75	0.65	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
SKCM	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	7.49	9.05e-11	1.15e-06	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	7.49	9.06e-11	1.15e-06	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
SKCM	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	7.48	9.67e-11	1.22e-06	0.84	0.65	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
SKCM	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-7.47	9.93e-11	1.26e-06	-0.82	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
SKCM	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	7.47	1.01e-10	1.28e-06	0.79	0.65	Depression;	chr6:28314871	chr6:28176188~28176674:+
SKCM	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	7.46	1.03e-10	1.3e-06	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
SKCM	cis	rs1431005	0.893	rs68010462	ENSG00000250620.1	RP11-91J3.3	7.46	1.04e-10	1.32e-06	0.86	0.65	Response to statin therapy;	chr4:187418181	chr4:187413564~187415697:+
SKCM	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-7.46	1.05e-10	1.32e-06	-0.75	-0.65	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
SKCM	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	7.46	1.05e-10	1.32e-06	0.83	0.65	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
SKCM	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	7.46	1.06e-10	1.33e-06	0.76	0.65	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	7.45	1.1e-10	1.38e-06	1.17	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
SKCM	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	7.43	1.2e-10	1.51e-06	0.75	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	7.42	1.21e-10	1.53e-06	0.75	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
SKCM	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-7.42	1.25e-10	1.57e-06	-0.82	-0.64	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	7.42	1.26e-10	1.58e-06	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	7.42	1.26e-10	1.58e-06	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	7.4	1.33e-10	1.67e-06	0.82	0.64	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	7.4	1.33e-10	1.67e-06	0.82	0.64	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-7.4	1.35e-10	1.69e-06	-0.78	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
SKCM	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
SKCM	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	7.4	1.36e-10	1.7e-06	1.18	0.64	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
SKCM	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	7.39	1.4e-10	1.73e-06	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
SKCM	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	7.39	1.43e-10	1.76e-06	0.82	0.64	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
SKCM	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	7.39	1.45e-10	1.79e-06	0.84	0.64	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
SKCM	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	7.38	1.48e-10	1.82e-06	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	7.38	1.48e-10	1.82e-06	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	7.38	1.48e-10	1.82e-06	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-7.38	1.5e-10	1.85e-06	-0.76	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-7.37	1.55e-10	1.91e-06	-0.74	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
SKCM	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	7.37	1.57e-10	1.94e-06	0.72	0.64	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
SKCM	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-7.36	1.61e-10	1.98e-06	-0.81	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
SKCM	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-7.35	1.66e-10	2.04e-06	-0.77	-0.64	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-7.35	1.67e-10	2.04e-06	-0.75	-0.64	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-7.35	1.7e-10	2.07e-06	-0.74	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
SKCM	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	7.35	1.71e-10	2.08e-06	1.2	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
SKCM	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	7.35	1.71e-10	2.08e-06	0.71	0.64	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	7.35	1.71e-10	2.09e-06	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	7.35	1.71e-10	2.09e-06	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	7.35	1.71e-10	2.09e-06	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
SKCM	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-7.32	1.9e-10	2.3e-06	-0.66	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	7.32	1.93e-10	2.34e-06	0.76	0.64	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
SKCM	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-7.32	1.95e-10	2.36e-06	-0.84	-0.64	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
SKCM	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-7.31	2e-10	2.42e-06	-0.81	-0.64	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-7.31	2e-10	2.42e-06	-0.81	-0.64	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
SKCM	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	7.31	2.02e-10	2.44e-06	1.17	0.64	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
SKCM	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-7.3	2.07e-10	2.5e-06	-0.83	-0.64	Depression;	chr6:28422360	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	7.3	2.07e-10	2.5e-06	0.74	0.64	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
SKCM	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	7.3	2.09e-10	2.52e-06	0.85	0.64	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
SKCM	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	7.3	2.09e-10	2.52e-06	0.85	0.64	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
SKCM	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.29	2.16e-10	2.61e-06	0.74	0.64	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
SKCM	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	7.29	2.2e-10	2.66e-06	0.87	0.64	Shingles;	chr7:38346957	chr7:38343894~38350022:-
SKCM	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-7.29	2.21e-10	2.66e-06	-0.78	-0.64	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
SKCM	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.29	2.25e-10	2.7e-06	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.29	2.25e-10	2.7e-06	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-7.28	2.26e-10	2.71e-06	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-7.28	2.26e-10	2.71e-06	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
SKCM	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	7.28	2.28e-10	2.75e-06	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	7.28	2.32e-10	2.79e-06	0.74	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	7.26	2.49e-10	2.98e-06	0.76	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	7.26	2.52e-10	3.01e-06	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-7.25	2.66e-10	3.17e-06	-0.74	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
SKCM	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	7.24	2.74e-10	3.26e-06	0.77	0.63	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
SKCM	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-7.23	2.9e-10	3.43e-06	-0.69	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	7.22	2.95e-10	3.49e-06	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	7.22	2.95e-10	3.49e-06	0.77	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
SKCM	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-7.22	3.02e-10	3.57e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-7.22	3.02e-10	3.57e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-7.22	3.02e-10	3.57e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.21	3.07e-10	3.62e-06	0.73	0.63	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-7.21	3.15e-10	3.71e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-7.21	3.15e-10	3.71e-06	-0.76	-0.63	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
SKCM	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-7.21	3.16e-10	3.72e-06	-0.82	-0.63	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-7.21	3.16e-10	3.72e-06	-0.82	-0.63	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
SKCM	cis	rs916888	0.558	rs199521	ENSG00000262539.1	RP11-259G18.3	-7.2	3.26e-10	3.82e-06	-0.82	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:46259551~46260606:-
SKCM	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	7.2	3.29e-10	3.86e-06	0.74	0.63	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
SKCM	cis	rs1431005	0.963	rs6553064	ENSG00000250620.1	RP11-91J3.3	7.2	3.31e-10	3.88e-06	0.83	0.63	Response to statin therapy;	chr4:187423507	chr4:187413564~187415697:+
SKCM	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	7.2	3.32e-10	3.89e-06	0.74	0.63	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	7.2	3.32e-10	3.89e-06	0.74	0.63	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	7.19	3.38e-10	3.96e-06	1.18	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
SKCM	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	7.19	3.41e-10	3.99e-06	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	7.19	3.41e-10	3.99e-06	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	7.19	3.41e-10	3.99e-06	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	7.19	3.48e-10	4.05e-06	0.71	0.63	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	7.18	3.57e-10	4.15e-06	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
SKCM	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-7.14	4.34e-10	5e-06	-0.73	-0.63	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-7.13	4.37e-10	5.03e-06	-0.75	-0.63	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-7.13	4.37e-10	5.03e-06	-0.75	-0.63	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	7.13	4.45e-10	5.13e-06	0.69	0.63	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	7.13	4.51e-10	5.19e-06	0.78	0.63	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	7.12	4.59e-10	5.29e-06	0.76	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-7.12	4.63e-10	5.33e-06	-0.72	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
SKCM	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	7.12	4.65e-10	5.34e-06	0.71	0.63	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	7.12	4.73e-10	5.43e-06	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
SKCM	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	7.11	4.8e-10	5.5e-06	0.8	0.63	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
SKCM	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	7.11	4.91e-10	5.63e-06	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	7.1	5.04e-10	5.77e-06	0.79	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	7.1	5.04e-10	5.77e-06	0.79	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
SKCM	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	7.1	5.06e-10	5.78e-06	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
SKCM	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-7.1	5.12e-10	5.86e-06	-0.75	-0.63	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
SKCM	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	7.1	5.14e-10	5.87e-06	0.8	0.63	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
SKCM	cis	rs2882667	0.83	rs28401588	ENSG00000253404.1	AC034243.1	7.09	5.21e-10	5.94e-06	0.77	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138960926	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-7.09	5.26e-10	5.99e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-7.09	5.26e-10	5.99e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-7.09	5.26e-10	5.99e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-7.09	5.26e-10	5.99e-06	-0.74	-0.63	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	7.09	5.31e-10	6.05e-06	0.81	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
SKCM	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	7.09	5.31e-10	6.05e-06	0.81	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
SKCM	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	7.08	5.54e-10	6.3e-06	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
SKCM	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	7.08	5.55e-10	6.31e-06	0.68	0.63	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	7.08	5.55e-10	6.31e-06	0.75	0.63	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
SKCM	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	7.08	5.62e-10	6.39e-06	1.17	0.63	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
SKCM	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	7.08	5.64e-10	6.41e-06	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	7.06	6e-10	6.81e-06	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
SKCM	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	7.06	6.17e-10	6.99e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
SKCM	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	7.06	6.17e-10	6.99e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
SKCM	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	7.06	6.17e-10	6.99e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
SKCM	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-7.06	6.17e-10	6.99e-06	-0.81	-0.62	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
SKCM	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	7.05	6.24e-10	7.07e-06	0.67	0.62	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	7.05	6.25e-10	7.07e-06	0.78	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	7.05	6.25e-10	7.07e-06	0.78	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	7.05	6.25e-10	7.07e-06	0.78	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-7.05	6.31e-10	7.14e-06	-0.76	-0.62	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
SKCM	cis	rs858239	0.676	rs199359	ENSG00000230658.1	KLHL7-AS1	-7.05	6.38e-10	7.21e-06	-0.66	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23298895	chr7:23101228~23105703:-
SKCM	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.04	6.59e-10	7.44e-06	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
SKCM	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	7.04	6.67e-10	7.52e-06	0.78	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
SKCM	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-7.04	6.69e-10	7.54e-06	-0.81	-0.62	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
SKCM	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	7.04	6.7e-10	7.55e-06	0.73	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	7.03	6.9e-10	7.77e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.821	rs199499	ENSG00000214401.4	KANSL1-AS1	7.02	7.16e-10	8.05e-06	1.06	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-7.02	7.34e-10	8.24e-06	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
SKCM	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	7.01	7.41e-10	8.31e-06	0.8	0.62	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
SKCM	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	7.01	7.51e-10	8.43e-06	0.75	0.62	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	7	7.86e-10	8.79e-06	0.77	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-6.99	8.2e-10	9.12e-06	-0.74	-0.62	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-6.99	8.2e-10	9.12e-06	-0.74	-0.62	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-6.99	8.2e-10	9.12e-06	-0.74	-0.62	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-6.99	8.2e-10	9.12e-06	-0.74	-0.62	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-6.99	8.2e-10	9.12e-06	-0.74	-0.62	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	6.98	8.52e-10	9.47e-06	0.7	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
SKCM	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	6.98	8.62e-10	9.57e-06	0.81	0.62	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
SKCM	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-6.98	8.65e-10	9.6e-06	-0.72	-0.62	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-6.98	8.65e-10	9.6e-06	-0.72	-0.62	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	6.97	8.86e-10	9.82e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	6.97	8.86e-10	9.82e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	6.97	8.86e-10	9.82e-06	0.76	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-6.97	8.97e-10	9.94e-06	-0.76	-0.62	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
SKCM	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	6.97	9.06e-10	1e-05	0.75	0.62	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	6.97	9.15e-10	1.01e-05	0.66	0.62	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-6.97	9.15e-10	1.01e-05	-0.66	-0.62	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	6.97	9.15e-10	1.01e-05	0.66	0.62	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	6.97	9.15e-10	1.01e-05	0.66	0.62	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28379133	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28379168	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28386473	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28391932	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28399846	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	6.96	9.22e-10	1.01e-05	0.79	0.62	Depression;	chr6:28402301	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	6.96	9.52e-10	1.05e-05	0.73	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	6.96	9.52e-10	1.05e-05	0.73	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
SKCM	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	6.95	9.86e-10	1.08e-05	0.77	0.62	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
SKCM	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	6.95	9.97e-10	1.09e-05	0.63	0.62	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	6.95	1e-09	1.1e-05	0.7	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
SKCM	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	6.94	1e-09	1.1e-05	1.32	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	6.94	1e-09	1.1e-05	1.32	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	6.94	1e-09	1.1e-05	1.32	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
SKCM	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	6.94	1.04e-09	1.13e-05	1.33	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
SKCM	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	6.93	1.05e-09	1.14e-05	0.83	0.62	Depression;	chr6:28407125	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	6.93	1.05e-09	1.14e-05	0.83	0.62	Depression;	chr6:28428413	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6.93	1.05e-09	1.14e-05	0.83	0.62	Depression;	chr6:28430971	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	6.93	1.05e-09	1.14e-05	0.83	0.62	Depression;	chr6:28431469	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6.93	1.05e-09	1.14e-05	0.83	0.62	Depression;	chr6:28432562	chr6:28176188~28176674:+
SKCM	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-6.92	1.1e-09	1.18e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-6.92	1.1e-09	1.18e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
SKCM	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	6.92	1.1e-09	1.19e-05	0.76	0.62	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
SKCM	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-6.92	1.11e-09	1.19e-05	-0.78	-0.62	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-6.92	1.11e-09	1.19e-05	-0.78	-0.62	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-6.92	1.11e-09	1.19e-05	-0.78	-0.62	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-6.92	1.11e-09	1.19e-05	-0.78	-0.62	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
SKCM	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-6.92	1.11e-09	1.19e-05	-0.78	-0.62	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
SKCM	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-6.92	1.11e-09	1.19e-05	-0.72	-0.62	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.92	1.12e-09	1.2e-05	0.77	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	6.9	1.21e-09	1.29e-05	0.72	0.62	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
SKCM	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	6.88	1.31e-09	1.39e-05	0.79	0.61	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
SKCM	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	6.88	1.32e-09	1.4e-05	0.75	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
SKCM	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	6.88	1.32e-09	1.4e-05	1.32	0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
SKCM	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	6.88	1.34e-09	1.42e-05	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
SKCM	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	6.88	1.34e-09	1.42e-05	0.72	0.61	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	6.88	1.34e-09	1.42e-05	0.72	0.61	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-6.88	1.36e-09	1.43e-05	-0.76	-0.61	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	6.88	1.36e-09	1.44e-05	0.72	0.61	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
SKCM	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	6.87	1.42e-09	1.5e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-6.86	1.46e-09	1.53e-05	-0.7	-0.61	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	6.86	1.46e-09	1.53e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	6.86	1.46e-09	1.53e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
SKCM	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	6.86	1.46e-09	1.53e-05	0.8	0.61	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.86	1.48e-09	1.55e-05	0.78	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.86	1.48e-09	1.55e-05	0.78	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
SKCM	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	6.85	1.49e-09	1.56e-05	1.32	0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
SKCM	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-6.85	1.53e-09	1.58e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-6.85	1.55e-09	1.58e-05	-0.73	-0.61	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-6.85	1.55e-09	1.58e-05	-0.73	-0.61	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	6.84	1.6e-09	1.63e-05	0.71	0.61	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-6.84	1.6e-09	1.63e-05	-0.73	-0.61	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
SKCM	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-6.84	1.61e-09	1.63e-05	-0.79	-0.61	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
SKCM	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	6.84	1.61e-09	1.63e-05	0.68	0.61	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
SKCM	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-6.84	1.61e-09	1.63e-05	-0.74	-0.61	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-6.84	1.61e-09	1.63e-05	-0.74	-0.61	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	6.82	1.7e-09	1.72e-05	0.75	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
SKCM	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	6.82	1.72e-09	1.73e-05	0.76	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	6.81	1.77e-09	1.78e-05	0.68	0.61	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-6.81	1.78e-09	1.79e-05	-0.74	-0.61	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
SKCM	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-6.81	1.81e-09	1.82e-05	-1.27	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
SKCM	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	6.8	1.86e-09	1.87e-05	0.73	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	6.8	1.86e-09	1.87e-05	0.73	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	6.8	1.86e-09	1.87e-05	0.73	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	6.8	1.89e-09	1.89e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
SKCM	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.8	1.9e-09	1.9e-05	-0.74	-0.61	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
SKCM	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	6.8	1.92e-09	1.93e-05	0.7	0.61	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	6.79	1.95e-09	1.94e-05	0.72	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.79	1.95e-09	1.94e-05	0.72	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-6.79	1.96e-09	1.95e-05	-0.75	-0.61	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-6.79	2.01e-09	2e-05	-0.73	-0.61	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-6.78	2.04e-09	2.02e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
SKCM	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	6.78	2.08e-09	2.06e-05	0.71	0.61	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	6.78	2.08e-09	2.06e-05	0.71	0.61	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
SKCM	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.78	2.09e-09	2.07e-05	0.75	0.61	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
SKCM	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	6.77	2.11e-09	2.09e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	6.77	2.12e-09	2.09e-05	0.71	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	6.76	2.22e-09	2.19e-05	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	6.75	2.31e-09	2.28e-05	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	6.75	2.31e-09	2.28e-05	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	6.75	2.31e-09	2.28e-05	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	6.75	2.39e-09	2.35e-05	0.7	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	6.74	2.42e-09	2.38e-05	0.73	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
SKCM	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-6.74	2.43e-09	2.38e-05	-0.75	-0.61	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-6.74	2.43e-09	2.38e-05	-0.72	-0.61	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	6.74	2.45e-09	2.4e-05	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	6.74	2.48e-09	2.43e-05	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
SKCM	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	6.74	2.5e-09	2.44e-05	0.77	0.61	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
SKCM	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	6.73	2.51e-09	2.46e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
SKCM	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-6.73	2.54e-09	2.48e-05	-0.78	-0.61	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
SKCM	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	6.72	2.63e-09	2.55e-05	0.77	0.61	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
SKCM	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	6.72	2.65e-09	2.57e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	6.72	2.65e-09	2.57e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	6.72	2.65e-09	2.57e-05	0.7	0.61	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-6.72	2.72e-09	2.63e-05	-0.7	-0.61	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
SKCM	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-6.71	2.83e-09	2.73e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-6.71	2.83e-09	2.73e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-6.71	2.83e-09	2.73e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-6.71	2.83e-09	2.73e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-6.71	2.83e-09	2.73e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
SKCM	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	6.7	2.92e-09	2.77e-05	1.43	0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
SKCM	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-6.7	2.93e-09	2.78e-05	-0.73	-0.6	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
SKCM	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	6.7	2.95e-09	2.79e-05	0.78	0.6	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	6.7	2.95e-09	2.79e-05	0.78	0.6	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	6.7	2.95e-09	2.79e-05	0.78	0.6	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
SKCM	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-6.7	2.97e-09	2.82e-05	-0.66	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	6.69	3.05e-09	2.87e-05	0.74	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	6.69	3.05e-09	2.87e-05	0.74	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
SKCM	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.68	3.14e-09	2.95e-05	0.77	0.6	Depression;	chr6:28364057	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	6.68	3.16e-09	2.98e-05	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
SKCM	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	6.68	3.2e-09	3.02e-05	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	6.68	3.23e-09	3.04e-05	0.72	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-6.67	3.36e-09	3.14e-05	-0.81	-0.6	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.66	3.4e-09	3.18e-05	-0.75	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	6.66	3.45e-09	3.22e-05	0.76	0.6	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	6.66	3.49e-09	3.25e-05	0.77	0.6	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
SKCM	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	6.65	3.55e-09	3.31e-05	0.72	0.6	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	6.65	3.63e-09	3.38e-05	0.69	0.6	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-6.65	3.66e-09	3.41e-05	-0.74	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	6.65	3.67e-09	3.41e-05	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
SKCM	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	6.65	3.68e-09	3.43e-05	0.65	0.6	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
SKCM	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-6.64	3.72e-09	3.46e-05	-0.72	-0.6	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
SKCM	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	6.64	3.78e-09	3.5e-05	1.1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
SKCM	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	6.64	3.8e-09	3.53e-05	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	6.63	3.91e-09	3.63e-05	0.73	0.6	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
SKCM	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	6.63	3.91e-09	3.63e-05	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
SKCM	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	6.63	4.01e-09	3.72e-05	0.64	0.6	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.62	4.1e-09	3.79e-05	-0.75	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-6.62	4.14e-09	3.82e-05	-0.65	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-6.62	4.14e-09	3.82e-05	-0.65	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	6.62	4.2e-09	3.87e-05	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	6.62	4.2e-09	3.87e-05	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-6.61	4.23e-09	3.9e-05	-0.71	-0.6	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	6.61	4.38e-09	4.03e-05	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	6.61	4.38e-09	4.03e-05	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	6.6	4.52e-09	4.12e-05	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
SKCM	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	6.6	4.56e-09	4.15e-05	0.76	0.6	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	6.6	4.56e-09	4.15e-05	0.76	0.6	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	6.6	4.56e-09	4.15e-05	0.76	0.6	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.6	4.56e-09	4.15e-05	0.76	0.6	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
SKCM	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-6.59	4.6e-09	4.18e-05	-0.74	-0.6	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
SKCM	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	6.59	4.61e-09	4.19e-05	0.69	0.6	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	6.59	4.73e-09	4.28e-05	0.76	0.6	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
SKCM	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-6.59	4.74e-09	4.28e-05	-0.72	-0.6	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
SKCM	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-6.58	4.91e-09	4.42e-05	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
SKCM	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	6.57	5.2e-09	4.64e-05	0.75	0.6	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
SKCM	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	6.56	5.31e-09	4.72e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-6.55	5.47e-09	4.85e-05	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-6.55	5.47e-09	4.85e-05	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
SKCM	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.55	5.61e-09	4.96e-05	-0.72	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
SKCM	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.55	5.61e-09	4.96e-05	-0.72	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
SKCM	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	6.55	5.63e-09	4.97e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.55	5.63e-09	4.97e-05	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	6.55	5.63e-09	4.97e-05	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	6.55	5.68e-09	5.01e-05	0.74	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	6.55	5.69e-09	5.02e-05	0.72	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	6.54	5.73e-09	5.05e-05	0.71	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-6.54	5.73e-09	5.05e-05	-0.72	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
SKCM	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	6.54	5.85e-09	5.14e-05	0.72	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-6.54	5.86e-09	5.15e-05	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-6.54	5.86e-09	5.15e-05	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-6.54	5.86e-09	5.15e-05	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	6.54	5.9e-09	5.18e-05	0.75	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
SKCM	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	6.54	5.91e-09	5.19e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
SKCM	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-6.54	5.92e-09	5.19e-05	-0.76	-0.59	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-6.54	5.93e-09	5.2e-05	-0.73	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	6.53	5.96e-09	5.21e-05	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
SKCM	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	6.53	5.98e-09	5.23e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	6.53	5.98e-09	5.23e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	6.53	5.98e-09	5.23e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-6.53	6.08e-09	5.31e-05	-0.71	-0.59	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
SKCM	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.53	6.1e-09	5.32e-05	0.71	0.59	Depression;	chr6:28273214	chr6:28176188~28176674:+
SKCM	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.53	6.1e-09	5.32e-05	0.71	0.59	Depression;	chr6:28273215	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-6.53	6.21e-09	5.41e-05	-0.75	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
SKCM	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	6.52	6.29e-09	5.47e-05	0.61	0.59	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-6.52	6.33e-09	5.51e-05	-0.67	-0.59	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
SKCM	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	6.52	6.46e-09	5.61e-05	0.74	0.59	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
SKCM	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	6.51	6.63e-09	5.75e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
SKCM	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	6.51	6.63e-09	5.75e-05	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-6.51	6.78e-09	5.87e-05	-0.67	-0.59	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-6.51	6.78e-09	5.87e-05	-0.67	-0.59	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	6.5	6.89e-09	5.95e-05	0.67	0.59	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	6.5	6.94e-09	5.99e-05	0.68	0.59	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	6.5	7.05e-09	6.07e-05	0.7	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	6.5	7.05e-09	6.07e-05	0.7	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.5	7.05e-09	6.07e-05	0.7	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
SKCM	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	6.49	7.3e-09	6.29e-05	0.66	0.59	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
SKCM	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	6.48	7.43e-09	6.38e-05	0.74	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
SKCM	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	6.48	7.47e-09	6.39e-05	0.74	0.59	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	6.48	7.56e-09	6.45e-05	0.75	0.59	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
SKCM	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.47	7.73e-09	6.58e-05	-0.74	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
SKCM	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-6.47	7.74e-09	6.58e-05	-0.67	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
SKCM	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-6.46	8.28e-09	6.99e-05	-0.69	-0.59	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-6.45	8.76e-09	7.32e-05	-0.76	-0.59	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
SKCM	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-6.44	8.96e-09	7.46e-05	-0.7	-0.59	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
SKCM	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	6.44	9.1e-09	7.56e-05	0.73	0.59	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
SKCM	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	6.43	9.18e-09	7.62e-05	0.71	0.59	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
SKCM	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	6.43	9.18e-09	7.62e-05	0.71	0.59	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
SKCM	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	6.43	9.21e-09	7.64e-05	0.63	0.59	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
SKCM	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	6.43	9.27e-09	7.69e-05	0.72	0.59	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	6.43	9.3e-09	7.71e-05	0.74	0.59	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
SKCM	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	6.43	9.35e-09	7.75e-05	1.12	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	6.43	9.35e-09	7.75e-05	1.12	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
SKCM	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.42	9.72e-09	8.03e-05	0.72	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
SKCM	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	6.41	1.01e-08	8.31e-05	0.68	0.59	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
SKCM	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	6.4	1.04e-08	8.61e-05	0.72	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
SKCM	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	6.4	1.05e-08	8.62e-05	0.73	0.59	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	6.4	1.05e-08	8.62e-05	0.73	0.59	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
SKCM	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-6.4	1.08e-08	8.91e-05	-0.68	-0.59	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
SKCM	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	6.39	1.09e-08	8.99e-05	0.69	0.59	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	6.39	1.12e-08	9.17e-05	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-6.39	1.12e-08	9.19e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-6.38	1.16e-08	9.45e-05	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	6.38	1.16e-08	9.46e-05	0.69	0.59	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-6.38	1.17e-08	9.52e-05	-0.67	-0.59	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
SKCM	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-6.38	1.17e-08	9.52e-05	-0.71	-0.59	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	6.37	1.21e-08	9.82e-05	0.74	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
SKCM	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	6.36	1.25e-08	0.000102	0.68	0.58	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	6.35	1.34e-08	0.000109	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
SKCM	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	6.34	1.37e-08	0.000111	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
SKCM	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-6.34	1.39e-08	0.000113	-0.89	-0.58	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
SKCM	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-6.33	1.41e-08	0.000114	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	6.33	1.42e-08	0.000115	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	6.33	1.42e-08	0.000115	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.33	1.42e-08	0.000115	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	6.33	1.45e-08	0.000117	0.8	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
SKCM	cis	rs997154	0.544	rs60950807	ENSG00000279656.1	RP11-298I3.6	-6.33	1.45e-08	0.000117	-0.85	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23013195	chr14:23023083~23024217:-
SKCM	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	6.33	1.45e-08	0.000117	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	6.33	1.45e-08	0.000117	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	6.33	1.46e-08	0.000117	0.72	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-6.33	1.46e-08	0.000118	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.32	1.48e-08	0.000119	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.32	1.48e-08	0.000119	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	6.32	1.49e-08	0.00012	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
SKCM	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	6.32	1.49e-08	0.00012	0.81	0.58	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
SKCM	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-6.32	1.5e-08	0.000121	-0.71	-0.58	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
SKCM	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-6.32	1.52e-08	0.000122	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-6.32	1.52e-08	0.000122	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	6.32	1.53e-08	0.000123	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	6.31	1.54e-08	0.000124	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	6.31	1.54e-08	0.000124	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
SKCM	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-6.31	1.54e-08	0.000124	-0.83	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
SKCM	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-6.3	1.63e-08	0.00013	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
SKCM	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	6.29	1.67e-08	0.000133	0.64	0.58	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
SKCM	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.29	1.67e-08	0.000133	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
SKCM	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	6.29	1.71e-08	0.000135	0.7	0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
SKCM	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	6.29	1.71e-08	0.000135	0.7	0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
SKCM	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-6.28	1.74e-08	0.000138	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
SKCM	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	6.28	1.75e-08	0.000138	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
SKCM	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	6.28	1.75e-08	0.000138	1.13	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
SKCM	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.28	1.76e-08	0.000139	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	6.28	1.79e-08	0.000141	0.67	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
SKCM	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	6.27	1.84e-08	0.000145	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
SKCM	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-6.27	1.88e-08	0.000148	-0.62	-0.58	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
SKCM	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	6.27	1.89e-08	0.000149	0.73	0.58	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
SKCM	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	6.26	1.9e-08	0.000149	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
SKCM	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-6.26	1.96e-08	0.000154	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
SKCM	cis	rs7195287	0.826	rs4280242	ENSG00000276791.1	CTD-2270P14.5	6.25	2.04e-08	0.00016	0.74	0.58	Eosinophil counts;	chr16:2780481	chr16:2777319~2780568:+
SKCM	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	6.25	2.06e-08	0.000161	0.7	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	6.24	2.12e-08	0.000165	0.7	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
SKCM	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	6.24	2.13e-08	0.000166	1.06	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
SKCM	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-6.23	2.17e-08	0.000169	-0.69	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
SKCM	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	6.21	2.36e-08	0.000183	0.88	0.58	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-6.2	2.48e-08	0.000193	-0.7	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
SKCM	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	6.2	2.55e-08	0.000196	0.7	0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
SKCM	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	6.18	2.73e-08	0.000209	0.68	0.57	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	6.18	2.73e-08	0.00021	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
SKCM	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	6.18	2.75e-08	0.000211	0.63	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	6.18	2.75e-08	0.000211	0.63	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	6.18	2.78e-08	0.000213	0.62	0.57	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
SKCM	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-6.17	2.8e-08	0.000215	-0.7	-0.57	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	6.17	2.83e-08	0.000216	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	6.16	2.96e-08	0.000226	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.16	2.96e-08	0.000226	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	6.16	2.99e-08	0.000228	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	6.16	3e-08	0.000229	0.71	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
SKCM	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-6.16	3.02e-08	0.00023	-1.11	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	6.16	3.02e-08	0.00023	1.11	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	6.16	3.02e-08	0.00023	1.11	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
SKCM	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	6.15	3.04e-08	0.000231	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	6.15	3.04e-08	0.000231	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	6.15	3.04e-08	0.000231	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	6.15	3.07e-08	0.000233	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	6.15	3.07e-08	0.000233	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	6.15	3.15e-08	0.000239	0.6	0.57	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
SKCM	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	6.14	3.2e-08	0.000242	0.65	0.57	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
SKCM	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	6.14	3.2e-08	0.000242	0.65	0.57	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
SKCM	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	6.14	3.2e-08	0.000242	0.65	0.57	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
SKCM	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-6.14	3.23e-08	0.000243	-0.68	-0.57	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
SKCM	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	6.14	3.27e-08	0.000246	0.63	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
SKCM	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-6.13	3.32e-08	0.00025	-0.7	-0.57	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
SKCM	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	6.13	3.41e-08	0.000256	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	6.12	3.45e-08	0.000259	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	6.12	3.45e-08	0.000259	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
SKCM	cis	rs7174755	0.772	rs958353	ENSG00000260657.2	RP11-315D16.4	-6.12	3.51e-08	0.000262	-0.81	-0.57	Major depressive disorder;	chr15:68272638	chr15:68267792~68277994:-
SKCM	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	6.12	3.52e-08	0.000263	0.62	0.57	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
SKCM	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-6.12	3.52e-08	0.000263	-0.6	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
SKCM	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	6.12	3.55e-08	0.000265	0.63	0.57	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
SKCM	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-6.12	3.56e-08	0.000266	-0.68	-0.57	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-6.12	3.56e-08	0.000266	-0.68	-0.57	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
SKCM	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-6.12	3.56e-08	0.000266	-0.68	-0.57	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
SKCM	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-6.12	3.57e-08	0.000266	-0.66	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
SKCM	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	6.11	3.6e-08	0.000269	0.79	0.57	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
SKCM	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-6.11	3.62e-08	0.00027	-0.65	-0.57	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
SKCM	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-6.1	3.83e-08	0.000284	-0.85	-0.57	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6.09	3.92e-08	0.000291	-0.7	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	6.09	4.05e-08	3e-04	0.63	0.57	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-6.08	4.13e-08	0.000306	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
SKCM	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	6.08	4.19e-08	0.00031	0.79	0.57	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	6.08	4.19e-08	0.00031	0.79	0.57	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	6.08	4.19e-08	0.00031	0.79	0.57	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	6.07	4.29e-08	0.000317	0.72	0.57	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
SKCM	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	6.07	4.43e-08	0.000326	0.77	0.57	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
SKCM	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-6.06	4.49e-08	0.00033	-0.63	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
SKCM	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	6.06	4.51e-08	0.000332	0.9	0.57	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
SKCM	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-6.06	4.53e-08	0.000334	-0.67	-0.57	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
SKCM	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	6.05	4.71e-08	0.000343	0.75	0.57	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
SKCM	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	6.04	4.98e-08	0.000361	0.64	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
SKCM	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	6.04	5e-08	0.000363	0.61	0.56	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
SKCM	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	6.04	5.02e-08	0.000364	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
SKCM	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	6.04	5.03e-08	0.000365	0.61	0.56	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
SKCM	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-6.03	5.15e-08	0.000372	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
SKCM	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-6.03	5.18e-08	0.000374	-0.61	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
SKCM	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-6.03	5.21e-08	0.000375	-0.72	-0.56	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
SKCM	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	6.03	5.22e-08	0.000375	0.6	0.56	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	6.03	5.22e-08	0.000375	0.6	0.56	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	6.03	5.22e-08	0.000375	0.6	0.56	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
SKCM	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	6.02	5.32e-08	0.000382	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
SKCM	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	6.02	5.32e-08	0.000382	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
SKCM	cis	rs1431005	0.858	rs77580406	ENSG00000250620.1	RP11-91J3.3	6.02	5.33e-08	0.000383	0.68	0.56	Response to statin therapy;	chr4:187493654	chr4:187413564~187415697:+
SKCM	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	6.02	5.39e-08	0.000387	0.7	0.56	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
SKCM	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-6.02	5.4e-08	0.000387	-0.72	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
SKCM	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-6.02	5.42e-08	0.000388	-0.66	-0.56	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
SKCM	cis	rs8062405	0.691	rs6565259	ENSG00000259982.1	CDC37P1	6.02	5.43e-08	0.000389	0.68	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28887472	chr16:28700294~28701540:-
SKCM	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	6.02	5.46e-08	0.000391	1.24	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
SKCM	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-6	5.73e-08	0.00041	-0.62	-0.56	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
SKCM	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	6	5.76e-08	0.000412	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
SKCM	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	6	5.8e-08	0.000414	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	6	5.87e-08	0.000419	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
SKCM	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-6	5.95e-08	0.000422	-0.75	-0.56	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
SKCM	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	6	5.95e-08	0.000422	0.7	0.56	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
SKCM	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	5.98	6.29e-08	0.000443	0.71	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
SKCM	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-5.98	6.38e-08	0.000448	-0.69	-0.56	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
SKCM	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-5.97	6.51e-08	0.000455	-0.64	-0.56	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
SKCM	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-5.97	6.53e-08	0.000457	-0.63	-0.56	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
SKCM	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	5.97	6.56e-08	0.000459	0.71	0.56	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
SKCM	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-5.97	6.68e-08	0.000467	-0.61	-0.56	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
SKCM	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	5.96	6.77e-08	0.000473	0.7	0.56	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
SKCM	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-5.96	6.81e-08	0.000475	-0.7	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
SKCM	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	5.96	6.9e-08	0.000482	0.65	0.56	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
SKCM	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.95	7.11e-08	0.000495	0.84	0.56	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.95	7.11e-08	0.000495	0.84	0.56	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.95	7.19e-08	5e-04	0.78	0.56	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
SKCM	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	5.94	7.44e-08	0.000513	0.62	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
SKCM	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	5.94	7.47e-08	0.000513	0.71	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
SKCM	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	5.93	7.71e-08	0.000529	0.61	0.56	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	5.93	7.71e-08	0.000529	0.61	0.56	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
SKCM	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	5.93	7.81e-08	0.000536	0.67	0.56	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	5.93	7.81e-08	0.000536	0.67	0.56	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
SKCM	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	5.93	7.83e-08	0.000537	0.61	0.56	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
SKCM	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-5.92	8.1e-08	0.000554	-0.68	-0.56	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
SKCM	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	5.92	8.1e-08	0.000555	0.81	0.56	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
SKCM	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-5.92	8.2e-08	0.000561	-0.84	-0.56	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
SKCM	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-5.91	8.38e-08	0.000572	-0.67	-0.56	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
SKCM	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	5.91	8.47e-08	0.000574	0.61	0.56	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	5.91	8.47e-08	0.000574	0.61	0.56	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	5.91	8.47e-08	0.000574	0.61	0.56	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
SKCM	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	5.91	8.66e-08	0.000584	0.76	0.56	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
SKCM	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	5.91	8.67e-08	0.000584	0.61	0.56	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
SKCM	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	5.9	8.73e-08	0.000587	0.71	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	5.9	8.75e-08	0.000589	0.76	0.56	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
SKCM	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	5.9	8.75e-08	0.000589	0.67	0.56	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
SKCM	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-5.9	8.95e-08	0.000601	-0.73	-0.56	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
SKCM	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	5.89	9.11e-08	0.000611	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
SKCM	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	5.89	9.29e-08	0.000622	0.62	0.55	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
SKCM	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-5.89	9.35e-08	0.000626	-0.7	-0.55	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-5.89	9.35e-08	0.000626	-0.7	-0.55	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
SKCM	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-5.88	9.48e-08	0.000634	-0.74	-0.55	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
SKCM	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	5.88	9.61e-08	0.000641	0.64	0.55	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
SKCM	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	5.88	9.65e-08	0.000643	0.67	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-5.88	9.65e-08	0.000643	-0.67	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-5.88	9.65e-08	0.000643	-0.67	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
SKCM	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	5.88	9.69e-08	0.000646	0.69	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
SKCM	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	5.88	9.84e-08	0.000656	0.6	0.55	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-5.87	9.88e-08	0.000658	-0.61	-0.55	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
SKCM	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	5.87	9.92e-08	0.00066	0.63	0.55	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
SKCM	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	5.87	1.01e-07	0.000671	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
SKCM	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	5.87	1.02e-07	0.00068	0.68	0.55	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
SKCM	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	5.87	1.03e-07	0.000682	0.68	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
SKCM	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	5.86	1.04e-07	0.000692	0.63	0.55	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
SKCM	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.69	0.55	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.67	0.55	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	5.86	1.05e-07	0.000693	0.67	0.55	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
SKCM	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	5.86	1.05e-07	0.000698	0.6	0.55	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
SKCM	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-5.85	1.08e-07	0.000711	-0.76	-0.55	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
SKCM	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-5.85	1.08e-07	0.000716	-0.63	-0.55	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
SKCM	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	5.85	1.09e-07	0.00072	0.76	0.55	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
SKCM	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-5.85	1.1e-07	0.000726	-0.62	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
SKCM	cis	rs916888	0.647	rs199520	ENSG00000214401.4	KANSL1-AS1	-5.85	1.11e-07	0.000732	-0.76	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.647	rs199519	ENSG00000214401.4	KANSL1-AS1	-5.85	1.11e-07	0.000732	-0.76	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:46193576~46196723:+
SKCM	cis	rs7224296	0.709	rs199518	ENSG00000214401.4	KANSL1-AS1	-5.85	1.11e-07	0.000732	-0.76	-0.55	Intelligence (multi-trait analysis);	chr17:46777214	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.647	rs199517	ENSG00000214401.4	KANSL1-AS1	-5.85	1.11e-07	0.000732	-0.76	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:46193576~46196723:+
SKCM	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	5.84	1.13e-07	0.000743	0.6	0.55	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
SKCM	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	5.84	1.14e-07	0.000748	0.67	0.55	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
SKCM	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-5.83	1.18e-07	0.00077	-0.6	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
SKCM	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-5.83	1.18e-07	0.000771	-0.86	-0.55	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
SKCM	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	5.83	1.21e-07	0.000783	0.71	0.55	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
SKCM	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-5.82	1.24e-07	0.000802	-0.67	-0.55	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
SKCM	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	5.82	1.24e-07	0.000802	0.82	0.55	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
SKCM	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-5.81	1.31e-07	0.00084	-0.67	-0.55	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
SKCM	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	5.8	1.36e-07	0.000872	0.59	0.55	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
SKCM	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	5.79	1.42e-07	0.000905	0.64	0.55	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	5.79	1.42e-07	0.000905	0.64	0.55	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	5.79	1.42e-07	0.000905	0.64	0.55	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
SKCM	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	5.79	1.43e-07	0.000916	0.71	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
SKCM	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-5.78	1.46e-07	0.00093	-0.62	-0.55	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-5.78	1.46e-07	0.00093	-0.62	-0.55	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-5.78	1.46e-07	0.00093	-0.62	-0.55	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-5.78	1.46e-07	0.00093	-0.62	-0.55	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-5.78	1.46e-07	0.00093	-0.62	-0.55	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
SKCM	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	5.78	1.48e-07	0.00094	0.7	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	5.78	1.5e-07	0.000952	0.8	0.55	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
SKCM	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	5.77	1.5e-07	0.000953	0.62	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
SKCM	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	5.77	1.5e-07	0.000956	0.66	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
SKCM	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	5.77	1.51e-07	0.00096	0.9	0.55	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
SKCM	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	5.77	1.51e-07	0.00096	0.64	0.55	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	5.77	1.51e-07	0.00096	0.64	0.55	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
SKCM	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-5.77	1.53e-07	0.000966	-0.72	-0.55	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
SKCM	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	5.77	1.53e-07	0.000968	0.69	0.55	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
SKCM	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-5.77	1.53e-07	0.000968	-0.67	-0.55	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
SKCM	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	5.77	1.55e-07	0.000979	0.65	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	5.77	1.55e-07	0.000979	0.65	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-5.76	1.57e-07	0.000992	-0.62	-0.55	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
SKCM	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	5.76	1.58e-07	0.000992	0.71	0.55	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	5.76	1.58e-07	0.000992	0.71	0.55	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	5.76	1.58e-07	0.000992	0.71	0.55	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
SKCM	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.76	1.59e-07	0.000999	0.82	0.55	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
SKCM	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	5.76	1.59e-07	0.000999	0.69	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
SKCM	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	5.75	1.64e-07	0.00103	0.58	0.55	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
SKCM	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	5.75	1.66e-07	0.00104	0.69	0.55	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
SKCM	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	5.75	1.67e-07	0.00105	0.66	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
SKCM	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	5.74	1.73e-07	0.00108	0.69	0.54	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
SKCM	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	5.74	1.76e-07	0.0011	0.73	0.54	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
SKCM	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	5.74	1.76e-07	0.0011	0.73	0.54	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
SKCM	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-5.74	1.76e-07	0.0011	-0.73	-0.54	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
SKCM	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-5.74	1.76e-07	0.0011	-0.73	-0.54	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
SKCM	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-5.74	1.76e-07	0.0011	-0.73	-0.54	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
SKCM	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-5.73	1.81e-07	0.00112	-0.6	-0.54	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
SKCM	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	5.73	1.83e-07	0.00113	0.6	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
SKCM	cis	rs380904	0.572	rs2060967	ENSG00000254859.1	RP11-661A12.5	-5.73	1.83e-07	0.00113	-0.85	-0.54	Venous thromboembolism (SNP x SNP interaction);	chr8:143521427	chr8:143541973~143549729:-
SKCM	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-5.73	1.84e-07	0.00114	-0.66	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
SKCM	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-5.72	1.87e-07	0.00115	-0.56	-0.54	Breast cancer;	chr11:743813	chr11:779617~780755:+
SKCM	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	5.72	1.87e-07	0.00115	0.69	0.54	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
SKCM	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-5.72	1.88e-07	0.00116	-0.61	-0.54	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
SKCM	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	5.72	1.89e-07	0.00117	0.6	0.54	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
SKCM	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	5.71	1.94e-07	0.00119	0.55	0.54	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
SKCM	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-5.69	2.11e-07	0.00129	-0.6	-0.54	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
SKCM	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	5.69	2.12e-07	0.00129	0.7	0.54	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
SKCM	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	5.69	2.14e-07	0.0013	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
SKCM	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	5.69	2.14e-07	0.0013	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
SKCM	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	5.69	2.14e-07	0.0013	0.71	0.54	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
SKCM	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-5.69	2.16e-07	0.00131	-0.65	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
SKCM	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	5.68	2.24e-07	0.00136	0.67	0.54	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
SKCM	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	5.68	2.24e-07	0.00136	0.67	0.54	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
SKCM	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	5.68	2.24e-07	0.00136	0.67	0.54	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
SKCM	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-5.67	2.29e-07	0.00138	-0.59	-0.54	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
SKCM	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	5.67	2.31e-07	0.0014	0.6	0.54	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
SKCM	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	5.67	2.35e-07	0.00142	0.68	0.54	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
SKCM	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	5.66	2.37e-07	0.00143	0.61	0.54	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
SKCM	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-5.66	2.43e-07	0.00146	-0.56	-0.54	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
SKCM	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	5.66	2.44e-07	0.00147	0.64	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
SKCM	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-5.65	2.48e-07	0.00149	-0.82	-0.54	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-5.65	2.48e-07	0.00149	-0.82	-0.54	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-5.65	2.48e-07	0.00149	-0.82	-0.54	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-5.65	2.48e-07	0.00149	-0.82	-0.54	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-5.65	2.48e-07	0.00149	-0.82	-0.54	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
SKCM	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	5.65	2.48e-07	0.00149	0.73	0.54	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
SKCM	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-5.65	2.5e-07	0.0015	-0.61	-0.54	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-5.65	2.5e-07	0.0015	-0.61	-0.54	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
SKCM	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	5.65	2.51e-07	0.0015	0.6	0.54	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
SKCM	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-5.65	2.54e-07	0.00152	-0.66	-0.54	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
SKCM	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-5.64	2.57e-07	0.00154	-0.73	-0.54	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
SKCM	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-5.64	2.59e-07	0.00155	-0.72	-0.54	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
SKCM	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	5.64	2.6e-07	0.00155	0.68	0.54	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	5.64	2.6e-07	0.00155	0.68	0.54	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	5.64	2.6e-07	0.00155	0.68	0.54	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	5.64	2.6e-07	0.00155	0.68	0.54	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
SKCM	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-5.64	2.66e-07	0.00158	-0.74	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-5.64	2.66e-07	0.00158	-0.74	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
SKCM	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	5.63	2.67e-07	0.00158	0.68	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
SKCM	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	5.63	2.72e-07	0.0016	0.6	0.54	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
SKCM	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-5.63	2.72e-07	0.0016	-0.64	-0.54	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
SKCM	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	5.63	2.76e-07	0.00163	0.65	0.54	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-5.63	2.76e-07	0.00163	-0.65	-0.54	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
SKCM	cis	rs916888	0.686	rs199501	ENSG00000214401.4	KANSL1-AS1	-5.62	2.79e-07	0.00164	-0.74	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46785247	chr17:46193576~46196723:+
SKCM	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-5.62	2.81e-07	0.00165	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-5.62	2.81e-07	0.00165	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-5.62	2.81e-07	0.00165	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-5.62	2.81e-07	0.00165	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
SKCM	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	5.62	2.85e-07	0.00166	0.6	0.54	Height;	chr11:118703185	chr11:118688039~118690600:-
SKCM	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	5.62	2.85e-07	0.00166	0.6	0.54	Height;	chr11:118703207	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	5.62	2.85e-07	0.00166	0.6	0.54	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
SKCM	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	5.62	2.85e-07	0.00166	0.6	0.54	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
SKCM	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	5.62	2.87e-07	0.00167	0.74	0.54	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
SKCM	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	5.61	2.9e-07	0.00169	0.63	0.54	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	5.61	2.9e-07	0.00169	0.63	0.54	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
SKCM	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-5.61	2.9e-07	0.00169	-0.63	-0.54	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
SKCM	cis	rs8062405	0.592	rs12919058	ENSG00000259982.1	CDC37P1	-5.61	2.91e-07	0.0017	-0.62	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28916497	chr16:28700294~28701540:-
SKCM	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-5.61	2.92e-07	0.0017	-0.59	-0.54	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-5.61	2.92e-07	0.0017	-0.59	-0.54	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
SKCM	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	5.61	2.95e-07	0.00172	0.64	0.54	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-5.61	2.95e-07	0.00172	-0.64	-0.54	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-5.61	2.95e-07	0.00172	-0.64	-0.54	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
SKCM	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	5.61	2.99e-07	0.00174	0.61	0.54	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
SKCM	cis	rs8062405	0.625	rs8060365	ENSG00000259982.1	CDC37P1	-5.61	2.99e-07	0.00174	-0.63	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-5.61	2.99e-07	0.00174	-0.63	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-5.61	2.99e-07	0.00174	-0.63	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
SKCM	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	5.61	3.01e-07	0.00175	0.62	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
SKCM	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	5.6	3.09e-07	0.00179	0.87	0.54	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
SKCM	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	5.6	3.09e-07	0.00179	0.63	0.54	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	5.6	3.09e-07	0.00179	0.63	0.54	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
SKCM	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	5.6	3.12e-07	0.00181	0.57	0.54	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	5.6	3.12e-07	0.00181	0.57	0.54	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-5.6	3.12e-07	0.00181	-0.57	-0.54	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
SKCM	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-5.6	3.15e-07	0.00182	-0.56	-0.54	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
SKCM	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-5.59	3.2e-07	0.00185	-0.77	-0.53	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
SKCM	cis	rs7174755	0.924	rs10444850	ENSG00000260657.2	RP11-315D16.4	5.59	3.22e-07	0.00186	0.76	0.53	Major depressive disorder;	chr15:68296597	chr15:68267792~68277994:-
SKCM	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-5.59	3.23e-07	0.00186	-0.65	-0.53	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	5.59	3.23e-07	0.00186	0.65	0.53	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	5.59	3.23e-07	0.00186	0.65	0.53	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	5.59	3.23e-07	0.00186	0.65	0.53	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	5.59	3.23e-07	0.00186	0.65	0.53	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	5.59	3.23e-07	0.00186	0.65	0.53	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
SKCM	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-5.59	3.26e-07	0.00188	-0.72	-0.53	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
SKCM	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	5.58	3.29e-07	0.0019	0.69	0.53	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
SKCM	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-5.58	3.3e-07	0.0019	-0.75	-0.53	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
SKCM	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-5.58	3.31e-07	0.0019	-0.67	-0.53	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	5.58	3.33e-07	0.00191	0.64	0.53	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
SKCM	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	5.58	3.37e-07	0.00193	0.67	0.53	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
SKCM	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-5.58	3.39e-07	0.00194	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
SKCM	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	5.57	3.43e-07	0.00196	0.8	0.53	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.57	3.43e-07	0.00196	0.8	0.53	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
SKCM	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.57	3.43e-07	0.00196	0.8	0.53	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
SKCM	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	5.57	3.45e-07	0.00197	0.67	0.53	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	5.57	3.45e-07	0.00197	0.67	0.53	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	5.57	3.45e-07	0.00197	0.67	0.53	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
SKCM	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	5.57	3.48e-07	0.00198	0.65	0.53	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	5.57	3.48e-07	0.00198	0.65	0.53	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	5.57	3.48e-07	0.00198	0.65	0.53	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-5.57	3.48e-07	0.00198	-0.65	-0.53	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-5.57	3.48e-07	0.00198	-0.65	-0.53	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-5.57	3.48e-07	0.00198	-0.65	-0.53	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
SKCM	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-5.57	3.48e-07	0.00198	-0.61	-0.53	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
SKCM	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-5.57	3.48e-07	0.00199	-0.6	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
SKCM	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	5.57	3.53e-07	0.00201	0.65	0.53	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-5.57	3.53e-07	0.00201	-0.65	-0.53	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
SKCM	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	5.56	3.59e-07	0.00204	0.6	0.53	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
SKCM	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-5.56	3.59e-07	0.00204	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	5.56	3.6e-07	0.00204	0.62	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	5.56	3.6e-07	0.00204	0.62	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	5.56	3.6e-07	0.00204	0.62	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
SKCM	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	5.56	3.63e-07	0.00206	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
SKCM	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-5.56	3.68e-07	0.00208	-0.81	-0.53	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
SKCM	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.55	3.74e-07	0.00212	0.65	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
SKCM	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-5.55	3.75e-07	0.00212	-0.57	-0.53	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
SKCM	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-5.55	3.75e-07	0.00212	-0.57	-0.53	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
SKCM	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-5.55	3.75e-07	0.00212	-0.57	-0.53	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
SKCM	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-5.55	3.75e-07	0.00212	-0.57	-0.53	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
SKCM	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-5.55	3.78e-07	0.00213	-0.71	-0.53	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
SKCM	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	5.55	3.83e-07	0.00215	0.6	0.53	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
SKCM	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	5.54	3.98e-07	0.00223	0.67	0.53	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
SKCM	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.54	4.01e-07	0.00225	0.68	0.53	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
SKCM	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	5.53	4.15e-07	0.00232	0.72	0.53	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
SKCM	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	5.53	4.15e-07	0.00232	0.72	0.53	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
SKCM	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-5.53	4.15e-07	0.00232	-0.72	-0.53	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
SKCM	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-5.52	4.22e-07	0.00236	-0.71	-0.53	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
SKCM	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-5.52	4.24e-07	0.00236	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-5.52	4.33e-07	0.00241	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
SKCM	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-5.52	4.37e-07	0.00243	-0.65	-0.53	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-5.52	4.37e-07	0.00243	-0.65	-0.53	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
SKCM	cis	rs380904	1	rs380904	ENSG00000254859.1	RP11-661A12.5	-5.51	4.45e-07	0.00248	-0.79	-0.53	Venous thromboembolism (SNP x SNP interaction);	chr8:143483735	chr8:143541973~143549729:-
SKCM	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	5.51	4.51e-07	0.0025	0.66	0.53	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
SKCM	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-5.5	4.56e-07	0.00253	-0.62	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
SKCM	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	5.5	4.67e-07	0.00256	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	5.49	4.82e-07	0.00263	0.65	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
SKCM	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-5.49	4.83e-07	0.00264	-0.7	-0.53	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-5.49	4.85e-07	0.00265	-0.71	-0.53	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-5.49	4.85e-07	0.00265	-0.71	-0.53	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-5.49	4.85e-07	0.00265	-0.71	-0.53	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-5.49	4.85e-07	0.00265	-0.71	-0.53	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
SKCM	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	5.48	5.02e-07	0.00274	0.74	0.53	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
SKCM	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-5.48	5.05e-07	0.00275	-0.53	-0.53	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
SKCM	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-5.48	5.06e-07	0.00276	-0.65	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
SKCM	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-5.48	5.07e-07	0.00276	-0.74	-0.53	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
SKCM	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	5.48	5.08e-07	0.00276	0.56	0.53	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
SKCM	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-5.47	5.19e-07	0.00282	-0.75	-0.53	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
SKCM	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-5.46	5.42e-07	0.00294	-0.49	-0.53	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
SKCM	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	5.46	5.43e-07	0.00294	0.73	0.53	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
SKCM	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	5.46	5.46e-07	0.00295	0.71	0.53	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
SKCM	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	5.46	5.47e-07	0.00296	0.57	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.46	5.47e-07	0.00296	0.57	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
SKCM	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-5.46	5.55e-07	0.003	-0.8	-0.53	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
SKCM	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-5.45	5.6e-07	0.00301	-0.57	-0.53	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
SKCM	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-5.45	5.66e-07	0.00301	-0.69	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
SKCM	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	5.45	5.7e-07	0.00303	0.67	0.53	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
SKCM	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	5.45	5.72e-07	0.00303	0.61	0.53	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
SKCM	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	5.45	5.74e-07	0.00304	0.64	0.53	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
SKCM	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	5.45	5.75e-07	0.00304	0.71	0.53	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
SKCM	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	5.45	5.75e-07	0.00304	0.71	0.53	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
SKCM	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-5.45	5.79e-07	0.00307	-0.71	-0.52	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
SKCM	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	5.44	5.82e-07	0.00308	0.6	0.52	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
SKCM	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-5.44	5.87e-07	0.0031	-0.58	-0.52	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
SKCM	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-5.44	5.95e-07	0.00314	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
SKCM	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-5.44	6.03e-07	0.00318	-0.56	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	5.43	6.13e-07	0.00323	0.61	0.52	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	5.43	6.13e-07	0.00323	0.61	0.52	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	5.43	6.13e-07	0.00323	0.61	0.52	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
SKCM	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-5.42	6.52e-07	0.0034	-0.57	-0.52	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-5.42	6.52e-07	0.0034	-0.57	-0.52	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-5.42	6.52e-07	0.0034	-0.57	-0.52	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
SKCM	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	5.41	6.77e-07	0.00348	0.61	0.52	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-5.41	6.77e-07	0.00348	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-5.41	6.77e-07	0.00348	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-5.41	6.77e-07	0.00348	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-5.41	6.77e-07	0.00348	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
SKCM	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-5.41	6.83e-07	0.00349	-0.74	-0.52	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-5.41	6.83e-07	0.00349	-0.74	-0.52	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	5.41	6.83e-07	0.00349	0.74	0.52	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
SKCM	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-5.4	7.03e-07	0.00357	-0.55	-0.52	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
SKCM	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	5.4	7.11e-07	0.00361	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
SKCM	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.4	7.11e-07	0.00361	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
SKCM	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	5.39	7.17e-07	0.00364	0.57	0.52	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
SKCM	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	5.39	7.29e-07	0.0037	0.66	0.52	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	5.39	7.29e-07	0.0037	0.66	0.52	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-5.39	7.29e-07	0.0037	-0.66	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
SKCM	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	5.39	7.35e-07	0.00372	0.55	0.52	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
SKCM	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	5.39	7.35e-07	0.00372	0.55	0.52	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
SKCM	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-5.39	7.36e-07	0.00373	-0.64	-0.52	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
SKCM	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	5.39	7.36e-07	0.00373	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
SKCM	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-5.38	7.53e-07	0.00381	-0.68	-0.52	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-5.38	7.53e-07	0.00381	-0.68	-0.52	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-5.38	7.53e-07	0.00381	-0.68	-0.52	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
SKCM	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-5.38	7.54e-07	0.00381	-0.64	-0.52	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-5.38	7.54e-07	0.00381	-0.64	-0.52	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-5.38	7.54e-07	0.00381	-0.64	-0.52	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
SKCM	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	5.38	7.55e-07	0.00381	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
SKCM	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	5.38	7.57e-07	0.00382	0.63	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
SKCM	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-5.38	7.58e-07	0.00382	-0.6	-0.52	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-5.38	7.58e-07	0.00382	-0.6	-0.52	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-5.38	7.58e-07	0.00382	-0.6	-0.52	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-5.38	7.58e-07	0.00382	-0.6	-0.52	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
SKCM	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	5.38	7.62e-07	0.00383	0.62	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
SKCM	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	5.38	7.66e-07	0.00385	0.67	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	5.38	7.66e-07	0.00385	0.67	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
SKCM	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-5.38	7.66e-07	0.00385	-0.63	-0.52	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
SKCM	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	5.37	7.96e-07	0.00398	0.69	0.52	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
SKCM	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-5.37	8.03e-07	0.00402	-0.47	-0.52	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
SKCM	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	5.36	8.11e-07	0.00406	0.67	0.52	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-5.36	8.15e-07	0.00408	-0.69	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
SKCM	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-5.36	8.17e-07	0.00408	-0.61	-0.52	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
SKCM	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	5.36	8.17e-07	0.00408	0.6	0.52	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
SKCM	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.35	8.46e-07	0.00422	0.63	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
SKCM	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	5.35	8.48e-07	0.00423	0.55	0.52	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
SKCM	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	5.35	8.53e-07	0.00425	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
SKCM	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	5.35	8.54e-07	0.00426	0.72	0.52	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
SKCM	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	5.35	8.59e-07	0.00428	0.6	0.52	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	5.35	8.59e-07	0.00428	0.6	0.52	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	5.35	8.59e-07	0.00428	0.6	0.52	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
SKCM	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	5.35	8.64e-07	0.0043	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
SKCM	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	5.34	8.73e-07	0.00434	0.77	0.52	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
SKCM	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.34	8.74e-07	0.00434	0.75	0.52	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
SKCM	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-5.34	8.87e-07	0.00439	-0.47	-0.52	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	5.34	8.87e-07	0.00439	0.47	0.52	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
SKCM	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-5.34	8.88e-07	0.00439	-0.56	-0.52	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
SKCM	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	5.34	8.89e-07	0.0044	0.7	0.52	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
SKCM	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	5.34	8.95e-07	0.00442	0.55	0.52	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
SKCM	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	5.34	9.02e-07	0.00443	0.65	0.52	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
SKCM	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	5.34	9.02e-07	0.00443	0.67	0.52	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
SKCM	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-5.34	9.07e-07	0.00445	-0.9	-0.52	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
SKCM	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	5.34	9.08e-07	0.00446	0.7	0.52	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
SKCM	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	5.33	9.22e-07	0.00452	0.64	0.52	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	5.33	9.22e-07	0.00452	0.64	0.52	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
SKCM	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.33	9.22e-07	0.00452	0.63	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
SKCM	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	5.33	9.28e-07	0.00454	0.56	0.52	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
SKCM	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	5.32	9.75e-07	0.00473	0.71	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
SKCM	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	5.32	9.75e-07	0.00473	0.71	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
SKCM	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	5.32	9.76e-07	0.00473	0.75	0.52	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
SKCM	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	5.32	9.8e-07	0.00474	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
SKCM	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	5.32	9.81e-07	0.00474	0.56	0.52	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
SKCM	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	5.31	9.86e-07	0.00476	0.59	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	5.31	9.86e-07	0.00476	0.59	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	5.31	9.95e-07	0.0048	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	5.31	9.95e-07	0.0048	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
SKCM	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-5.31	9.96e-07	0.0048	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
SKCM	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-5.31	9.97e-07	0.00481	-0.63	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
SKCM	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-5.31	9.97e-07	0.00481	-0.63	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
SKCM	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-5.31	1e-06	0.00484	-0.71	-0.52	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-5.31	1e-06	0.00484	-0.71	-0.52	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
SKCM	cis	rs7104764	0.879	rs511744	ENSG00000277290.1	RP11-326C3.16	-5.31	1.01e-06	0.00486	-0.47	-0.52	Menarche (age at onset);	chr11:219089	chr11:243099~243483:-
SKCM	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-5.31	1.01e-06	0.00487	-0.67	-0.52	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
SKCM	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	5.31	1.02e-06	0.00493	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	5.31	1.02e-06	0.00493	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	5.31	1.02e-06	0.00493	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	5.31	1.02e-06	0.00493	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
SKCM	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-5.3	1.05e-06	0.00504	-0.81	-0.51	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
SKCM	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-5.3	1.06e-06	0.00506	-0.57	-0.51	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
SKCM	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-5.29	1.07e-06	0.00507	-0.69	-0.51	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
SKCM	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-5.29	1.07e-06	0.00507	-0.69	-0.51	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
SKCM	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.29	1.07e-06	0.00507	0.62	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
SKCM	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-5.29	1.09e-06	0.0051	-0.72	-0.51	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
SKCM	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-5.28	1.14e-06	0.0053	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-5.28	1.14e-06	0.0053	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
SKCM	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	5.28	1.15e-06	0.0053	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
SKCM	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	5.28	1.16e-06	0.00532	0.58	0.51	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
SKCM	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
SKCM	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	5.27	1.17e-06	0.00536	1.02	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
SKCM	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	5.27	1.19e-06	0.00545	0.68	0.51	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	5.27	1.19e-06	0.00545	0.68	0.51	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
SKCM	cis	rs8062405	0.757	rs34835	ENSG00000259982.1	CDC37P1	5.27	1.19e-06	0.00546	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28487970	chr16:28700294~28701540:-
SKCM	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	5.26	1.22e-06	0.00555	0.67	0.51	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
SKCM	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-5.26	1.22e-06	0.00555	-0.67	-0.51	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
SKCM	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	5.26	1.23e-06	0.00557	0.61	0.51	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
SKCM	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-5.26	1.25e-06	0.00563	-0.71	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
SKCM	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	5.26	1.25e-06	0.00565	0.66	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
SKCM	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	5.25	1.27e-06	0.00571	0.64	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-5.25	1.27e-06	0.00571	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
SKCM	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-5.25	1.29e-06	0.00577	-0.66	-0.51	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	5.25	1.29e-06	0.00577	0.66	0.51	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
SKCM	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	5.24	1.31e-06	0.00583	0.56	0.51	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
SKCM	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	5.24	1.31e-06	0.00585	0.63	0.51	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
SKCM	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	5.24	1.32e-06	0.00588	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
SKCM	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-5.24	1.32e-06	0.00589	-0.46	-0.51	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
SKCM	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-5.24	1.33e-06	0.00592	-0.67	-0.51	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
SKCM	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	5.24	1.33e-06	0.00594	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	5.24	1.33e-06	0.00594	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	5.24	1.33e-06	0.00594	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
SKCM	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-5.24	1.33e-06	0.00594	-0.72	-0.51	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
SKCM	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-5.23	1.4e-06	0.00618	-0.52	-0.51	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
SKCM	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	5.23	1.4e-06	0.00619	0.66	0.51	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	5.23	1.4e-06	0.00619	0.66	0.51	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
SKCM	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	5.23	1.41e-06	0.00623	0.7	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
SKCM	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	5.22	1.42e-06	0.00626	0.58	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
SKCM	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-5.22	1.42e-06	0.00628	-0.61	-0.51	Migraine;	chr4:56937339	chr4:56960927~56961373:-
SKCM	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-5.22	1.42e-06	0.00628	-0.61	-0.51	Migraine;	chr4:56940917	chr4:56960927~56961373:-
SKCM	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-5.22	1.42e-06	0.00628	-0.61	-0.51	Migraine;	chr4:56943905	chr4:56960927~56961373:-
SKCM	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-5.22	1.42e-06	0.00628	-0.61	-0.51	Migraine;	chr4:56950140	chr4:56960927~56961373:-
SKCM	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-5.22	1.42e-06	0.00629	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-5.22	1.42e-06	0.00629	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	5.22	1.42e-06	0.00629	0.58	0.51	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
SKCM	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	5.22	1.42e-06	0.00629	0.56	0.51	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
SKCM	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-5.22	1.43e-06	0.00632	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
SKCM	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-5.22	1.44e-06	0.00634	-0.6	-0.51	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
SKCM	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-5.22	1.44e-06	0.00636	-0.63	-0.51	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
SKCM	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-5.22	1.46e-06	0.00637	-0.67	-0.51	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
SKCM	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	5.21	1.47e-06	0.00637	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	5.21	1.47e-06	0.00637	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	5.21	1.47e-06	0.00637	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	5.21	1.47e-06	0.00637	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
SKCM	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	5.21	1.48e-06	0.00639	0.61	0.51	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	5.21	1.48e-06	0.00639	0.61	0.51	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
SKCM	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-5.21	1.48e-06	0.00639	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
SKCM	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-5.21	1.49e-06	0.00644	-0.55	-0.51	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-5.21	1.49e-06	0.00644	-0.55	-0.51	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
SKCM	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	5.21	1.51e-06	0.00648	0.66	0.51	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	5.21	1.51e-06	0.00648	0.66	0.51	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
SKCM	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	5.21	1.52e-06	0.00653	0.58	0.51	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
SKCM	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-5.21	1.53e-06	0.00655	-0.66	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	5.21	1.53e-06	0.00655	0.66	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	5.2	1.54e-06	0.00661	0.59	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	5.2	1.57e-06	0.00672	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
SKCM	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	5.2	1.57e-06	0.00674	0.61	0.51	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
SKCM	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	5.2	1.58e-06	0.00674	0.66	0.51	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
SKCM	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	5.2	1.58e-06	0.00675	0.56	0.51	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
SKCM	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-5.2	1.58e-06	0.00675	-0.63	-0.51	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
SKCM	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	5.2	1.58e-06	0.00675	0.55	0.51	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
SKCM	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	5.19	1.6e-06	0.00677	0.64	0.51	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
SKCM	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-5.19	1.6e-06	0.00677	-0.65	-0.51	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
SKCM	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-5.19	1.63e-06	0.00677	-1.03	-0.51	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
SKCM	cis	rs10847980	0.623	rs7955367	ENSG00000256092.2	RP13-942N8.1	5.19	1.63e-06	0.00677	1.03	0.51	Adiponectin levels;	chr12:123344245	chr12:123363868~123366113:+
SKCM	cis	rs10847980	0.623	rs28613486	ENSG00000256092.2	RP13-942N8.1	5.19	1.63e-06	0.00677	1.03	0.51	Adiponectin levels;	chr12:123382721	chr12:123363868~123366113:+
SKCM	cis	rs10847980	0.623	rs28681105	ENSG00000256092.2	RP13-942N8.1	5.19	1.63e-06	0.00677	1.03	0.51	Adiponectin levels;	chr12:123390978	chr12:123363868~123366113:+
SKCM	cis	rs10847980	0.623	rs28501453	ENSG00000256092.2	RP13-942N8.1	5.19	1.63e-06	0.00677	1.03	0.51	Adiponectin levels;	chr12:123392765	chr12:123363868~123366113:+
SKCM	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	5.19	1.66e-06	0.00687	0.6	0.51	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
SKCM	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	5.18	1.68e-06	0.00695	0.65	0.51	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
SKCM	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-5.18	1.7e-06	0.00704	-0.71	-0.51	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
SKCM	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-5.18	1.72e-06	0.00711	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
SKCM	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-5.17	1.75e-06	0.00722	-0.63	-0.51	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-5.17	1.75e-06	0.00722	-0.63	-0.51	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
SKCM	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	5.16	1.8e-06	0.00739	0.58	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	5.16	1.8e-06	0.0074	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	5.16	1.8e-06	0.0074	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	5.16	1.81e-06	0.00742	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
SKCM	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	5.16	1.82e-06	0.00748	0.47	0.5	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
SKCM	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.16	1.85e-06	0.00757	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
SKCM	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-5.16	1.85e-06	0.00757	-0.57	-0.5	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
SKCM	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-5.15	1.92e-06	0.00782	-0.67	-0.5	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
SKCM	cis	rs6946494	0.568	rs6973446	ENSG00000231794.4	AC009542.2	5.15	1.93e-06	0.00786	0.67	0.5	Visceral adipose tissue adjusted for BMI;	chr7:135801497	chr7:135198401~135209837:+
SKCM	cis	rs6946494	0.568	rs4728366	ENSG00000231794.4	AC009542.2	5.15	1.93e-06	0.00786	0.67	0.5	Visceral adipose tissue adjusted for BMI;	chr7:135801673	chr7:135198401~135209837:+
SKCM	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	5.14	1.96e-06	0.00796	0.52	0.5	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
SKCM	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-5.14	1.97e-06	0.008	-0.6	-0.5	Migraine;	chr4:56956882	chr4:56960927~56961373:-
SKCM	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-5.14	1.97e-06	0.008	-0.6	-0.5	Migraine;	chr4:56957291	chr4:56960927~56961373:-
SKCM	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-5.14	1.98e-06	0.00803	-0.66	-0.5	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
SKCM	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	5.14	2e-06	0.0081	0.63	0.5	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
SKCM	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5.14	2.01e-06	0.00813	-0.65	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	5.14	2.01e-06	0.00813	0.65	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	5.14	2.01e-06	0.00813	0.65	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
SKCM	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-5.14	2.02e-06	0.00817	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	5.14	2.02e-06	0.00818	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
SKCM	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	5.13	2.03e-06	0.0082	0.65	0.5	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
SKCM	cis	rs7174755	0.672	rs11631719	ENSG00000260657.2	RP11-315D16.4	5.13	2.03e-06	0.0082	0.71	0.5	Major depressive disorder;	chr15:68261576	chr15:68267792~68277994:-
SKCM	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	5.13	2.04e-06	0.00823	0.55	0.5	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
SKCM	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	5.13	2.07e-06	0.00833	0.65	0.5	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-5.13	2.1e-06	0.00843	-0.65	-0.5	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs1870124	ENSG00000261338.2	RP11-378A13.1	5.13	2.1e-06	0.00843	0.65	0.5	Colorectal cancer;	chr2:218323017	chr2:218255319~218257366:+
SKCM	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.12	2.11e-06	0.00846	-0.56	-0.5	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
SKCM	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	5.12	2.14e-06	0.00857	0.62	0.5	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
SKCM	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-5.12	2.14e-06	0.00857	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
SKCM	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-5.12	2.15e-06	0.00861	-0.64	-0.5	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
SKCM	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-5.12	2.16e-06	0.00865	-0.69	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
SKCM	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5.12	2.16e-06	0.00866	0.63	0.5	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
SKCM	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-5.12	2.16e-06	0.00866	-0.65	-0.5	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
SKCM	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-5.12	2.17e-06	0.00868	-0.57	-0.5	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
SKCM	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	5.11	2.21e-06	0.00882	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
SKCM	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-5.11	2.23e-06	0.00887	-0.7	-0.5	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	5.11	2.24e-06	0.00888	0.57	0.5	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
SKCM	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-5.11	2.25e-06	0.00892	-0.62	-0.5	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
SKCM	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-5.11	2.26e-06	0.00894	-0.47	-0.5	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
SKCM	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-5.11	2.28e-06	0.00901	-0.75	-0.5	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
SKCM	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-5.11	2.28e-06	0.00901	-0.75	-0.5	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
SKCM	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	5.1	2.29e-06	0.00902	0.53	0.5	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
SKCM	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-5.1	2.29e-06	0.00902	-0.61	-0.5	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
SKCM	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	5.1	2.29e-06	0.00904	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	5.1	2.29e-06	0.00904	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	5.1	2.29e-06	0.00904	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
SKCM	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-5.09	2.38e-06	0.00936	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-5.09	2.38e-06	0.00936	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-5.09	2.38e-06	0.00936	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
SKCM	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-5.09	2.4e-06	0.00941	-0.55	-0.5	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-5.09	2.4e-06	0.00941	-0.55	-0.5	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-5.09	2.4e-06	0.00941	-0.55	-0.5	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-5.09	2.4e-06	0.00941	-0.55	-0.5	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	5.09	2.4e-06	0.00941	0.55	0.5	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
SKCM	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	5.09	2.41e-06	0.00944	0.65	0.5	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
SKCM	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-5.09	2.42e-06	0.00945	-0.59	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
SKCM	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-5.09	2.43e-06	0.00947	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-5.09	2.43e-06	0.00947	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-5.09	2.43e-06	0.00947	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-5.09	2.43e-06	0.00947	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
SKCM	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	5.09	2.44e-06	0.00949	0.52	0.5	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
SKCM	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	5.09	2.44e-06	0.0095	0.66	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
SKCM	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-5.09	2.46e-06	0.00957	-0.63	-0.5	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
SKCM	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	5.09	2.46e-06	0.00957	0.59	0.5	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	5.09	2.46e-06	0.00957	0.59	0.5	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
SKCM	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	5.09	2.46e-06	0.00958	0.56	0.5	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
SKCM	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-5.08	2.5e-06	0.0097	-0.64	-0.5	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
SKCM	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-5.08	2.5e-06	0.00971	-0.61	-0.5	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
SKCM	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	5.08	2.51e-06	0.00974	0.64	0.5	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	5.08	2.51e-06	0.00974	0.64	0.5	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
SKCM	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
SKCM	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
SKCM	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	5.08	2.54e-06	0.00983	0.57	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
SKCM	cis	rs916888	0.558	rs199521	ENSG00000214401.4	KANSL1-AS1	-5.08	2.55e-06	0.00989	-0.71	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:46193576~46196723:+
SKCM	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-5.08	2.56e-06	0.0099	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	5.08	2.56e-06	0.0099	0.58	0.5	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	5.08	2.56e-06	0.0099	0.58	0.5	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
SKCM	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	5.07	2.58e-06	0.00995	0.64	0.5	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
SKCM	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.07	2.58e-06	0.00996	0.59	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
SKCM	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.07	2.58e-06	0.00996	0.59	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
SKCM	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.07	2.58e-06	0.00996	0.59	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
SKCM	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-5.07	2.58e-06	0.00996	-0.56	-0.5	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
SKCM	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-5.07	2.58e-06	0.00997	-0.7	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
SKCM	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	5.07	2.59e-06	0.00999	0.63	0.5	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
SKCM	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-5.07	2.59e-06	0.00999	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
SKCM	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-5.07	2.61e-06	0.0101	-0.63	-0.5	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
SKCM	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	5.07	2.63e-06	0.0101	0.59	0.5	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	5.07	2.63e-06	0.0101	0.59	0.5	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
SKCM	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	5.07	2.64e-06	0.0102	0.64	0.5	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
SKCM	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	5.07	2.64e-06	0.0102	0.8	0.5	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-5.06	2.7e-06	0.0103	-0.63	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
SKCM	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	5.06	2.7e-06	0.0103	0.58	0.5	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
SKCM	cis	rs61041384	0.661	rs4474478	ENSG00000256092.2	RP13-942N8.1	-5.06	2.7e-06	0.0103	-1.12	-0.5	Schizophrenia;	chr12:123249821	chr12:123363868~123366113:+
SKCM	cis	rs61041384	0.661	rs4759411	ENSG00000256092.2	RP13-942N8.1	-5.06	2.7e-06	0.0103	-1.12	-0.5	Schizophrenia;	chr12:123256296	chr12:123363868~123366113:+
SKCM	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	5.06	2.71e-06	0.0104	0.63	0.5	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
SKCM	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	5.06	2.73e-06	0.0104	0.64	0.5	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
SKCM	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	5.06	2.73e-06	0.0104	0.66	0.5	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	5.06	2.75e-06	0.0105	0.61	0.5	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
SKCM	cis	rs992157	0.932	rs1870125	ENSG00000261338.2	RP11-378A13.1	5.06	2.77e-06	0.0106	0.65	0.5	Colorectal cancer;	chr2:218323178	chr2:218255319~218257366:+
SKCM	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-5.05	2.86e-06	0.0108	-0.6	-0.5	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
SKCM	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-5.05	2.89e-06	0.0109	-0.61	-0.5	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
SKCM	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	5.04	2.9e-06	0.011	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
SKCM	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-5.04	2.94e-06	0.0111	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.04	2.94e-06	0.0111	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
SKCM	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.04	2.96e-06	0.0111	0.74	0.5	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
SKCM	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-5.04	2.96e-06	0.0111	-0.56	-0.5	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-5.04	2.96e-06	0.0111	-0.56	-0.5	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-5.04	2.96e-06	0.0111	-0.56	-0.5	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
SKCM	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	5.03	3.01e-06	0.0113	0.79	0.5	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
SKCM	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	5.03	3.01e-06	0.0113	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
SKCM	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	5.03	3.03e-06	0.0114	0.61	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
SKCM	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	5.03	3.03e-06	0.0114	0.62	0.5	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
SKCM	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-5.03	3.06e-06	0.0115	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
SKCM	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-5.03	3.09e-06	0.0115	-0.64	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
SKCM	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-5.03	3.09e-06	0.0115	-0.64	-0.49	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
SKCM	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-5.03	3.09e-06	0.0115	-0.64	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
SKCM	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	5.03	3.09e-06	0.0115	0.7	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
SKCM	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	5.03	3.1e-06	0.0115	0.6	0.49	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-5.03	3.1e-06	0.0115	-0.6	-0.49	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
SKCM	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	5.03	3.1e-06	0.0116	0.45	0.49	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
SKCM	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	5.03	3.11e-06	0.0116	0.67	0.49	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
SKCM	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	5.03	3.12e-06	0.0116	0.64	0.49	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
SKCM	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.02	3.12e-06	0.0116	0.65	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
SKCM	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-5.02	3.15e-06	0.0117	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
SKCM	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-5.02	3.16e-06	0.0117	-0.46	-0.49	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
SKCM	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-5.02	3.17e-06	0.0117	-0.6	-0.49	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
SKCM	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-5.02	3.17e-06	0.0117	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
SKCM	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-5.02	3.17e-06	0.0118	-0.63	-0.49	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
SKCM	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-5.02	3.21e-06	0.0119	-0.66	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
SKCM	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
SKCM	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-5.01	3.26e-06	0.012	-0.55	-0.49	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
SKCM	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	5.01	3.27e-06	0.0121	0.79	0.49	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
SKCM	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	5.01	3.27e-06	0.0121	0.79	0.49	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
SKCM	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	5.01	3.27e-06	0.0121	0.79	0.49	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
SKCM	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.01	3.27e-06	0.0121	0.79	0.49	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
SKCM	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-5.01	3.27e-06	0.0121	-0.65	-0.49	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
SKCM	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-5.01	3.29e-06	0.0121	-0.6	-0.49	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
SKCM	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-5.01	3.37e-06	0.0124	-0.78	-0.49	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
SKCM	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-5	3.41e-06	0.0125	-0.5	-0.49	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
SKCM	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	5	3.45e-06	0.0125	0.64	0.49	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
SKCM	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	5	3.45e-06	0.0125	0.6	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
SKCM	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-5	3.46e-06	0.0125	-0.64	-0.49	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
SKCM	cis	rs2324229	0.797	rs1180237	ENSG00000219951.4	RP11-378G13.2	-5	3.47e-06	0.0126	-0.5	-0.49	Platelet-derived growth factor BB levels;	chr6:83234209	chr6:83392416~83393409:+
SKCM	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-5	3.48e-06	0.0126	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-5	3.48e-06	0.0126	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-5	3.48e-06	0.0126	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-5	3.48e-06	0.0126	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
SKCM	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	5	3.48e-06	0.0126	0.46	0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	5	3.48e-06	0.0126	0.46	0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-5	3.48e-06	0.0126	-0.46	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
SKCM	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	5	3.51e-06	0.0127	0.63	0.49	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
SKCM	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-4.99	3.53e-06	0.0127	-0.64	-0.49	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
SKCM	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-4.99	3.53e-06	0.0127	-0.64	-0.49	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
SKCM	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-4.99	3.53e-06	0.0127	-0.64	-0.49	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
SKCM	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	4.99	3.53e-06	0.0128	0.64	0.49	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
SKCM	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	4.99	3.54e-06	0.0128	0.62	0.49	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-4.99	3.59e-06	0.013	-0.61	-0.49	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
SKCM	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-4.99	3.61e-06	0.013	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-4.99	3.61e-06	0.013	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
SKCM	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	4.99	3.62e-06	0.0131	0.59	0.49	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	4.99	3.62e-06	0.0131	0.59	0.49	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	4.99	3.62e-06	0.0131	0.59	0.49	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
SKCM	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	4.99	3.62e-06	0.0131	0.57	0.49	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
SKCM	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-4.99	3.65e-06	0.0131	-0.64	-0.49	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
SKCM	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	4.98	3.71e-06	0.0133	0.57	0.49	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
SKCM	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	4.98	3.73e-06	0.0134	0.52	0.49	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
SKCM	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-4.98	3.75e-06	0.0134	-0.74	-0.49	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
SKCM	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	4.98	3.75e-06	0.0135	0.61	0.49	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
SKCM	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	4.98	3.75e-06	0.0135	0.54	0.49	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
SKCM	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-4.97	3.81e-06	0.0137	-0.61	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
SKCM	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	4.97	3.83e-06	0.0137	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
SKCM	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-4.97	3.83e-06	0.0137	-0.62	-0.49	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
SKCM	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
SKCM	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	4.97	3.84e-06	0.0137	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
SKCM	cis	rs2392780	0.576	rs12549518	ENSG00000224722.3	RP11-255B23.1	-4.97	3.87e-06	0.0138	-0.53	-0.49	Breast cancer (early onset);	chr8:127297346	chr8:127086263~127087510:-
SKCM	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-4.97	3.87e-06	0.0138	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
SKCM	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	4.97	3.92e-06	0.0139	0.45	0.49	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
SKCM	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-4.97	3.95e-06	0.014	-0.53	-0.49	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
SKCM	cis	rs992157	0.764	rs10193189	ENSG00000261338.2	RP11-378A13.1	4.96	3.97e-06	0.0141	0.65	0.49	Colorectal cancer;	chr2:218322880	chr2:218255319~218257366:+
SKCM	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	4.96	3.98e-06	0.0141	0.48	0.49	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
SKCM	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-4.96	3.99e-06	0.0141	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-4.96	3.99e-06	0.0141	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-4.96	3.99e-06	0.0141	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
SKCM	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-4.96	3.99e-06	0.0141	-0.54	-0.49	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-4.96	3.99e-06	0.0141	-0.54	-0.49	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
SKCM	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	4.96	4e-06	0.0142	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
SKCM	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	4.96	4e-06	0.0142	0.45	0.49	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
SKCM	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-4.96	4.01e-06	0.0142	-0.58	-0.49	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
SKCM	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
SKCM	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
SKCM	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
SKCM	cis	rs2665103	0.632	rs3902959	ENSG00000259429.4	UBE2Q2P2	-4.96	4.03e-06	0.0142	-0.5	-0.49	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82355142~82420075:+
SKCM	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-4.96	4.06e-06	0.0143	-0.59	-0.49	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-4.96	4.06e-06	0.0143	-0.59	-0.49	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-4.96	4.06e-06	0.0143	-0.59	-0.49	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-4.96	4.06e-06	0.0143	-0.59	-0.49	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
SKCM	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	4.96	4.06e-06	0.0143	0.57	0.49	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
SKCM	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	4.96	4.06e-06	0.0143	0.69	0.49	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
SKCM	cis	rs6946494	0.568	rs9656462	ENSG00000231794.4	AC009542.2	4.96	4.07e-06	0.0143	0.65	0.49	Visceral adipose tissue adjusted for BMI;	chr7:135800304	chr7:135198401~135209837:+
SKCM	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-4.96	4.11e-06	0.0144	-0.63	-0.49	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
SKCM	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	4.96	4.11e-06	0.0144	0.66	0.49	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	4.96	4.11e-06	0.0144	0.66	0.49	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
SKCM	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-4.96	4.11e-06	0.0144	-0.66	-0.49	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
SKCM	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-4.96	4.11e-06	0.0144	-0.52	-0.49	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-4.96	4.11e-06	0.0144	-0.52	-0.49	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-4.96	4.11e-06	0.0144	-0.52	-0.49	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
SKCM	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-4.95	4.13e-06	0.0145	-0.64	-0.49	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
SKCM	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-4.95	4.13e-06	0.0145	-0.64	-0.49	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
SKCM	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-4.95	4.13e-06	0.0145	-0.64	-0.49	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
SKCM	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-4.95	4.14e-06	0.0145	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-4.95	4.14e-06	0.0145	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
SKCM	cis	rs7546668	0.652	rs12691551	ENSG00000272510.1	RP4-680D5.8	4.95	4.16e-06	0.0145	0.55	0.49	Glomerular filtration rate (creatinine);	chr1:15581413	chr1:15565611~15565956:-
SKCM	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.17e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.17e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.17e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.17e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.17e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
SKCM	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-4.95	4.18e-06	0.0146	-0.44	-0.49	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
SKCM	cis	rs7563124	1	rs7563124	ENSG00000243389.1	AC012442.5	-4.95	4.18e-06	0.0146	-0.82	-0.49	Hematocrit;	chr2:113207621	chr2:112589040~112614431:+
SKCM	cis	rs7560180	1	rs7560180	ENSG00000243389.1	AC012442.5	-4.95	4.18e-06	0.0146	-0.82	-0.49	Hemoglobin concentration;	chr2:113207623	chr2:112589040~112614431:+
SKCM	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-4.95	4.19e-06	0.0146	-0.52	-0.49	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
SKCM	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-4.95	4.2e-06	0.0146	-0.61	-0.49	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
SKCM	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-4.95	4.2e-06	0.0146	-0.61	-0.49	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
SKCM	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-4.95	4.2e-06	0.0146	-0.61	-0.49	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
SKCM	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-4.95	4.2e-06	0.0146	-0.61	-0.49	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
SKCM	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	4.95	4.2e-06	0.0146	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
SKCM	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-4.95	4.21e-06	0.0147	-0.6	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
SKCM	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-4.95	4.21e-06	0.0147	-0.6	-0.49	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
SKCM	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-4.95	4.21e-06	0.0147	-0.6	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
SKCM	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-4.95	4.21e-06	0.0147	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
SKCM	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	4.95	4.21e-06	0.0147	0.67	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
SKCM	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-4.95	4.23e-06	0.0147	-0.59	-0.49	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
SKCM	cis	rs867371	0.82	rs7164362	ENSG00000259429.4	UBE2Q2P2	-4.95	4.25e-06	0.0147	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82355142~82420075:+
SKCM	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-4.95	4.25e-06	0.0147	-0.45	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
SKCM	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	4.94	4.3e-06	0.0149	0.58	0.49	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	4.94	4.36e-06	0.015	0.61	0.49	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	4.94	4.36e-06	0.015	0.61	0.49	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	4.94	4.36e-06	0.015	0.61	0.49	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
SKCM	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	4.94	4.36e-06	0.015	0.63	0.49	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	4.94	4.36e-06	0.015	0.63	0.49	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	4.94	4.36e-06	0.015	0.63	0.49	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
SKCM	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	4.94	4.39e-06	0.0151	0.65	0.49	Depression;	chr6:28251492	chr6:28176188~28176674:+
SKCM	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	4.94	4.4e-06	0.0151	0.63	0.49	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-4.94	4.4e-06	0.0151	-0.6	-0.49	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	4.94	4.4e-06	0.0151	0.6	0.49	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
SKCM	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-4.94	4.43e-06	0.0152	-0.61	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
SKCM	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	4.93	4.45e-06	0.0153	0.63	0.49	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
SKCM	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-4.93	4.45e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-4.93	4.5e-06	0.0153	-0.57	-0.49	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
SKCM	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-4.93	4.53e-06	0.0154	-0.63	-0.49	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
SKCM	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-4.93	4.56e-06	0.0155	-0.74	-0.49	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
SKCM	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	4.93	4.56e-06	0.0155	0.63	0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
SKCM	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-4.93	4.61e-06	0.0156	-0.49	-0.49	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
SKCM	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-4.92	4.66e-06	0.0157	-0.56	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
SKCM	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	4.92	4.67e-06	0.0158	0.61	0.49	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
SKCM	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-4.92	4.68e-06	0.0158	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-4.92	4.69e-06	0.0158	-0.53	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
SKCM	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-4.92	4.7e-06	0.0158	-0.54	-0.49	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
SKCM	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-4.92	4.71e-06	0.0158	-0.57	-0.49	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	4.92	4.77e-06	0.016	0.55	0.49	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
SKCM	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	4.92	4.78e-06	0.016	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
SKCM	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-4.92	4.8e-06	0.0161	-0.56	-0.49	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-4.91	4.82e-06	0.0161	-0.61	-0.49	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
SKCM	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-4.91	4.83e-06	0.0162	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
SKCM	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	4.91	4.84e-06	0.0162	0.54	0.49	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	4.91	4.84e-06	0.0162	0.54	0.49	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
SKCM	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-4.91	4.84e-06	0.0162	-0.6	-0.49	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
SKCM	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	4.91	4.89e-06	0.0163	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
SKCM	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-4.91	4.9e-06	0.0164	-0.62	-0.49	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
SKCM	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	4.91	4.9e-06	0.0164	0.64	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
SKCM	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	4.91	4.92e-06	0.0164	0.61	0.49	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
SKCM	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-4.91	4.93e-06	0.0165	-0.61	-0.49	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
SKCM	cis	rs11638815	0.859	rs12437785	ENSG00000255769.6	GOLGA2P10	4.91	4.94e-06	0.0165	0.66	0.49	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82718605	chr15:82472993~82513950:-
SKCM	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	4.91	4.94e-06	0.0165	0.55	0.49	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
SKCM	cis	rs11638815	0.954	rs783544	ENSG00000259429.4	UBE2Q2P2	-4.91	4.94e-06	0.0165	-0.51	-0.49	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82571543	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.859	rs12437785	ENSG00000259429.4	UBE2Q2P2	4.91	4.98e-06	0.0166	0.5	0.49	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82718605	chr15:82355142~82420075:+
SKCM	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	4.9	5.04e-06	0.0168	0.71	0.49	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
SKCM	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	4.9	5.05e-06	0.0168	0.62	0.49	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
SKCM	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-4.9	5.05e-06	0.0168	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-4.9	5.05e-06	0.0168	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-4.9	5.05e-06	0.0168	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-4.9	5.05e-06	0.0168	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
SKCM	cis	rs1029738	0.615	rs717624	ENSG00000228649.7	AC005682.5	4.9	5.05e-06	0.0168	0.65	0.49	Fibrinogen levels;	chr7:22854868	chr7:22854178~22861579:+
SKCM	cis	rs1029738	0.615	rs3757447	ENSG00000228649.7	AC005682.5	4.9	5.05e-06	0.0168	0.65	0.49	Fibrinogen levels;	chr7:22855116	chr7:22854178~22861579:+
SKCM	cis	rs1029738	0.659	rs1608553	ENSG00000228649.7	AC005682.5	4.9	5.05e-06	0.0168	0.65	0.49	Fibrinogen levels;	chr7:22856612	chr7:22854178~22861579:+
SKCM	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
SKCM	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-4.9	5.12e-06	0.017	-0.54	-0.49	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
SKCM	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-4.9	5.14e-06	0.017	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
SKCM	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-4.9	5.16e-06	0.017	-0.54	-0.48	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-4.9	5.16e-06	0.017	-0.54	-0.48	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-4.9	5.16e-06	0.017	-0.54	-0.48	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-4.9	5.16e-06	0.017	-0.54	-0.48	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
SKCM	cis	rs11638815	0.871	rs8033106	ENSG00000259429.4	UBE2Q2P2	-4.89	5.2e-06	0.0172	-0.5	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82630710	chr15:82355142~82420075:+
SKCM	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	4.89	5.22e-06	0.0172	0.5	0.48	Breast cancer;	chr11:750849	chr11:779617~780755:+
SKCM	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	4.89	5.24e-06	0.0173	0.6	0.48	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
SKCM	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-4.89	5.25e-06	0.0173	-0.68	-0.48	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
SKCM	cis	rs2211698	0.764	rs79698117	ENSG00000273102.1	AP000569.9	-4.89	5.28e-06	0.0174	-0.81	-0.48	Cancer;	chr21:34519264	chr21:33967101~33968573:-
SKCM	cis	rs2211698	0.764	rs75083220	ENSG00000273102.1	AP000569.9	-4.89	5.28e-06	0.0174	-0.81	-0.48	Cancer;	chr21:34520833	chr21:33967101~33968573:-
SKCM	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-4.89	5.32e-06	0.0175	-0.6	-0.48	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
SKCM	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-4.89	5.39e-06	0.0177	-0.54	-0.48	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
SKCM	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-4.88	5.41e-06	0.0177	-0.73	-0.48	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
SKCM	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-4.88	5.41e-06	0.0177	-0.73	-0.48	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
SKCM	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	4.88	5.41e-06	0.0178	0.62	0.48	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
SKCM	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-4.88	5.44e-06	0.0178	-0.59	-0.48	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-4.88	5.46e-06	0.0179	-0.57	-0.48	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
SKCM	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-4.88	5.48e-06	0.0179	-0.57	-0.48	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
SKCM	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-4.88	5.5e-06	0.018	-0.64	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
SKCM	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	4.88	5.5e-06	0.018	0.59	0.48	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
SKCM	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	4.88	5.53e-06	0.0181	0.57	0.48	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
SKCM	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-4.88	5.54e-06	0.0181	-0.59	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
SKCM	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	4.88	5.54e-06	0.0181	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
SKCM	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	4.88	5.56e-06	0.0182	0.6	0.48	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
SKCM	cis	rs11638815	0.859	rs11631182	ENSG00000255769.6	GOLGA2P10	4.88	5.57e-06	0.0182	0.67	0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725328	chr15:82472993~82513950:-
SKCM	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-4.87	5.62e-06	0.0183	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
SKCM	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-4.87	5.62e-06	0.0183	-0.78	-0.48	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
SKCM	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	4.87	5.62e-06	0.0183	0.47	0.48	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
SKCM	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	4.87	5.63e-06	0.0183	0.62	0.48	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
SKCM	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	4.87	5.66e-06	0.0184	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
SKCM	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	4.87	5.67e-06	0.0184	0.58	0.48	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
SKCM	cis	rs7174755	0.924	rs10444805	ENSG00000260657.2	RP11-315D16.4	4.87	5.67e-06	0.0184	0.67	0.48	Major depressive disorder;	chr15:68297033	chr15:68267792~68277994:-
SKCM	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	4.87	5.76e-06	0.0186	0.52	0.48	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
SKCM	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	4.87	5.78e-06	0.0186	0.49	0.48	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
SKCM	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	4.87	5.78e-06	0.0186	0.49	0.48	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
SKCM	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-4.86	5.86e-06	0.0189	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-4.86	5.86e-06	0.0189	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-4.86	5.86e-06	0.0189	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-4.86	5.86e-06	0.0189	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
SKCM	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	4.86	5.87e-06	0.0189	0.66	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
SKCM	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	4.86	5.87e-06	0.0189	0.61	0.48	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
SKCM	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	4.86	5.88e-06	0.0189	0.57	0.48	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
SKCM	cis	rs1970584	0.737	rs1971603	ENSG00000261094.2	RP11-355O1.11	-4.86	5.89e-06	0.0189	-0.7	-0.48	Educational attainment;	chr9:123343835	chr9:122937623~122940333:+
SKCM	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-4.86	5.9e-06	0.0189	-0.56	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
SKCM	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-4.86	5.9e-06	0.0189	-0.56	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
SKCM	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-4.86	5.91e-06	0.019	-0.61	-0.48	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	4.86	5.91e-06	0.019	0.61	0.48	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
SKCM	cis	rs867371	0.614	rs1814739	ENSG00000259429.4	UBE2Q2P2	-4.86	5.94e-06	0.0191	-0.46	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82355142~82420075:+
SKCM	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	4.86	6.02e-06	0.0193	0.61	0.48	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
SKCM	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-4.86	6.03e-06	0.0193	-0.66	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
SKCM	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-4.86	6.05e-06	0.0194	-0.59	-0.48	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
SKCM	cis	rs867371	0.502	rs8025964	ENSG00000259429.4	UBE2Q2P2	-4.85	6.24e-06	0.0199	-0.49	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82355142~82420075:+
SKCM	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	4.85	6.27e-06	0.02	0.55	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
SKCM	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-4.84	6.37e-06	0.0203	-0.6	-0.48	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
SKCM	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	4.84	6.38e-06	0.0203	0.48	0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
SKCM	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	4.84	6.4e-06	0.0203	0.53	0.48	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
SKCM	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	4.84	6.43e-06	0.0204	0.61	0.48	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
SKCM	cis	rs1497406	0.744	rs4537547	ENSG00000235084.3	CHCHD2P6	4.84	6.48e-06	0.0205	0.54	0.48	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16184303	chr1:15604597~15605043:+
SKCM	cis	rs1497406	0.744	rs12057175	ENSG00000235084.3	CHCHD2P6	-4.84	6.48e-06	0.0205	-0.54	-0.48	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181880	chr1:15604597~15605043:+
SKCM	cis	rs1497406	0.744	rs12057222	ENSG00000235084.3	CHCHD2P6	-4.84	6.48e-06	0.0205	-0.54	-0.48	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16182039	chr1:15604597~15605043:+
SKCM	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-4.83	6.56e-06	0.0207	-0.54	-0.48	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
SKCM	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	4.83	6.6e-06	0.0208	0.56	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
SKCM	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	4.83	6.61e-06	0.0209	0.6	0.48	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	4.83	6.66e-06	0.021	0.59	0.48	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
SKCM	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	4.83	6.68e-06	0.021	0.59	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
SKCM	cis	rs1930961	0.702	rs9624843	ENSG00000100058.11	CRYBB2P1	4.83	6.69e-06	0.021	1.37	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25499395	chr22:25448105~25520854:+
SKCM	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	4.83	6.69e-06	0.0211	0.54	0.48	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
SKCM	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-4.83	6.69e-06	0.0211	-0.52	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
SKCM	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-4.83	6.73e-06	0.0211	-0.44	-0.48	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
SKCM	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-4.83	6.75e-06	0.0212	-0.56	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
SKCM	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	4.83	6.77e-06	0.0213	0.65	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
SKCM	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	4.82	6.82e-06	0.0214	0.68	0.48	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	4.82	6.82e-06	0.0214	0.68	0.48	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	4.82	6.82e-06	0.0214	0.68	0.48	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	4.82	6.82e-06	0.0214	0.68	0.48	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	4.82	6.82e-06	0.0214	0.68	0.48	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
SKCM	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	4.82	6.82e-06	0.0214	0.62	0.48	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	4.82	6.82e-06	0.0214	0.62	0.48	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	4.82	6.82e-06	0.0214	0.62	0.48	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
SKCM	cis	rs1497406	0.744	rs4661718	ENSG00000235084.3	CHCHD2P6	-4.82	6.82e-06	0.0214	-0.54	-0.48	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16179413	chr1:15604597~15605043:+
SKCM	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-4.82	6.86e-06	0.0215	-0.75	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
SKCM	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-4.82	6.9e-06	0.0216	-0.67	-0.48	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-4.82	6.9e-06	0.0216	-0.67	-0.48	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-4.82	6.9e-06	0.0216	-0.67	-0.48	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-4.82	6.9e-06	0.0216	-0.67	-0.48	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
SKCM	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-4.82	6.92e-06	0.0216	-0.56	-0.48	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
SKCM	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-4.82	6.99e-06	0.0217	-0.78	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
SKCM	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-4.82	6.99e-06	0.0217	-0.78	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
SKCM	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	4.82	7.01e-06	0.0217	0.61	0.48	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	4.82	7.01e-06	0.0217	0.61	0.48	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	4.82	7.01e-06	0.0217	0.61	0.48	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
SKCM	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	4.81	7.09e-06	0.022	0.61	0.48	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
SKCM	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-4.81	7.1e-06	0.022	-0.57	-0.48	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
SKCM	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-4.81	7.1e-06	0.022	-0.65	-0.48	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-4.81	7.1e-06	0.022	-0.65	-0.48	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-4.81	7.1e-06	0.022	-0.65	-0.48	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
SKCM	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	4.81	7.11e-06	0.022	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
SKCM	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	4.81	7.13e-06	0.0221	0.6	0.48	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	4.81	7.13e-06	0.0221	0.6	0.48	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
SKCM	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	4.81	7.15e-06	0.0221	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
SKCM	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-4.81	7.17e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-4.81	7.17e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-4.81	7.17e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-4.81	7.17e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-4.81	7.17e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
SKCM	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-4.81	7.18e-06	0.0222	-0.54	-0.48	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
SKCM	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-4.81	7.2e-06	0.0222	-0.44	-0.48	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
SKCM	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-4.81	7.21e-06	0.0223	-0.62	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
SKCM	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	4.81	7.23e-06	0.0223	0.61	0.48	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
SKCM	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
SKCM	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	4.81	7.24e-06	0.0223	0.61	0.48	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
SKCM	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
SKCM	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	4.81	7.26e-06	0.0223	0.44	0.48	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
SKCM	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-4.81	7.27e-06	0.0224	-0.69	-0.48	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
SKCM	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-4.81	7.28e-06	0.0224	-0.51	-0.48	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
SKCM	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
SKCM	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
SKCM	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
SKCM	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
SKCM	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
SKCM	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
SKCM	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
SKCM	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
SKCM	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
SKCM	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	4.81	7.3e-06	0.0224	0.47	0.48	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
SKCM	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-4.81	7.3e-06	0.0224	-0.47	-0.48	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
SKCM	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	4.81	7.33e-06	0.0225	0.57	0.48	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
SKCM	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	4.8	7.38e-06	0.0226	0.6	0.48	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
SKCM	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	4.8	7.38e-06	0.0226	0.6	0.48	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
SKCM	cis	rs1119582	0.571	rs7703325	ENSG00000279118.1	RP11-517I3.2	-4.8	7.44e-06	0.0228	-0.72	-0.48	Select biomarker traits;	chr5:125863889	chr5:126496279~126498604:+
SKCM	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-4.8	7.47e-06	0.0228	-0.49	-0.48	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
SKCM	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-4.8	7.47e-06	0.0229	-0.57	-0.48	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
SKCM	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-4.8	7.48e-06	0.0229	-0.61	-0.48	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
SKCM	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	4.8	7.54e-06	0.023	0.57	0.48	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
SKCM	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-4.8	7.56e-06	0.0231	-0.61	-0.48	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
SKCM	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	4.8	7.59e-06	0.0232	0.54	0.48	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
SKCM	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-4.8	7.62e-06	0.0232	-0.62	-0.48	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
SKCM	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	4.79	7.67e-06	0.0234	0.63	0.48	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
SKCM	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-4.79	7.71e-06	0.0235	-0.53	-0.48	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
SKCM	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-4.79	7.73e-06	0.0235	-0.49	-0.48	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
SKCM	cis	rs12922040	0.651	rs35288467	ENSG00000263065.1	AF001548.6	-4.79	7.77e-06	0.0236	-0.54	-0.48	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15741151~15741791:+
SKCM	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	4.79	7.8e-06	0.0237	0.59	0.48	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	4.79	7.81e-06	0.0237	0.43	0.48	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
SKCM	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-4.79	7.82e-06	0.0237	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-4.79	7.82e-06	0.0237	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-4.79	7.82e-06	0.0237	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
SKCM	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.79	7.82e-06	0.0237	0.49	0.48	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
SKCM	cis	rs1951681	0.51	rs17408295	ENSG00000259045.1	RP11-320M16.1	4.79	7.87e-06	0.0238	1.22	0.48	Economic and political preferences (environmentalism);	chr14:32419707	chr14:32484098~32484800:-
SKCM	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.79	7.89e-06	0.0239	0.6	0.48	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
SKCM	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-4.79	7.89e-06	0.0239	-0.55	-0.48	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
SKCM	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-4.78	7.95e-06	0.0241	-0.66	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
SKCM	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-4.78	7.99e-06	0.0242	-0.57	-0.48	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
SKCM	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	4.78	7.99e-06	0.0242	0.6	0.48	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
SKCM	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	4.78	8.01e-06	0.0242	0.48	0.48	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
SKCM	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	4.78	8.02e-06	0.0242	0.56	0.48	Height;	chr11:118781100	chr11:118688039~118690600:-
SKCM	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	4.78	8.03e-06	0.0242	0.65	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
SKCM	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-4.78	8.03e-06	0.0242	-0.65	-0.48	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-4.78	8.03e-06	0.0242	-0.65	-0.48	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-4.78	8.03e-06	0.0242	-0.65	-0.48	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-4.78	8.03e-06	0.0242	-0.65	-0.48	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-4.78	8.03e-06	0.0242	-0.65	-0.48	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
SKCM	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	4.78	8.05e-06	0.0243	0.48	0.48	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	4.78	8.05e-06	0.0243	0.48	0.48	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	4.78	8.05e-06	0.0243	0.48	0.48	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
SKCM	cis	rs11638815	0.954	rs783544	ENSG00000255769.6	GOLGA2P10	-4.78	8.07e-06	0.0243	-0.66	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82571543	chr15:82472993~82513950:-
SKCM	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	4.78	8.07e-06	0.0243	0.66	0.48	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
SKCM	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	4.78	8.2e-06	0.0247	0.57	0.48	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
SKCM	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.77	8.26e-06	0.0249	0.53	0.48	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
SKCM	cis	rs11638815	0.581	rs783535	ENSG00000259429.4	UBE2Q2P2	-4.77	8.27e-06	0.0249	-0.44	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.581	rs783537	ENSG00000259429.4	UBE2Q2P2	-4.77	8.27e-06	0.0249	-0.44	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.626	rs1313492	ENSG00000259429.4	UBE2Q2P2	-4.77	8.27e-06	0.0249	-0.44	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.626	rs11633829	ENSG00000259429.4	UBE2Q2P2	4.77	8.27e-06	0.0249	0.44	0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:82355142~82420075:+
SKCM	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	4.77	8.27e-06	0.0249	0.56	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
SKCM	cis	rs11638815	0.581	rs2870965	ENSG00000259429.4	UBE2Q2P2	-4.77	8.29e-06	0.0249	-0.44	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:82355142~82420075:+
SKCM	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	4.77	8.32e-06	0.025	0.59	0.48	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
SKCM	cis	rs11638815	0.728	rs4779056	ENSG00000259429.4	UBE2Q2P2	4.77	8.45e-06	0.0253	0.49	0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719974	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.859	rs11633991	ENSG00000259429.4	UBE2Q2P2	-4.77	8.45e-06	0.0253	-0.49	-0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82726588	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.859	rs34125390	ENSG00000259429.4	UBE2Q2P2	4.77	8.45e-06	0.0253	0.49	0.48	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82730221	chr15:82355142~82420075:+
SKCM	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	4.77	8.51e-06	0.0254	0.59	0.48	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-4.76	8.62e-06	0.0257	-0.43	-0.47	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
SKCM	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.76	8.68e-06	0.0258	0.48	0.47	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
SKCM	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-4.76	8.7e-06	0.0258	-0.46	-0.47	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
SKCM	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-4.76	8.71e-06	0.0258	-0.43	-0.47	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
SKCM	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	4.76	8.79e-06	0.026	0.6	0.47	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
SKCM	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-4.76	8.89e-06	0.0263	-0.5	-0.47	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
SKCM	cis	rs30117	0.965	rs246749	ENSG00000244331.1	CTB-47B8.1	4.76	8.9e-06	0.0263	0.54	0.47	Daytime sleep phenotypes;	chr5:157219302	chr5:157931258~157931563:-
SKCM	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	4.75	8.94e-06	0.0264	0.5	0.47	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
SKCM	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-4.75	8.94e-06	0.0264	-0.47	-0.47	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
SKCM	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-4.75	8.95e-06	0.0264	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-4.75	8.95e-06	0.0264	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-4.75	8.95e-06	0.0264	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
SKCM	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-4.75	8.95e-06	0.0264	-0.5	-0.47	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
SKCM	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
SKCM	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-4.75	8.96e-06	0.0264	-0.55	-0.47	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
SKCM	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-4.75	8.98e-06	0.0264	-0.89	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
SKCM	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	4.75	9.01e-06	0.0265	0.55	0.47	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	4.75	9.01e-06	0.0265	0.55	0.47	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
SKCM	cis	rs11638815	0.859	rs11631182	ENSG00000259429.4	UBE2Q2P2	4.75	9.04e-06	0.0266	0.5	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725328	chr15:82355142~82420075:+
SKCM	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-4.75	9.05e-06	0.0266	-0.55	-0.47	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
SKCM	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	4.75	9.08e-06	0.0266	0.44	0.47	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
SKCM	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	4.75	9.09e-06	0.0266	0.63	0.47	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
SKCM	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-4.75	9.1e-06	0.0267	-0.56	-0.47	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-4.75	9.1e-06	0.0267	-0.56	-0.47	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
SKCM	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	4.75	9.15e-06	0.0267	0.61	0.47	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
SKCM	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-4.75	9.15e-06	0.0267	-0.47	-0.47	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
SKCM	cis	rs1497406	0.744	rs6677710	ENSG00000235084.3	CHCHD2P6	-4.75	9.18e-06	0.0268	-0.53	-0.47	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181123	chr1:15604597~15605043:+
SKCM	cis	rs380904	0.833	rs402011	ENSG00000254859.1	RP11-661A12.5	-4.75	9.18e-06	0.0268	-0.68	-0.47	Venous thromboembolism (SNP x SNP interaction);	chr8:143481294	chr8:143541973~143549729:-
SKCM	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	4.75	9.19e-06	0.0268	0.55	0.47	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-4.75	9.26e-06	0.027	-0.6	-0.47	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-4.75	9.26e-06	0.027	-0.6	-0.47	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
SKCM	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-4.74	9.36e-06	0.0272	-0.46	-0.47	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-4.74	9.36e-06	0.0272	-0.46	-0.47	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
SKCM	cis	rs11638815	0.626	rs1367841	ENSG00000259429.4	UBE2Q2P2	4.74	9.36e-06	0.0272	0.43	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:82355142~82420075:+
SKCM	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
SKCM	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
SKCM	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
SKCM	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-4.74	9.39e-06	0.0273	-0.63	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
SKCM	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-4.74	9.41e-06	0.0273	-0.51	-0.47	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-4.74	9.42e-06	0.0273	-0.5	-0.47	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
SKCM	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	4.74	9.47e-06	0.0275	0.58	0.47	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	4.74	9.47e-06	0.0275	0.58	0.47	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
SKCM	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	4.74	9.47e-06	0.0275	0.53	0.47	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
SKCM	cis	rs11638815	0.581	rs28808991	ENSG00000259429.4	UBE2Q2P2	-4.73	9.65e-06	0.0279	-0.43	-0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.603	rs2678448	ENSG00000259429.4	UBE2Q2P2	-4.73	9.65e-06	0.0279	-0.43	-0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.603	rs783520	ENSG00000259429.4	UBE2Q2P2	-4.73	9.65e-06	0.0279	-0.43	-0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.603	rs10162807	ENSG00000259429.4	UBE2Q2P2	-4.73	9.65e-06	0.0279	-0.43	-0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:82355142~82420075:+
SKCM	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
SKCM	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.73	9.87e-06	0.0285	0.65	0.47	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
SKCM	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	4.73	9.9e-06	0.0286	0.49	0.47	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
SKCM	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	4.73	9.9e-06	0.0286	0.49	0.47	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
SKCM	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	4.73	9.92e-06	0.0286	0.59	0.47	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
SKCM	cis	rs10943724	0.917	rs12207977	ENSG00000233967.5	RP11-250B2.3	-4.73	9.99e-06	0.0288	-0.53	-0.47	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80518457	chr6:80443344~80465927:+
SKCM	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	4.72	1e-05	0.0289	0.62	0.47	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
SKCM	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-4.72	1.01e-05	0.029	-0.58	-0.47	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
SKCM	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	4.72	1.01e-05	0.0291	0.63	0.47	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-4.72	1.01e-05	0.0291	-0.68	-0.47	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
SKCM	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-4.72	1.02e-05	0.0293	-0.56	-0.47	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
SKCM	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-4.72	1.02e-05	0.0293	-0.55	-0.47	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
SKCM	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	4.72	1.03e-05	0.0294	0.54	0.47	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
SKCM	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-4.72	1.03e-05	0.0295	-0.46	-0.47	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
SKCM	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	4.72	1.03e-05	0.0295	0.58	0.47	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
SKCM	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	4.72	1.04e-05	0.0297	0.51	0.47	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	4.72	1.04e-05	0.0297	0.51	0.47	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	4.72	1.04e-05	0.0297	0.51	0.47	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	4.71	1.04e-05	0.0297	0.54	0.47	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	4.71	1.04e-05	0.0297	0.54	0.47	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	4.71	1.04e-05	0.0297	0.54	0.47	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	4.71	1.04e-05	0.0297	0.54	0.47	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	4.71	1.04e-05	0.0297	0.54	0.47	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
SKCM	cis	rs11242661	0.808	rs723396	ENSG00000249921.2	CTC-329H14.1	4.71	1.05e-05	0.0298	0.44	0.47	Response to amphetamines;	chr5:108012133	chr5:108784098~108785552:+
SKCM	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-4.71	1.05e-05	0.03	-0.58	-0.47	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-4.71	1.05e-05	0.03	-0.58	-0.47	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
SKCM	cis	rs9921338	0.59	rs75012323	ENSG00000262420.3	RP11-490O6.2	-4.71	1.06e-05	0.0302	-1.19	-0.47	Vein graft stenosis in coronary artery bypass grafting;	chr16:11291713	chr16:11741910~11744506:+
SKCM	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	4.71	1.06e-05	0.0303	0.52	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
SKCM	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-4.71	1.07e-05	0.0304	-0.58	-0.47	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
SKCM	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-4.71	1.07e-05	0.0304	-0.58	-0.47	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
SKCM	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	4.71	1.07e-05	0.0304	0.6	0.47	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
SKCM	cis	rs11638815	0.728	rs4779056	ENSG00000255769.6	GOLGA2P10	4.71	1.07e-05	0.0304	0.65	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719974	chr15:82472993~82513950:-
SKCM	cis	rs11638815	0.859	rs11633991	ENSG00000255769.6	GOLGA2P10	-4.71	1.07e-05	0.0304	-0.65	-0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82726588	chr15:82472993~82513950:-
SKCM	cis	rs11638815	0.859	rs34125390	ENSG00000255769.6	GOLGA2P10	4.71	1.07e-05	0.0304	0.65	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82730221	chr15:82472993~82513950:-
SKCM	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-4.71	1.07e-05	0.0305	-0.58	-0.47	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
SKCM	cis	rs9910055	0.607	rs13726	ENSG00000260793.2	RP5-882C2.2	-4.7	1.09e-05	0.0308	-0.43	-0.47	Total body bone mineral density;	chr17:44162193	chr17:44221401~44223710:+
SKCM	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-4.7	1.09e-05	0.0308	-0.54	-0.47	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
SKCM	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	4.7	1.09e-05	0.0308	0.52	0.47	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
SKCM	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-4.7	1.09e-05	0.0308	-0.76	-0.47	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
SKCM	cis	rs11638815	0.603	rs7171180	ENSG00000259429.4	UBE2Q2P2	4.7	1.1e-05	0.031	0.42	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:82355142~82420075:+
SKCM	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	4.7	1.11e-05	0.0312	0.55	0.47	Height;	chr11:118786602	chr11:118688039~118690600:-
SKCM	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	4.7	1.12e-05	0.0314	0.52	0.47	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
SKCM	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-4.7	1.12e-05	0.0315	-0.48	-0.47	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
SKCM	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-4.69	1.13e-05	0.0319	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
SKCM	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	4.69	1.14e-05	0.0319	0.58	0.47	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
SKCM	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	4.69	1.14e-05	0.032	0.57	0.47	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-4.69	1.15e-05	0.0321	-0.61	-0.47	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
SKCM	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-4.69	1.15e-05	0.0321	-0.46	-0.47	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
SKCM	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-4.69	1.15e-05	0.0322	-0.5	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-4.69	1.15e-05	0.0323	-0.53	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
SKCM	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-4.69	1.15e-05	0.0323	-0.53	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
SKCM	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-4.69	1.16e-05	0.0324	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	4.69	1.16e-05	0.0324	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
SKCM	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-4.69	1.16e-05	0.0325	-0.49	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
SKCM	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-4.68	1.17e-05	0.0325	-0.54	-0.47	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
SKCM	cis	rs11638815	0.954	rs11635442	ENSG00000255769.6	GOLGA2P10	4.68	1.17e-05	0.0325	0.65	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82659790	chr15:82472993~82513950:-
SKCM	cis	rs11638815	0.954	rs11635476	ENSG00000255769.6	GOLGA2P10	4.68	1.17e-05	0.0325	0.65	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82670748	chr15:82472993~82513950:-
SKCM	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	4.68	1.17e-05	0.0325	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
SKCM	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.17e-05	0.0326	-0.5	-0.47	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.17e-05	0.0326	-0.5	-0.47	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
SKCM	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	4.68	1.18e-05	0.0327	0.48	0.47	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
SKCM	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	4.68	1.18e-05	0.0327	0.56	0.47	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	4.68	1.18e-05	0.0327	0.56	0.47	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	4.68	1.18e-05	0.0327	0.56	0.47	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
SKCM	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-4.68	1.18e-05	0.0328	-0.56	-0.47	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
SKCM	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
SKCM	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
SKCM	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-4.68	1.18e-05	0.0328	-0.5	-0.47	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
SKCM	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	4.68	1.19e-05	0.0329	0.53	0.47	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
SKCM	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	4.68	1.19e-05	0.0329	0.46	0.47	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
SKCM	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	4.68	1.2e-05	0.0332	0.63	0.47	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	4.68	1.2e-05	0.0332	0.63	0.47	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
SKCM	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-4.68	1.2e-05	0.0332	-0.46	-0.47	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
SKCM	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	4.67	1.21e-05	0.0335	0.6	0.47	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
SKCM	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-4.67	1.22e-05	0.0336	-0.58	-0.47	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
SKCM	cis	rs6084875	1	rs6084876	ENSG00000278595.1	RP5-1068H6.6	4.67	1.23e-05	0.0337	0.55	0.47	Systemic lupus erythematosus;	chr20:4762291	chr20:4761300~4761696:+
SKCM	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	4.67	1.23e-05	0.0337	0.6	0.47	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
SKCM	cis	rs752590	0.943	rs13407583	ENSG00000243389.1	AC012442.5	-4.67	1.23e-05	0.0337	-0.77	-0.47	Mucinous ovarian carcinoma;	chr2:113210163	chr2:112589040~112614431:+
SKCM	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
SKCM	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-4.67	1.24e-05	0.0337	-0.59	-0.47	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
SKCM	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-4.67	1.24e-05	0.0337	-0.58	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	4.67	1.24e-05	0.0337	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-4.67	1.24e-05	0.0337	-0.58	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
SKCM	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-4.67	1.24e-05	0.0337	-0.62	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
SKCM	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	4.67	1.24e-05	0.0338	0.61	0.47	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
SKCM	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	4.67	1.24e-05	0.0338	0.51	0.47	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
SKCM	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
SKCM	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
SKCM	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-4.67	1.24e-05	0.0338	-0.54	-0.47	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
SKCM	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-4.67	1.24e-05	0.0338	-0.58	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
SKCM	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-4.67	1.25e-05	0.034	-0.53	-0.47	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
SKCM	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-4.67	1.25e-05	0.034	-0.54	-0.47	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-4.67	1.25e-05	0.034	-0.54	-0.47	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-4.67	1.25e-05	0.034	-0.54	-0.47	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-4.67	1.25e-05	0.034	-0.54	-0.47	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-4.67	1.25e-05	0.034	-0.54	-0.47	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
SKCM	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-4.67	1.25e-05	0.034	-0.55	-0.47	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
SKCM	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	4.67	1.26e-05	0.0341	0.55	0.47	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
SKCM	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.66	1.26e-05	0.0342	0.51	0.47	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
SKCM	cis	rs4759375	1	rs4759375	ENSG00000256092.2	RP13-942N8.1	-4.66	1.27e-05	0.0344	-0.79	-0.47	HDL cholesterol;	chr12:123311691	chr12:123363868~123366113:+
SKCM	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-4.66	1.27e-05	0.0345	-0.61	-0.47	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
SKCM	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
SKCM	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
SKCM	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
SKCM	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
SKCM	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
SKCM	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-4.66	1.28e-05	0.0345	-0.55	-0.47	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
SKCM	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-4.66	1.28e-05	0.0346	-0.61	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
SKCM	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-4.66	1.28e-05	0.0347	-0.64	-0.47	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
SKCM	cis	rs10946737	0.838	rs9393600	ENSG00000168405.13	CMAHP	-4.66	1.29e-05	0.0349	-0.39	-0.47	Liver injury in anti-tuberculosis drug treatment;	chr6:24975963	chr6:25081068~25166555:-
SKCM	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-4.66	1.3e-05	0.035	-0.54	-0.47	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
SKCM	cis	rs11638815	0.954	rs11635442	ENSG00000259429.4	UBE2Q2P2	4.66	1.3e-05	0.0351	0.49	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82659790	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.954	rs11635476	ENSG00000259429.4	UBE2Q2P2	4.66	1.3e-05	0.0351	0.49	0.47	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82670748	chr15:82355142~82420075:+
SKCM	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-4.66	1.3e-05	0.0351	-0.65	-0.47	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-4.66	1.3e-05	0.0351	-0.65	-0.47	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
SKCM	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-4.66	1.3e-05	0.0351	-0.65	-0.47	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
SKCM	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-4.66	1.3e-05	0.0351	-0.58	-0.47	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
SKCM	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-4.65	1.31e-05	0.0352	-0.55	-0.47	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
SKCM	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-4.65	1.31e-05	0.0353	-0.59	-0.47	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
SKCM	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	4.65	1.31e-05	0.0353	0.54	0.47	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
SKCM	cis	rs6878727	0.813	rs10063748	ENSG00000253807.4	LINC01170	-4.65	1.31e-05	0.0354	-0.62	-0.47	Breast cancer;	chr5:124368441	chr5:124059794~124405079:-
SKCM	cis	rs6878727	0.85	rs10055879	ENSG00000253807.4	LINC01170	-4.65	1.31e-05	0.0354	-0.62	-0.47	Breast cancer;	chr5:124368565	chr5:124059794~124405079:-
SKCM	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-4.65	1.32e-05	0.0354	-0.55	-0.47	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
SKCM	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-4.65	1.32e-05	0.0356	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
SKCM	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	4.65	1.33e-05	0.0356	0.59	0.47	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
SKCM	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	4.65	1.33e-05	0.0356	0.53	0.47	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
SKCM	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-4.65	1.34e-05	0.0358	-0.47	-0.47	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
SKCM	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-4.65	1.35e-05	0.0361	-0.53	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
SKCM	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-4.65	1.35e-05	0.0361	-0.55	-0.47	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
SKCM	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-4.65	1.35e-05	0.0361	-0.54	-0.47	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-4.65	1.35e-05	0.0361	-0.54	-0.47	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-4.65	1.35e-05	0.0361	-0.54	-0.47	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
SKCM	cis	rs16828019	0.561	rs12025777	ENSG00000235358.1	RP11-399E6.1	4.65	1.35e-05	0.0362	0.98	0.47	Intelligence (multi-trait analysis);	chr1:41283225	chr1:41242373~41284861:+
SKCM	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
SKCM	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-4.64	1.37e-05	0.0364	-0.52	-0.47	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
SKCM	cis	rs4437462	0.503	rs1883238	ENSG00000230314.5	ELOVL2-AS1	-4.64	1.37e-05	0.0365	-0.7	-0.47	HIV-1 susceptibility;	chr6:11329582	chr6:11043524~11078226:+
SKCM	cis	rs6051080	1	rs6051080	ENSG00000204556.4	CTD-2514C3.1	-4.64	1.39e-05	0.0369	-0.52	-0.47	Colorectal or endometrial cancer;	chr20:25995038	chr20:26018832~26020684:+
SKCM	cis	rs55823223	0.618	rs72860390	ENSG00000267342.1	RP11-552F3.10	-4.64	1.39e-05	0.0369	-0.6	-0.47	Psoriasis;	chr17:75873833	chr17:75897060~75900148:+
SKCM	cis	rs55823223	0.648	rs66584478	ENSG00000267342.1	RP11-552F3.10	-4.64	1.39e-05	0.0369	-0.6	-0.47	Psoriasis;	chr17:75874122	chr17:75897060~75900148:+
SKCM	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	4.64	1.39e-05	0.037	0.43	0.46	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
SKCM	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-4.64	1.4e-05	0.0371	-0.61	-0.46	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
SKCM	cis	rs6084875	1	rs6084875	ENSG00000278595.1	RP5-1068H6.6	4.64	1.4e-05	0.0371	0.54	0.46	Systemic lupus erythematosus;	chr20:4762059	chr20:4761300~4761696:+
SKCM	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	4.64	1.4e-05	0.0371	0.58	0.46	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	4.64	1.4e-05	0.0372	0.65	0.46	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
SKCM	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	4.64	1.4e-05	0.0372	0.65	0.46	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
SKCM	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-4.64	1.41e-05	0.0373	-0.52	-0.46	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-4.64	1.41e-05	0.0373	-0.52	-0.46	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
SKCM	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-4.64	1.41e-05	0.0373	-0.52	-0.46	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
SKCM	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	4.64	1.41e-05	0.0373	0.58	0.46	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	4.64	1.41e-05	0.0373	0.58	0.46	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.54	0.46	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
SKCM	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-4.63	1.41e-05	0.0373	-0.65	-0.46	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
SKCM	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	4.63	1.41e-05	0.0373	0.63	0.46	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
SKCM	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	4.63	1.41e-05	0.0373	0.57	0.46	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-4.63	1.41e-05	0.0373	-0.57	-0.46	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-4.63	1.41e-05	0.0373	-0.57	-0.46	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
SKCM	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	4.63	1.41e-05	0.0374	0.51	0.46	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
SKCM	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-4.63	1.42e-05	0.0376	-0.53	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
SKCM	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-4.63	1.42e-05	0.0376	-0.53	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
SKCM	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-4.63	1.42e-05	0.0376	-0.53	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
SKCM	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	4.63	1.42e-05	0.0376	0.86	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-4.63	1.42e-05	0.0376	-0.86	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
SKCM	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-4.63	1.42e-05	0.0376	-0.86	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
SKCM	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-4.63	1.42e-05	0.0376	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
SKCM	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-4.63	1.42e-05	0.0377	-0.63	-0.46	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
SKCM	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-4.63	1.44e-05	0.038	-0.46	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
SKCM	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-4.63	1.44e-05	0.038	-0.53	-0.46	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
SKCM	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	4.63	1.44e-05	0.038	0.5	0.46	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
SKCM	cis	rs11638815	0.871	rs8033106	ENSG00000255769.6	GOLGA2P10	-4.63	1.44e-05	0.038	-0.64	-0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82630710	chr15:82472993~82513950:-
SKCM	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-4.63	1.46e-05	0.0383	-0.58	-0.46	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
SKCM	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-4.63	1.46e-05	0.0383	-0.63	-0.46	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-4.63	1.46e-05	0.0383	-0.63	-0.46	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
SKCM	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
SKCM	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	4.62	1.47e-05	0.0386	0.62	0.46	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
SKCM	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-4.62	1.47e-05	0.0386	-0.57	-0.46	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
SKCM	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	4.62	1.47e-05	0.0386	0.57	0.46	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
SKCM	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-4.62	1.47e-05	0.0387	-0.71	-0.46	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
SKCM	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-4.62	1.47e-05	0.0387	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-4.62	1.47e-05	0.0387	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
SKCM	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-4.62	1.47e-05	0.0387	-0.54	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-4.62	1.47e-05	0.0387	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
SKCM	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-4.62	1.47e-05	0.0387	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
SKCM	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-4.62	1.48e-05	0.0389	-0.55	-0.46	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
SKCM	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-4.62	1.49e-05	0.039	-0.55	-0.46	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-4.62	1.49e-05	0.039	-0.55	-0.46	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
SKCM	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-4.62	1.49e-05	0.039	-0.55	-0.46	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
SKCM	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-4.62	1.49e-05	0.039	-0.55	-0.46	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
SKCM	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-4.62	1.49e-05	0.039	-0.48	-0.46	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
SKCM	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-4.62	1.49e-05	0.039	-0.57	-0.46	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
SKCM	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-4.62	1.5e-05	0.0391	-0.55	-0.46	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
SKCM	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-4.62	1.5e-05	0.0393	-0.58	-0.46	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
SKCM	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	4.62	1.5e-05	0.0393	0.59	0.46	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
SKCM	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	4.62	1.51e-05	0.0394	0.47	0.46	Temperament;	chr17:13996939	chr17:14024514~14025488:+
SKCM	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-4.62	1.51e-05	0.0394	-0.52	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
SKCM	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.62	1.51e-05	0.0395	0.64	0.46	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
SKCM	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-4.62	1.51e-05	0.0396	-0.73	-0.46	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
SKCM	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	4.61	1.52e-05	0.0397	0.6	0.46	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
SKCM	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-4.61	1.52e-05	0.0397	-0.52	-0.46	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-4.61	1.52e-05	0.0397	-0.52	-0.46	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-4.61	1.52e-05	0.0397	-0.52	-0.46	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-4.61	1.52e-05	0.0397	-0.52	-0.46	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
SKCM	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.61	1.52e-05	0.0397	0.53	0.46	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
SKCM	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-4.61	1.53e-05	0.0399	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-4.61	1.53e-05	0.0399	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
SKCM	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.61	1.53e-05	0.04	0.56	0.46	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.61	1.53e-05	0.04	0.56	0.46	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.61	1.53e-05	0.04	0.56	0.46	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.61	1.53e-05	0.04	0.56	0.46	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.61	1.53e-05	0.04	0.56	0.46	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
SKCM	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-4.61	1.53e-05	0.04	-0.54	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
SKCM	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	4.61	1.54e-05	0.0402	0.62	0.46	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
SKCM	cis	rs11638815	0.954	rs35734713	ENSG00000255769.6	GOLGA2P10	4.61	1.55e-05	0.0403	0.64	0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82669753	chr15:82472993~82513950:-
SKCM	cis	rs11638815	1	rs11638815	ENSG00000255769.6	GOLGA2P10	4.61	1.55e-05	0.0403	0.64	0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82683530	chr15:82472993~82513950:-
SKCM	cis	rs11638815	0.906	rs4779048	ENSG00000255769.6	GOLGA2P10	4.61	1.55e-05	0.0403	0.64	0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82692911	chr15:82472993~82513950:-
SKCM	cis	rs11638815	0.954	rs4779049	ENSG00000255769.6	GOLGA2P10	4.61	1.55e-05	0.0403	0.64	0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82693022	chr15:82472993~82513950:-
SKCM	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	4.61	1.55e-05	0.0403	0.49	0.46	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
SKCM	cis	rs8062405	0.722	rs28729187	ENSG00000259982.1	CDC37P1	-4.61	1.55e-05	0.0404	-0.57	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.789	rs28480369	ENSG00000259982.1	CDC37P1	-4.61	1.55e-05	0.0404	-0.57	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28700294~28701540:-
SKCM	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-4.61	1.55e-05	0.0404	-0.57	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
SKCM	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	4.61	1.56e-05	0.0407	0.5	0.46	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	4.61	1.56e-05	0.0407	0.5	0.46	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
SKCM	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-4.61	1.56e-05	0.0407	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
SKCM	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	4.61	1.56e-05	0.0407	0.61	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
SKCM	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.61	1.57e-05	0.0409	0.63	0.46	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
SKCM	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	4.61	1.57e-05	0.0409	0.63	0.46	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
SKCM	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	4.6	1.58e-05	0.041	0.55	0.46	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
SKCM	cis	rs10946737	0.782	rs2149452	ENSG00000168405.13	CMAHP	4.6	1.59e-05	0.0413	0.39	0.46	Liver injury in anti-tuberculosis drug treatment;	chr6:24983994	chr6:25081068~25166555:-
SKCM	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.6	1.59e-05	0.0413	0.59	0.46	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
SKCM	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.6	1.59e-05	0.0413	0.59	0.46	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
SKCM	cis	rs240707	1	rs240707	ENSG00000259982.1	CDC37P1	4.6	1.6e-05	0.0415	0.54	0.46	Intelligence (multi-trait analysis);	chr16:28513291	chr16:28700294~28701540:-
SKCM	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-4.6	1.6e-05	0.0415	-0.57	-0.46	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-4.6	1.6e-05	0.0415	-0.57	-0.46	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
SKCM	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-4.6	1.61e-05	0.0418	-0.61	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
SKCM	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	4.6	1.61e-05	0.0418	0.52	0.46	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
SKCM	cis	rs228769	0.636	rs11656104	ENSG00000260793.2	RP5-882C2.2	-4.6	1.62e-05	0.042	-0.45	-0.46	Bone mineral density (hip);Bone mineral density (spine);	chr17:44181597	chr17:44221401~44223710:+
SKCM	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-4.6	1.63e-05	0.0421	-0.53	-0.46	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-4.6	1.63e-05	0.0421	-0.53	-0.46	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
SKCM	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-4.6	1.64e-05	0.0423	-0.6	-0.46	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
SKCM	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-4.59	1.64e-05	0.0423	-0.69	-0.46	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
SKCM	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	4.59	1.64e-05	0.0424	0.42	0.46	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
SKCM	cis	rs2483519	0.762	rs217194	ENSG00000226428.1	RP11-106M7.4	-4.59	1.64e-05	0.0424	-0.5	-0.46	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114703321	chr10:114900722~114901366:+
SKCM	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.59	1.65e-05	0.0424	0.58	0.46	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	4.59	1.65e-05	0.0424	0.58	0.46	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	4.59	1.65e-05	0.0424	0.58	0.46	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
SKCM	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	4.59	1.65e-05	0.0425	0.52	0.46	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
SKCM	cis	rs10946737	0.838	rs1410686	ENSG00000168405.13	CMAHP	4.59	1.65e-05	0.0426	0.39	0.46	Liver injury in anti-tuberculosis drug treatment;	chr6:24980383	chr6:25081068~25166555:-
SKCM	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-4.59	1.66e-05	0.0426	-0.64	-0.46	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-4.59	1.66e-05	0.0426	-0.64	-0.46	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
SKCM	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	4.59	1.66e-05	0.0427	0.54	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
SKCM	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	4.59	1.66e-05	0.0427	0.51	0.46	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
SKCM	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-4.59	1.66e-05	0.0428	-0.73	-0.46	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
SKCM	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-4.59	1.66e-05	0.0428	-0.73	-0.46	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
SKCM	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-4.59	1.66e-05	0.0428	-0.73	-0.46	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
SKCM	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-4.59	1.67e-05	0.0428	-0.54	-0.46	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
SKCM	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-4.59	1.67e-05	0.0428	-0.54	-0.46	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
SKCM	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-4.59	1.67e-05	0.0429	-0.54	-0.46	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-4.59	1.67e-05	0.0429	-0.54	-0.46	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-4.59	1.67e-05	0.0429	-0.54	-0.46	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-4.59	1.67e-05	0.0429	-0.54	-0.46	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-4.59	1.67e-05	0.0429	-0.54	-0.46	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
SKCM	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	4.59	1.67e-05	0.0429	0.53	0.46	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	4.59	1.67e-05	0.0429	0.53	0.46	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
SKCM	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.59	1.67e-05	0.0429	0.65	0.46	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
SKCM	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.59	1.67e-05	0.0429	0.65	0.46	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
SKCM	cis	rs7923837	0.687	rs11187139	ENSG00000236493.2	EIF2S2P3	4.59	1.68e-05	0.0431	0.53	0.46	Multiple sclerosis;Body mass index;	chr10:92706670	chr10:92668745~92669743:-
SKCM	cis	rs7923837	0.687	rs10882102	ENSG00000236493.2	EIF2S2P3	4.59	1.68e-05	0.0431	0.53	0.46	Multiple sclerosis;Body mass index;	chr10:92706738	chr10:92668745~92669743:-
SKCM	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-4.59	1.69e-05	0.0432	-0.53	-0.46	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
SKCM	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-4.59	1.69e-05	0.0433	-0.51	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
SKCM	cis	rs11638815	0.689	rs1267656	ENSG00000259429.4	UBE2Q2P2	-4.59	1.69e-05	0.0433	-0.5	-0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82551349	chr15:82355142~82420075:+
SKCM	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	4.59	1.7e-05	0.0434	0.57	0.46	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
SKCM	cis	rs1879352	0.623	rs11664501	ENSG00000265399.1	RP13-270P17.2	-4.58	1.71e-05	0.0437	-0.89	-0.46	Acute lymphoblastic leukemia (childhood);	chr18:2528254	chr18:3190397~3247277:+
SKCM	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	4.58	1.72e-05	0.0438	0.5	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
SKCM	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	4.58	1.72e-05	0.0438	0.5	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
SKCM	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	4.58	1.72e-05	0.0439	0.69	0.46	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
SKCM	cis	rs4372836	1	rs7579277	ENSG00000226833.4	AC097724.3	4.58	1.72e-05	0.0439	0.59	0.46	Body mass index;	chr2:28773429	chr2:28708953~28736205:-
SKCM	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	4.58	1.74e-05	0.0442	0.54	0.46	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
SKCM	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-4.58	1.74e-05	0.0443	-0.55	-0.46	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
SKCM	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-4.58	1.74e-05	0.0443	-0.63	-0.46	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
SKCM	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-4.58	1.75e-05	0.0445	-0.46	-0.46	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-4.58	1.75e-05	0.0445	-0.46	-0.46	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-4.58	1.75e-05	0.0445	-0.46	-0.46	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
SKCM	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-4.58	1.75e-05	0.0445	-0.46	-0.46	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
SKCM	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.58	1.75e-05	0.0445	-0.59	-0.46	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
SKCM	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-4.58	1.76e-05	0.0447	-0.51	-0.46	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
SKCM	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-4.58	1.76e-05	0.0447	-0.51	-0.46	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
SKCM	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-4.58	1.76e-05	0.0447	-0.51	-0.46	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
SKCM	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-4.58	1.76e-05	0.0447	-0.51	-0.46	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
SKCM	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	4.58	1.77e-05	0.0448	0.47	0.46	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
SKCM	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-4.57	1.77e-05	0.0449	-0.56	-0.46	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-4.57	1.79e-05	0.0452	-0.54	-0.46	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
SKCM	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-4.57	1.8e-05	0.0455	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-4.57	1.8e-05	0.0455	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-4.57	1.8e-05	0.0455	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
SKCM	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-4.57	1.8e-05	0.0455	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
SKCM	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	4.57	1.81e-05	0.0455	0.51	0.46	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
SKCM	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-4.57	1.81e-05	0.0455	-0.51	-0.46	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
SKCM	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-4.57	1.82e-05	0.0456	-0.58	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
SKCM	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-4.57	1.83e-05	0.0458	-0.53	-0.46	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-4.57	1.83e-05	0.0458	-0.53	-0.46	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
SKCM	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-4.56	1.84e-05	0.0459	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
SKCM	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	4.56	1.84e-05	0.0459	0.78	0.46	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
SKCM	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	4.56	1.84e-05	0.0459	0.78	0.46	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
SKCM	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	4.56	1.84e-05	0.0459	0.78	0.46	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
SKCM	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	4.56	1.84e-05	0.0459	0.78	0.46	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
SKCM	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	4.56	1.84e-05	0.0459	0.62	0.46	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
SKCM	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	4.56	1.85e-05	0.0461	0.5	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
SKCM	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	4.56	1.85e-05	0.0461	0.58	0.46	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	4.56	1.85e-05	0.0461	0.58	0.46	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	4.56	1.85e-05	0.0461	0.58	0.46	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	4.56	1.85e-05	0.0461	0.58	0.46	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
SKCM	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-4.56	1.86e-05	0.0462	-0.57	-0.46	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
SKCM	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-4.56	1.86e-05	0.0462	-0.57	-0.46	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
SKCM	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-4.56	1.86e-05	0.0462	-0.54	-0.46	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-4.56	1.86e-05	0.0462	-0.54	-0.46	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-4.56	1.86e-05	0.0462	-0.54	-0.46	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-4.56	1.86e-05	0.0462	-0.54	-0.46	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
SKCM	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	4.56	1.86e-05	0.0463	0.58	0.46	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
SKCM	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	4.56	1.86e-05	0.0463	0.58	0.46	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
SKCM	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	4.56	1.86e-05	0.0463	0.61	0.46	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
SKCM	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-4.56	1.86e-05	0.0464	-0.49	-0.46	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
SKCM	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-4.56	1.87e-05	0.0464	-0.47	-0.46	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
SKCM	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.57	0.46	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.57	0.46	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
SKCM	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-4.56	1.87e-05	0.0464	-0.57	-0.46	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	4.56	1.87e-05	0.0464	0.54	0.46	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
SKCM	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	4.56	1.87e-05	0.0464	0.64	0.46	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
SKCM	cis	rs11638815	0.626	rs11635624	ENSG00000259429.4	UBE2Q2P2	-4.56	1.87e-05	0.0464	-0.42	-0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:82355142~82420075:+
SKCM	cis	rs11638815	0.626	rs4779039	ENSG00000259429.4	UBE2Q2P2	4.56	1.87e-05	0.0464	0.42	0.46	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:82355142~82420075:+
SKCM	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	4.56	1.87e-05	0.0464	0.58	0.46	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
SKCM	cis	rs893971	0.674	rs28789746	ENSG00000270720.1	RP11-84C13.2	-4.56	1.89e-05	0.0468	-0.58	-0.46	Conduct disorder (maternal expressed emotions interaction);	chr4:88309350	chr4:89119284~89119871:+
SKCM	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-4.56	1.9e-05	0.047	-0.61	-0.46	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-4.56	1.9e-05	0.047	-0.61	-0.46	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-4.56	1.9e-05	0.047	-0.61	-0.46	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
SKCM	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-4.56	1.9e-05	0.047	-0.61	-0.46	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
SKCM	cis	rs7546668	1	rs6429746	ENSG00000272510.1	RP4-680D5.8	-4.55	1.91e-05	0.047	-0.52	-0.46	Glomerular filtration rate (creatinine);	chr1:15489084	chr1:15565611~15565956:-
SKCM	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-4.55	1.91e-05	0.0472	-0.52	-0.46	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
SKCM	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-4.55	1.91e-05	0.0472	-0.58	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
SKCM	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	4.55	1.92e-05	0.0473	0.54	0.46	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
SKCM	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
SKCM	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
SKCM	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.55	1.93e-05	0.0473	0.56	0.46	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
SKCM	cis	rs435306	0.883	rs6104410	ENSG00000273555.1	MIR6812	4.55	1.93e-05	0.0473	0.52	0.46	HDL cholesterol;	chr20:45978962	chr20:45425510~45425573:+
SKCM	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-4.55	1.96e-05	0.0479	-0.52	-0.46	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
SKCM	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	4.55	1.96e-05	0.0479	0.58	0.46	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
SKCM	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	4.55	1.96e-05	0.048	0.57	0.46	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
SKCM	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
SKCM	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-4.55	1.97e-05	0.0482	-0.54	-0.46	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
SKCM	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.55	1.97e-05	0.0482	0.57	0.46	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
SKCM	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-4.55	1.97e-05	0.0482	-0.63	-0.46	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
SKCM	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-4.55	1.97e-05	0.0482	-0.63	-0.46	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
SKCM	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.53	-0.46	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.53	-0.46	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.53	-0.46	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.53	-0.46	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.53	-0.46	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
SKCM	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-4.54	1.98e-05	0.0483	-0.52	-0.46	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
SKCM	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	4.54	1.99e-05	0.0484	0.49	0.46	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
SKCM	cis	rs6084875	0.965	rs11699362	ENSG00000278595.1	RP5-1068H6.6	-4.54	2e-05	0.0486	-0.55	-0.46	Systemic lupus erythematosus;	chr20:4763334	chr20:4761300~4761696:+
SKCM	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	4.54	2e-05	0.0486	0.54	0.46	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
SKCM	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	4.54	2.01e-05	0.049	0.54	0.46	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
SKCM	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	4.54	2.02e-05	0.0491	0.5	0.46	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
SKCM	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	4.54	2.02e-05	0.0491	0.72	0.46	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
SKCM	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-4.54	2.03e-05	0.0492	-0.73	-0.46	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
SKCM	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-4.54	2.05e-05	0.0496	-0.54	-0.46	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
SKCM	cis	rs7923837	0.687	rs1111875	ENSG00000236493.2	EIF2S2P3	4.54	2.05e-05	0.0496	0.5	0.46	Multiple sclerosis;Body mass index;	chr10:92703125	chr10:92668745~92669743:-
SKCM	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-4.54	2.05e-05	0.0497	-0.5	-0.46	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
SKCM	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-4.54	2.05e-05	0.0497	-0.5	-0.46	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
SKCM	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-4.53	2.06e-05	0.0498	-0.53	-0.46	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
SKCM	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	4.53	2.06e-05	0.0499	0.58	0.46	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
SKCM	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
SKCM	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-4.53	2.07e-05	0.05	-0.42	-0.46	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
SKCM	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	4.53	2.07e-05	0.05	0.71	0.46	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
SKCM	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	4.53	2.07e-05	0.05	0.71	0.46	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
SKCM	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	4.53	2.07e-05	0.05	0.42	0.46	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
SKCM	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	14.67	3.86e-24	5.2e-14	1.14	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	14.55	6.17e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	14.5	7.58e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	14.5	7.58e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	14.5	7.58e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	14.5	7.58e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	14.5	7.58e-24	5.2e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
SKCM	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	14.33	1.5e-23	6.5e-14	0.91	0.85	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
SKCM	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	14.32	1.54e-23	6.5e-14	1.13	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	14.09	3.93e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	14.02	5.17e-23	1.09e-13	1.16	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	13.89	8.78e-23	1.66e-13	1.12	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-13.83	1.09e-22	1.76e-13	-1.16	-0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-13.83	1.09e-22	1.76e-13	-1.16	-0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-13.83	1.09e-22	1.76e-13	-1.16	-0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	13.83	1.09e-22	1.76e-13	1.16	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
SKCM	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	13.24	1.19e-21	1.48e-12	0.87	0.83	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
SKCM	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	13.22	1.33e-21	1.62e-12	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	13.1	2.13e-21	2.48e-12	1.15	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
SKCM	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-12.9	4.81e-21	3.92e-12	-0.89	-0.83	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	12.89	5.09e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	12.89	5.09e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	12.86	5.75e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	12.81	7.23e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
SKCM	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	12.81	7.23e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	12.81	7.23e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	12.78	8.19e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-12.77	8.37e-21	3.92e-12	-0.86	-0.82	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
SKCM	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	12.77	8.37e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	12.77	8.4e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	12.74	9.49e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	12.74	9.49e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	12.74	9.49e-21	3.92e-12	0.88	0.82	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
SKCM	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
SKCM	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	12.74	9.65e-21	3.92e-12	0.86	0.82	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
SKCM	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	12.69	1.17e-20	4.19e-12	0.86	0.82	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	12.68	1.21e-20	4.24e-12	0.86	0.82	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	12.67	1.28e-20	4.4e-12	0.86	0.82	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
SKCM	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	12.64	1.46e-20	4.7e-12	1.08	0.82	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	12.63	1.5e-20	4.74e-12	1.07	0.82	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
SKCM	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	12.55	2.09e-20	6.42e-12	1.09	0.82	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	12.55	2.09e-20	6.42e-12	1.09	0.82	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	12.55	2.09e-20	6.42e-12	1.09	0.82	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
SKCM	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	12.55	2.14e-20	6.51e-12	0.86	0.82	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	12.46	3.08e-20	8.11e-12	0.96	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
SKCM	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	12.43	3.43e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	12.43	3.43e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	12.43	3.46e-20	8.11e-12	0.86	0.82	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
SKCM	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	12.39	4.08e-20	9.26e-12	1.08	0.81	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
SKCM	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	12.39	4.11e-20	9.26e-12	0.87	0.81	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	12.39	4.11e-20	9.26e-12	0.87	0.81	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
SKCM	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	12.36	4.63e-20	1.03e-11	1.09	0.81	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
SKCM	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	12.35	4.95e-20	1.06e-11	0.85	0.81	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
SKCM	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	12.33	5.3e-20	1.13e-11	1.12	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
SKCM	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	12.3	6.02e-20	1.25e-11	1.04	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
SKCM	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-12.26	7.03e-20	1.45e-11	-1.06	-0.81	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
SKCM	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	12.26	7.05e-20	1.45e-11	0.96	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
SKCM	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-12.24	7.67e-20	1.55e-11	-0.86	-0.81	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-12.24	7.69e-20	1.55e-11	-0.97	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
SKCM	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-12.24	7.78e-20	1.55e-11	-1.07	-0.81	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
SKCM	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	12.12	1.26e-19	2.47e-11	0.96	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
SKCM	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	12.09	1.44e-19	2.79e-11	0.86	0.81	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	12.07	1.56e-19	2.83e-11	0.95	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	12.07	1.56e-19	2.83e-11	0.95	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	12.07	1.56e-19	2.83e-11	0.95	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	12.07	1.56e-19	2.83e-11	0.95	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	12.07	1.56e-19	2.83e-11	0.95	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	12.06	1.62e-19	2.83e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	12.06	1.69e-19	2.89e-11	1.02	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	12.06	1.69e-19	2.89e-11	1.02	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	12.06	1.69e-19	2.89e-11	1.02	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	12.06	1.69e-19	2.89e-11	1.02	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	12.06	1.69e-19	2.89e-11	1.02	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	12.02	1.94e-19	2.93e-11	1.03	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	11.96	2.48e-19	3.37e-11	0.99	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	11.96	2.48e-19	3.37e-11	0.99	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	11.93	2.84e-19	3.82e-11	1.08	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
SKCM	trans	rs1816752	0.875	rs947305	ENSG00000237917.1	PARP4P1	11.91	3.2e-19	4.25e-11	0.9	0.8	Obesity-related traits;	chr13:24460841	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	11.9	3.2e-19	4.25e-11	1.06	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	11.9	3.2e-19	4.25e-11	1.06	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
SKCM	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	11.88	3.59e-19	4.7e-11	0.83	0.8	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	11.88	3.59e-19	4.7e-11	0.83	0.8	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-11.84	4.18e-19	5.46e-11	-1.03	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	11.84	4.25e-19	5.52e-11	1.12	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	11.84	4.25e-19	5.52e-11	1.12	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
SKCM	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	11.81	4.72e-19	6.09e-11	1.11	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
SKCM	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-11.76	5.88e-19	7.02e-11	-1.09	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	11.68	8.31e-19	9.33e-11	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	11.56	1.42e-18	1.59e-10	1.07	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	11.53	1.61e-18	1.76e-10	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	11.53	1.61e-18	1.76e-10	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	11.53	1.61e-18	1.76e-10	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	11.53	1.61e-18	1.76e-10	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	11.53	1.61e-18	1.76e-10	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
SKCM	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	11.51	1.73e-18	1.88e-10	1.12	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
SKCM	trans	rs7949030	0.929	rs11231173	ENSG00000186676.3	EEF1GP1	11.51	1.73e-18	1.88e-10	1.12	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62651449	chr7:125033453~125035301:+
SKCM	trans	rs1816752	1	rs9511272	ENSG00000237917.1	PARP4P1	11.5	1.81e-18	1.97e-10	0.87	0.79	Obesity-related traits;	chr13:24446495	chrY:26594851~26634652:-
SKCM	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	11.48	1.97e-18	2.04e-10	0.98	0.79	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	11.48	1.98e-18	2.04e-10	0.98	0.79	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	11.48	1.98e-18	2.04e-10	0.98	0.79	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	11.43	2.4e-18	2.46e-10	0.99	0.79	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
SKCM	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	11.36	3.3e-18	3.32e-10	1.05	0.79	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
SKCM	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	11.35	3.47e-18	3.49e-10	0.98	0.79	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	11.34	3.53e-18	3.53e-10	0.99	0.79	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	11.32	3.93e-18	3.93e-10	0.96	0.79	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
SKCM	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-11.29	4.41e-18	4.37e-10	-0.83	-0.79	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	11.27	4.96e-18	4.88e-10	0.93	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	11.27	4.96e-18	4.88e-10	0.93	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
SKCM	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-11.25	5.37e-18	5.24e-10	-1.05	-0.79	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-11.25	5.37e-18	5.24e-10	-1.05	-0.79	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-11.25	5.37e-18	5.24e-10	-1.05	-0.79	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-11.25	5.37e-18	5.24e-10	-1.05	-0.79	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
SKCM	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	11.19	7.02e-18	6.77e-10	1	0.78	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
SKCM	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-11.13	9.03e-18	8.62e-10	-1.1	-0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
SKCM	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-11.12	9.29e-18	8.84e-10	-1	-0.78	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	11.12	9.36e-18	8.87e-10	1	0.78	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
SKCM	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	11.11	9.86e-18	9.27e-10	1.09	0.78	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
SKCM	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	11.1	1.02e-17	9.54e-10	1.06	0.78	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
SKCM	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-11.1	1.03e-17	9.61e-10	-1.05	-0.78	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-11.1	1.03e-17	9.61e-10	-1.05	-0.78	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-11.1	1.03e-17	9.61e-10	-1.05	-0.78	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
SKCM	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	11.09	1.08e-17	1e-09	0.87	0.78	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.581	rs2245384	ENSG00000224114.1	RP11-343H5.4	11.06	1.22e-17	1.12e-09	0.94	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:206695837~206696269:-
SKCM	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	11.06	1.24e-17	1.12e-09	1.07	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
SKCM	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	11.06	1.24e-17	1.12e-09	1.07	0.78	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
SKCM	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-11.03	1.38e-17	1.25e-09	-1.02	-0.78	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
SKCM	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	10.99	1.61e-17	1.45e-09	0.98	0.78	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
SKCM	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	10.99	1.61e-17	1.45e-09	0.93	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	10.99	1.61e-17	1.45e-09	0.93	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	10.99	1.61e-17	1.45e-09	0.93	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	10.88	2.68e-17	2.37e-09	0.88	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
SKCM	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	10.86	2.86e-17	2.53e-09	0.83	0.78	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
SKCM	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	10.86	2.9e-17	2.55e-09	0.9	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
SKCM	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-10.82	3.4e-17	2.91e-09	-1.07	-0.77	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
SKCM	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-10.81	3.58e-17	3.04e-09	-1.08	-0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
SKCM	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	10.79	3.97e-17	3.36e-09	1.46	0.77	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	10.79	3.97e-17	3.36e-09	1.46	0.77	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	10.78	4.13e-17	3.48e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
SKCM	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	10.74	4.84e-17	4.06e-09	1.09	0.77	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	10.74	4.84e-17	4.06e-09	1.09	0.77	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
SKCM	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	10.73	4.99e-17	4.18e-09	1.47	0.77	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
SKCM	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-10.7	5.85e-17	4.88e-09	-1.03	-0.77	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
SKCM	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-10.68	6.34e-17	5.28e-09	-1.05	-0.77	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
SKCM	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	10.67	6.52e-17	5.43e-09	0.98	0.77	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	10.62	8.36e-17	6.9e-09	1	0.77	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
SKCM	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	10.6	8.96e-17	7.15e-09	1.45	0.77	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
SKCM	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	10.52	1.27e-16	1.01e-08	1.14	0.77	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
SKCM	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	10.47	1.59e-16	1.25e-08	1.01	0.76	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
SKCM	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	10.41	2.1e-16	1.6e-08	1.04	0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
SKCM	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	10.36	2.6e-16	1.96e-08	0.85	0.76	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
SKCM	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-10.36	2.61e-16	1.97e-08	-1.03	-0.76	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	10.32	3.06e-16	2.27e-08	1.03	0.76	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
SKCM	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	10.31	3.28e-16	2.42e-08	1.18	0.76	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
SKCM	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	10.31	3.28e-16	2.42e-08	1.18	0.76	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
SKCM	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	10.3	3.3e-16	2.42e-08	1.03	0.76	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	10.27	3.9e-16	2.85e-08	1.03	0.76	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
SKCM	trans	rs9899728	0.572	rs9915968	ENSG00000234925.2	ATP5HP4	10.26	4.01e-16	2.92e-08	1.13	0.76	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr12:68642519~68642993:-
SKCM	trans	rs9899728	0.572	rs4365317	ENSG00000234925.2	ATP5HP4	10.26	4.01e-16	2.92e-08	1.13	0.76	Alzheimer's disease or small vessel stroke;	chr17:75063725	chr12:68642519~68642993:-
SKCM	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-10.23	4.57e-16	3.32e-08	-1.02	-0.76	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
SKCM	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	10.18	5.57e-16	4e-08	1.45	0.76	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
SKCM	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	10.17	5.87e-16	4.18e-08	1.05	0.76	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	10.17	5.87e-16	4.18e-08	1.05	0.76	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	10.17	5.87e-16	4.18e-08	1.05	0.76	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	10.17	5.87e-16	4.18e-08	1.05	0.76	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
SKCM	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	10.16	6.19e-16	4.39e-08	1.03	0.75	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	10.16	6.19e-16	4.39e-08	1.03	0.75	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
SKCM	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	10.15	6.43e-16	4.55e-08	1.01	0.75	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
SKCM	trans	rs13177918	0.581	rs2245384	ENSG00000239528.1	RPS14P8	10.11	7.73e-16	5.43e-08	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr5:116562562~116562930:+
SKCM	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	10.11	7.82e-16	5.47e-08	1.01	0.75	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
SKCM	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	10.08	8.78e-16	6.11e-08	0.97	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
SKCM	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	10.08	9.04e-16	6.28e-08	1.02	0.75	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
SKCM	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-10.07	9.3e-16	6.41e-08	-1.02	-0.75	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
SKCM	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	10.07	9.35e-16	6.43e-08	0.86	0.75	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
SKCM	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	10.03	1.1e-15	7.05e-08	1.03	0.75	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
SKCM	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	9.97	1.45e-15	9.16e-08	1.04	0.75	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	9.97	1.45e-15	9.16e-08	1.04	0.75	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
SKCM	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	9.95	1.56e-15	9.75e-08	0.98	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
SKCM	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	9.95	1.56e-15	9.75e-08	0.98	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
SKCM	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	9.95	1.56e-15	9.75e-08	0.98	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
SKCM	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	9.95	1.56e-15	9.75e-08	0.98	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	9.93	1.73e-15	1.07e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
SKCM	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	9.93	1.73e-15	1.07e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
SKCM	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	9.93	1.73e-15	1.07e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
SKCM	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	9.93	1.73e-15	1.07e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
SKCM	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	9.92	1.76e-15	1.09e-07	1.02	0.75	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
SKCM	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	9.9	2e-15	1.22e-07	0.95	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	9.9	2e-15	1.22e-07	0.95	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
SKCM	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-9.88	2.18e-15	1.33e-07	-1.16	-0.75	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	9.82	2.84e-15	1.71e-07	0.87	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.581	rs2245384	ENSG00000213058.3	RP4-765C7.2	9.74	3.92e-15	2.28e-07	0.96	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	9.72	4.38e-15	2.54e-07	0.98	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	9.7	4.7e-15	2.72e-07	0.99	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	9.7	4.7e-15	2.72e-07	0.99	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	9.7	4.73e-15	2.73e-07	0.95	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	9.7	4.73e-15	2.73e-07	0.95	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
SKCM	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	9.7	4.73e-15	2.73e-07	0.95	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
SKCM	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	9.68	5.21e-15	2.97e-07	1.26	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	9.66	5.72e-15	3.2e-07	1.25	0.74	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	9.66	5.75e-15	3.2e-07	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	9.66	5.75e-15	3.2e-07	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	9.66	5.75e-15	3.2e-07	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
SKCM	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	9.63	6.53e-15	3.55e-07	1.25	0.74	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
SKCM	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	9.63	6.53e-15	3.55e-07	1.25	0.74	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
SKCM	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	9.61	7.13e-15	3.77e-07	0.99	0.74	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
SKCM	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	9.57	8.53e-15	4.44e-07	1.24	0.73	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
SKCM	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	9.54	9.93e-15	5.16e-07	1.4	0.73	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
SKCM	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-9.52	1.05e-14	5.43e-07	-0.98	-0.73	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	9.48	1.29e-14	6.34e-07	1	0.73	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	9.44	1.51e-14	7.33e-07	1.2	0.73	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
SKCM	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	9.42	1.68e-14	8.06e-07	1.37	0.73	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	9.42	1.68e-14	8.06e-07	1.37	0.73	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	9.42	1.68e-14	8.06e-07	1.37	0.73	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	9.42	1.68e-14	8.06e-07	1.37	0.73	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	9.41	1.71e-14	8.23e-07	1.37	0.73	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
SKCM	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	9.34	2.35e-14	1.08e-06	1.16	0.73	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	9.34	2.35e-14	1.08e-06	1.16	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	9.34	2.35e-14	1.08e-06	1.16	0.73	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	9.34	2.35e-14	1.08e-06	1.16	0.73	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	9.34	2.35e-14	1.08e-06	1.16	0.73	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	9.33	2.52e-14	1.15e-06	1.23	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	9.31	2.66e-14	1.21e-06	1.21	0.73	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	9.31	2.66e-14	1.21e-06	1.21	0.73	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	9.31	2.66e-14	1.21e-06	1.21	0.73	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	9.31	2.66e-14	1.21e-06	1.21	0.73	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
SKCM	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	9.3	2.83e-14	1.28e-06	0.98	0.73	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	9.3	2.85e-14	1.29e-06	1.16	0.73	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	9.3	2.85e-14	1.29e-06	1.16	0.73	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	9.27	3.21e-14	1.43e-06	0.85	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
SKCM	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-9.27	3.24e-14	1.43e-06	-1.15	-0.72	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
SKCM	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	9.27	3.24e-14	1.43e-06	1.15	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	9.24	3.71e-14	1.63e-06	1.15	0.72	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	9.22	4.03e-14	1.75e-06	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
SKCM	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	9.22	4.03e-14	1.75e-06	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
SKCM	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	9.22	4.03e-14	1.75e-06	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
SKCM	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	9.22	4.03e-14	1.75e-06	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
SKCM	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	9.22	4.07e-14	1.76e-06	0.98	0.72	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	9.22	4.07e-14	1.76e-06	0.98	0.72	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	9.22	4.07e-14	1.76e-06	0.98	0.72	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	9.22	4.08e-14	1.77e-06	0.98	0.72	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
SKCM	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	9.19	4.55e-14	1.94e-06	1.37	0.72	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	9.19	4.55e-14	1.94e-06	1.37	0.72	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	9.19	4.55e-14	1.94e-06	1.37	0.72	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	9.19	4.55e-14	1.94e-06	1.37	0.72	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
SKCM	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-9.17	5.04e-14	2.12e-06	-1.09	-0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-9.15	5.57e-14	2.3e-06	-1.11	-0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	9.14	5.82e-14	2.39e-06	1.24	0.72	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-9.13	6.03e-14	2.47e-06	-1.11	-0.72	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
SKCM	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	9.12	6.23e-14	2.55e-06	1.03	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
SKCM	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-9.12	6.31e-14	2.59e-06	-1.18	-0.72	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	9.08	7.44e-14	3.02e-06	1.17	0.72	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	9.07	7.82e-14	3.17e-06	1.2	0.72	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	9.07	7.83e-14	3.17e-06	1.15	0.72	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	9.06	8.31e-14	3.35e-06	1.15	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	9.06	8.31e-14	3.35e-06	1.15	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-9.05	8.68e-14	3.48e-06	-0.86	-0.72	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
SKCM	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	9.03	9.32e-14	3.66e-06	1.21	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	9.03	9.32e-14	3.66e-06	1.21	0.72	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-9.03	9.36e-14	3.66e-06	-1.14	-0.71	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	9.03	9.37e-14	3.66e-06	1.17	0.71	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	9.02	9.67e-14	3.78e-06	0.87	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
SKCM	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	9.01	1.03e-13	3.98e-06	1.15	0.71	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	9	1.1e-13	4.25e-06	0.86	0.71	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-8.99	1.11e-13	4.29e-06	-1.2	-0.71	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	8.99	1.11e-13	4.29e-06	1.2	0.71	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
SKCM	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	8.99	1.14e-13	4.39e-06	1.19	0.71	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
SKCM	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	8.97	1.22e-13	4.66e-06	0.99	0.71	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	8.97	1.22e-13	4.66e-06	0.99	0.71	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	8.97	1.22e-13	4.66e-06	0.99	0.71	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	8.97	1.22e-13	4.66e-06	0.99	0.71	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-8.95	1.34e-13	5.09e-06	-1.14	-0.71	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	8.95	1.37e-13	5.17e-06	1.21	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	8.95	1.37e-13	5.17e-06	1.21	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	8.95	1.37e-13	5.17e-06	1.21	0.71	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	8.95	1.37e-13	5.17e-06	1.21	0.71	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	8.94	1.41e-13	5.32e-06	1.18	0.71	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	8.94	1.44e-13	5.41e-06	1.17	0.71	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	8.94	1.44e-13	5.41e-06	1.17	0.71	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
SKCM	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	8.92	1.53e-13	5.7e-06	0.89	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
SKCM	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-8.92	1.54e-13	5.76e-06	-0.87	-0.71	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
SKCM	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	8.92	1.55e-13	5.78e-06	0.99	0.71	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
SKCM	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	8.91	1.6e-13	5.95e-06	1.02	0.71	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
SKCM	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-8.9	1.71e-13	6.37e-06	-1.13	-0.71	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-8.89	1.73e-13	6.38e-06	-1.13	-0.71	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-8.89	1.73e-13	6.38e-06	-1.13	-0.71	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-8.89	1.73e-13	6.38e-06	-1.13	-0.71	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-8.89	1.73e-13	6.38e-06	-1.13	-0.71	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-8.89	1.73e-13	6.38e-06	-1.13	-0.71	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	8.89	1.75e-13	6.41e-06	1.17	0.71	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	8.89	1.75e-13	6.41e-06	1.17	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	8.87	1.94e-13	7.08e-06	1.2	0.71	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
SKCM	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	8.87	1.94e-13	7.08e-06	1.2	0.71	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	8.87	1.94e-13	7.08e-06	1.2	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
SKCM	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
SKCM	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	8.86	1.98e-13	7.16e-06	0.95	0.71	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
SKCM	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-8.86	1.98e-13	7.16e-06	-1.12	-0.71	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-8.86	1.98e-13	7.16e-06	-1.12	-0.71	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-8.86	1.98e-13	7.16e-06	-1.12	-0.71	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
SKCM	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-8.85	2.06e-13	7.31e-06	-0.87	-0.71	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-8.8	2.64e-13	9.17e-06	-0.87	-0.71	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-8.8	2.64e-13	9.17e-06	-0.87	-0.71	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	8.8	2.68e-13	9.29e-06	1.24	0.71	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
SKCM	trans	rs13253073	0.545	rs13265660	ENSG00000260318.1	COX6CP1	8.79	2.74e-13	9.48e-06	1.47	0.71	Glucose homeostasis traits;	chr8:99815931	chr16:11903923~11904137:-
SKCM	trans	rs13253073	0.545	rs13260744	ENSG00000260318.1	COX6CP1	8.79	2.74e-13	9.48e-06	1.47	0.71	Glucose homeostasis traits;	chr8:99819032	chr16:11903923~11904137:-
SKCM	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-8.77	3.05e-13	1.05e-05	-0.84	-0.7	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
SKCM	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-8.75	3.31e-13	1.13e-05	-0.96	-0.7	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
SKCM	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-8.75	3.36e-13	1.14e-05	-0.85	-0.7	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
SKCM	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	8.74	3.39e-13	1.15e-05	0.99	0.7	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
SKCM	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-8.71	3.93e-13	1.32e-05	-0.92	-0.7	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
SKCM	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	8.69	4.25e-13	1.42e-05	1.23	0.7	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-8.69	4.26e-13	1.43e-05	-0.87	-0.7	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-8.69	4.26e-13	1.43e-05	-0.87	-0.7	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
SKCM	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	8.69	4.36e-13	1.46e-05	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
SKCM	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-8.68	4.52e-13	1.51e-05	-1.1	-0.7	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	8.68	4.52e-13	1.51e-05	1.16	0.7	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	8.66	4.87e-13	1.62e-05	1.18	0.7	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	8.66	4.91e-13	1.63e-05	0.91	0.7	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
SKCM	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	8.65	5.26e-13	1.74e-05	0.94	0.7	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-8.63	5.59e-13	1.82e-05	-1.15	-0.7	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	8.63	5.59e-13	1.82e-05	1.15	0.7	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
SKCM	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	8.61	6.05e-13	1.96e-05	0.93	0.7	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
SKCM	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	8.6	6.37e-13	2.05e-05	0.98	0.7	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
SKCM	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	8.6	6.37e-13	2.05e-05	0.98	0.7	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
SKCM	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-8.59	6.71e-13	2.15e-05	-1.14	-0.7	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
SKCM	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	8.59	6.73e-13	2.15e-05	0.93	0.7	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
SKCM	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-8.59	6.77e-13	2.16e-05	-0.84	-0.7	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
SKCM	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	8.58	6.94e-13	2.21e-05	0.93	0.7	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	8.58	6.94e-13	2.21e-05	0.93	0.7	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
SKCM	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	8.58	6.94e-13	2.21e-05	0.93	0.7	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	8.58	6.94e-13	2.21e-05	0.93	0.7	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
SKCM	trans	rs1816752	0.624	rs2862901	ENSG00000237917.1	PARP4P1	-8.57	7.22e-13	2.29e-05	-0.85	-0.7	Obesity-related traits;	chr13:24461101	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-8.57	7.34e-13	2.33e-05	-1.17	-0.7	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-8.57	7.34e-13	2.33e-05	-1.17	-0.7	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-8.57	7.34e-13	2.33e-05	-1.17	-0.7	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	8.55	8.07e-13	2.54e-05	1.1	0.7	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	8.55	8.21e-13	2.58e-05	1.01	0.7	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
SKCM	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	8.54	8.48e-13	2.66e-05	1.19	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-8.51	9.49e-13	2.96e-05	-1.03	-0.69	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
SKCM	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	8.49	1.04e-12	3.22e-05	0.99	0.69	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
SKCM	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	8.49	1.04e-12	3.22e-05	1.17	0.69	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	8.48	1.12e-12	3.43e-05	1.1	0.69	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	8.48	1.12e-12	3.43e-05	1.1	0.69	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
SKCM	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	8.48	1.12e-12	3.44e-05	0.97	0.69	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
SKCM	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	8.45	1.27e-12	3.89e-05	0.92	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
SKCM	trans	rs5022636	0.525	rs4971013	ENSG00000180764.13	PIPSL	8.44	1.3e-12	3.96e-05	0.74	0.69	Gut microbiota (functional units);	chr1:151200637	chr10:93958191~93961540:-
SKCM	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	8.43	1.37e-12	4.17e-05	1.14	0.69	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
SKCM	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	8.43	1.4e-12	4.27e-05	0.96	0.69	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
SKCM	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-8.43	1.4e-12	4.27e-05	-0.8	-0.69	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-8.43	1.4e-12	4.27e-05	-0.8	-0.69	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
SKCM	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	8.4	1.57e-12	4.76e-05	0.93	0.69	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
SKCM	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-8.38	1.7e-12	5.07e-05	-0.85	-0.69	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-8.38	1.73e-12	5.14e-05	-0.85	-0.69	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-8.38	1.73e-12	5.14e-05	-0.85	-0.69	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
SKCM	trans	rs5022636	0.525	rs4291501	ENSG00000180764.13	PIPSL	8.37	1.79e-12	5.29e-05	0.74	0.69	Gut microbiota (functional units);	chr1:151196681	chr10:93958191~93961540:-
SKCM	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	8.37	1.82e-12	5.38e-05	1.16	0.69	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	8.37	1.82e-12	5.38e-05	1.16	0.69	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-8.37	1.82e-12	5.38e-05	-1.16	-0.69	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-8.36	1.92e-12	5.64e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-8.36	1.93e-12	5.65e-05	-0.84	-0.69	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-8.36	1.93e-12	5.65e-05	-0.84	-0.69	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-8.36	1.93e-12	5.65e-05	-0.84	-0.69	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-8.36	1.93e-12	5.65e-05	-0.84	-0.69	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-8.36	1.93e-12	5.65e-05	-0.84	-0.69	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
SKCM	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-8.35	2e-12	5.85e-05	-0.86	-0.69	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
SKCM	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-8.34	2.07e-12	6.06e-05	-0.74	-0.69	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
SKCM	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	8.33	2.12e-12	6.18e-05	1.04	0.69	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-8.33	2.13e-12	6.22e-05	-0.98	-0.69	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
SKCM	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	8.31	2.33e-12	6.77e-05	1.08	0.69	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
SKCM	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-8.3	2.45e-12	7.1e-05	-0.94	-0.68	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	8.3	2.45e-12	7.1e-05	0.94	0.68	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
SKCM	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	8.3	2.47e-12	7.17e-05	1.53	0.68	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
SKCM	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	8.3	2.47e-12	7.17e-05	0.97	0.68	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
SKCM	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	8.26	2.95e-12	8.44e-05	0.73	0.68	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
SKCM	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-8.25	3.08e-12	8.82e-05	-0.8	-0.68	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	8.24	3.24e-12	9.21e-05	1.03	0.68	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-8.23	3.3e-12	9.32e-05	-0.86	-0.68	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	8.21	3.62e-12	0.000102	1.12	0.68	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-8.21	3.67e-12	0.000103	-0.82	-0.68	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
SKCM	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	8.21	3.68e-12	0.000103	1.63	0.68	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
SKCM	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	8.21	3.69e-12	0.000104	0.86	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
SKCM	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-8.2	3.84e-12	0.000105	-0.82	-0.68	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
SKCM	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	8.2	3.87e-12	0.000105	1.13	0.68	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	8.2	3.87e-12	0.000105	1.13	0.68	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
SKCM	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	8.19	4.04e-12	0.000109	0.73	0.68	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
SKCM	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	8.18	4.26e-12	0.000115	1.35	0.68	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
SKCM	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-8.18	4.31e-12	0.000115	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-8.18	4.31e-12	0.000115	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
SKCM	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	8.17	4.35e-12	0.000116	0.85	0.68	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	8.17	4.35e-12	0.000116	0.85	0.68	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	8.17	4.35e-12	0.000116	0.85	0.68	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
SKCM	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-8.17	4.5e-12	0.000117	-0.98	-0.68	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	8.17	4.5e-12	0.000117	0.98	0.68	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
SKCM	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	8.16	4.58e-12	0.000119	0.73	0.68	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
SKCM	trans	rs7258465	1	rs4808804	ENSG00000267533.1	RP11-815J4.7	8.16	4.63e-12	0.000121	0.89	0.68	Breast cancer;	chr19:18474515	chr18:12067173~12068417:-
SKCM	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	8.14	5.11e-12	0.000132	1.51	0.68	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
SKCM	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-8.12	5.48e-12	0.000142	-1.07	-0.68	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	8.12	5.57e-12	0.000144	1.07	0.68	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
SKCM	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	8.11	5.7e-12	0.000147	0.7	0.68	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	8.11	5.7e-12	0.000147	0.7	0.68	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
SKCM	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-8.11	5.72e-12	0.000147	-0.9	-0.68	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
SKCM	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-8.11	5.88e-12	0.000151	-0.83	-0.68	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-8.11	5.88e-12	0.000151	-0.83	-0.68	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-8.11	5.88e-12	0.000151	-0.83	-0.68	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-8.11	5.88e-12	0.000151	-0.83	-0.68	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	8.11	5.89e-12	0.000151	1.05	0.68	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.542	rs11171986	ENSG00000121089.4	NACA3P	-8.09	6.19e-12	0.000158	-0.83	-0.68	Platelet count;	chr12:56819043	chr4:164943290~164943937:+
SKCM	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	8.09	6.38e-12	0.00016	1	0.68	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-8.09	6.38e-12	0.00016	-1	-0.68	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
SKCM	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-8.08	6.73e-12	0.000168	-0.83	-0.67	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-8.07	6.82e-12	0.000169	-0.83	-0.67	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-8.07	6.82e-12	0.000169	-0.83	-0.67	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-8.07	6.82e-12	0.000169	-0.83	-0.67	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-8.07	6.82e-12	0.000169	-0.83	-0.67	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-8.07	6.82e-12	0.000169	-0.83	-0.67	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	8.07	6.82e-12	0.000169	0.83	0.67	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
SKCM	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	8.07	6.94e-12	0.000172	0.95	0.67	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
SKCM	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-8.06	7.07e-12	0.000175	-1.12	-0.67	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
SKCM	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	8.06	7.26e-12	0.000179	0.96	0.67	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	8.06	7.26e-12	0.000179	0.96	0.67	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
SKCM	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-8.05	7.58e-12	0.000186	-0.85	-0.67	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
SKCM	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-8.03	8.06e-12	0.000197	-1.1	-0.67	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
SKCM	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	8.03	8.13e-12	0.000198	0.87	0.67	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
SKCM	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-8.03	8.17e-12	0.000199	-0.7	-0.67	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-8.03	8.17e-12	0.000199	-0.7	-0.67	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-8.03	8.17e-12	0.000199	-0.7	-0.67	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-8.03	8.17e-12	0.000199	-0.7	-0.67	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
SKCM	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-8.03	8.37e-12	0.000203	-0.85	-0.67	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-8.02	8.65e-12	0.000209	-1.05	-0.67	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-8.01	9.03e-12	0.000218	-0.97	-0.67	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
SKCM	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-8	9.45e-12	0.000228	-0.77	-0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
SKCM	trans	rs941207	0.547	rs56183434	ENSG00000121089.4	NACA3P	8	9.51e-12	0.000229	0.85	0.67	Platelet count;	chr12:56676145	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	8	9.51e-12	0.000229	1.18	0.67	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	7.98	1.02e-11	0.000245	1.14	0.67	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-7.98	1.03e-11	0.000247	-0.84	-0.67	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-7.98	1.03e-11	0.000247	-0.84	-0.67	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-7.98	1.03e-11	0.000247	-0.84	-0.67	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
SKCM	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-7.97	1.05e-11	0.000252	-0.99	-0.67	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
SKCM	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-7.97	1.09e-11	0.000261	-0.85	-0.67	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
SKCM	trans	rs55665837	0.778	rs11023212	ENSG00000236360.2	RP11-334A14.2	7.96	1.1e-11	0.000263	0.97	0.67	Vitamin D levels;	chr11:14410163	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-7.95	1.17e-11	0.000276	-1.09	-0.67	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
SKCM	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	7.94	1.22e-11	0.000287	0.69	0.67	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	7.93	1.26e-11	0.000296	0.68	0.67	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
SKCM	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	7.93	1.26e-11	0.000296	0.68	0.67	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	7.93	1.26e-11	0.000296	0.68	0.67	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
SKCM	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-7.93	1.28e-11	0.000299	-0.86	-0.67	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
SKCM	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-7.93	1.31e-11	0.000307	-1.04	-0.67	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-7.93	1.31e-11	0.000307	-1.04	-0.67	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-7.93	1.31e-11	0.000307	-1.04	-0.67	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	7.93	1.31e-11	0.000307	0.84	0.67	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-7.92	1.33e-11	0.00031	-1.12	-0.67	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-7.92	1.33e-11	0.00031	-1.12	-0.67	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-7.92	1.33e-11	0.00031	-1.12	-0.67	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-7.91	1.38e-11	0.000318	-1.11	-0.67	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-7.91	1.38e-11	0.000318	-1.11	-0.67	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
SKCM	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	7.91	1.38e-11	0.000318	1.11	0.67	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
SKCM	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	7.9	1.45e-11	0.000333	1.51	0.67	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
SKCM	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	7.9	1.46e-11	0.000336	1.49	0.67	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
SKCM	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	7.9	1.5e-11	0.000344	1.48	0.67	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
SKCM	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	7.9	1.5e-11	0.000344	1.48	0.67	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
SKCM	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	7.9	1.5e-11	0.000344	1.48	0.67	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
SKCM	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	7.9	1.5e-11	0.000344	1.48	0.67	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
SKCM	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-7.89	1.52e-11	0.000347	-0.81	-0.67	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-7.88	1.58e-11	0.000359	-0.81	-0.67	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
SKCM	trans	rs7258465	0.965	rs748609	ENSG00000267533.1	RP11-815J4.7	7.88	1.6e-11	0.000363	0.85	0.67	Breast cancer;	chr19:18449472	chr18:12067173~12068417:-
SKCM	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	7.88	1.6e-11	0.000364	0.67	0.67	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
SKCM	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-7.84	1.93e-11	0.000433	-0.91	-0.66	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
SKCM	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	7.83	1.98e-11	0.000444	1.52	0.66	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
SKCM	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-7.83	1.99e-11	0.000446	-0.96	-0.66	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
SKCM	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	7.83	1.99e-11	0.000446	1.53	0.66	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
SKCM	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	7.83	2.04e-11	0.000457	0.7	0.66	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
SKCM	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	7.82	2.06e-11	0.000461	0.83	0.66	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-7.82	2.09e-11	0.000465	-1.07	-0.66	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-7.82	2.09e-11	0.000465	-1.07	-0.66	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	7.82	2.09e-11	0.000465	1.07	0.66	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	7.8	2.24e-11	0.000497	0.97	0.66	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
SKCM	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	7.8	2.27e-11	0.000498	0.84	0.66	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	7.8	2.29e-11	0.000498	1.16	0.66	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	7.8	2.29e-11	0.000498	1.16	0.66	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	7.8	2.29e-11	0.000498	1.16	0.66	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
SKCM	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	7.8	2.31e-11	5e-04	0.68	0.66	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	7.8	2.31e-11	5e-04	0.68	0.66	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
SKCM	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-7.8	2.33e-11	0.000505	-0.98	-0.66	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
SKCM	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	7.79	2.39e-11	0.000517	0.83	0.66	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
SKCM	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	7.77	2.6e-11	0.000553	1.48	0.66	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
SKCM	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-7.77	2.64e-11	0.00056	-1.05	-0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
SKCM	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-7.77	2.64e-11	0.00056	-1.05	-0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
SKCM	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	7.77	2.66e-11	0.000564	0.83	0.66	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	7.77	2.66e-11	0.000564	0.83	0.66	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
SKCM	trans	rs28375303	1	rs28375303	ENSG00000267533.1	RP11-815J4.7	7.77	2.67e-11	0.000566	0.88	0.66	Monocyte count;	chr19:18419351	chr18:12067173~12068417:-
SKCM	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	7.76	2.71e-11	0.000573	0.73	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	7.76	2.71e-11	0.000573	0.73	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
SKCM	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	7.76	2.71e-11	0.000573	0.73	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
SKCM	trans	rs7258465	0.931	rs11673604	ENSG00000267533.1	RP11-815J4.7	7.75	2.81e-11	0.000593	0.85	0.66	Breast cancer;	chr19:18430178	chr18:12067173~12068417:-
SKCM	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	7.75	2.9e-11	0.000611	0.74	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
SKCM	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-7.75	2.91e-11	0.000612	-0.85	-0.66	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
SKCM	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	7.74	2.95e-11	0.000618	1.48	0.66	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
SKCM	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	7.74	3e-11	0.000629	0.92	0.66	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
SKCM	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	7.74	3e-11	0.000629	0.92	0.66	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
SKCM	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	7.73	3.17e-11	0.000662	1	0.66	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	7.72	3.22e-11	0.000673	1.02	0.66	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
SKCM	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	7.71	3.38e-11	0.000698	1.5	0.66	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
SKCM	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-7.71	3.45e-11	0.000709	-0.7	-0.66	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
SKCM	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-7.71	3.49e-11	0.000715	-0.82	-0.66	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-7.71	3.49e-11	0.000715	-0.82	-0.66	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-7.71	3.49e-11	0.000715	-0.82	-0.66	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
SKCM	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-7.7	3.52e-11	0.000719	-0.68	-0.66	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
SKCM	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-7.69	3.75e-11	0.000763	-1	-0.66	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	7.69	3.75e-11	0.000763	1	0.66	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	7.69	3.75e-11	0.000763	1	0.66	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	7.69	3.75e-11	0.000763	1	0.66	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	7.69	3.75e-11	0.000763	1	0.66	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
SKCM	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	7.69	3.76e-11	0.000763	0.68	0.66	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	7.69	3.76e-11	0.000763	0.68	0.66	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	7.69	3.76e-11	0.000763	0.68	0.66	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	7.69	3.82e-11	0.000774	0.68	0.66	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	7.69	3.82e-11	0.000774	0.68	0.66	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
SKCM	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	7.68	3.94e-11	0.000794	0.68	0.66	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
SKCM	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	7.67	4e-11	0.000806	0.98	0.66	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	7.66	4.19e-11	0.00084	0.99	0.66	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
SKCM	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-7.65	4.38e-11	0.000875	-1.3	-0.65	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
SKCM	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-7.65	4.48e-11	0.000892	-0.83	-0.65	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
SKCM	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-7.65	4.51e-11	0.000897	-0.95	-0.65	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
SKCM	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	7.64	4.73e-11	0.000939	0.83	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
SKCM	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-7.63	4.81e-11	0.000954	-0.67	-0.65	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-7.63	4.81e-11	0.000954	-0.67	-0.65	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-7.63	4.81e-11	0.000954	-0.67	-0.65	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
SKCM	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	7.62	5.13e-11	0.00101	0.76	0.65	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
SKCM	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-7.61	5.26e-11	0.00104	-1.02	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-7.61	5.26e-11	0.00104	-1.02	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
SKCM	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-7.61	5.29e-11	0.00104	-1.02	-0.65	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
SKCM	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	7.61	5.33e-11	0.00105	0.78	0.65	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
SKCM	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	7.61	5.33e-11	0.00105	0.78	0.65	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
SKCM	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	7.61	5.4e-11	0.00106	0.89	0.65	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
SKCM	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-7.6	5.46e-11	0.00107	-1.02	-0.65	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
SKCM	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	7.6	5.54e-11	0.00108	1.02	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
SKCM	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-7.59	5.72e-11	0.00112	-0.84	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
SKCM	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	7.59	5.84e-11	0.00114	0.81	0.65	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
SKCM	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	7.59	5.89e-11	0.00114	0.84	0.65	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	7.58	6.06e-11	0.00117	0.84	0.65	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	7.58	6.06e-11	0.00117	0.84	0.65	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	7.58	6.06e-11	0.00117	0.84	0.65	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	7.57	6.25e-11	0.0012	1.14	0.65	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-7.57	6.28e-11	0.00121	-0.79	-0.65	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-7.57	6.28e-11	0.00121	-0.79	-0.65	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-7.57	6.28e-11	0.00121	-0.79	-0.65	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
SKCM	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	7.57	6.29e-11	0.00121	0.81	0.65	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
SKCM	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	7.57	6.29e-11	0.00121	1.42	0.65	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	7.57	6.29e-11	0.00121	1.42	0.65	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	7.57	6.29e-11	0.00121	1.42	0.65	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
SKCM	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-7.57	6.38e-11	0.00122	-0.81	-0.65	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
SKCM	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	7.56	6.54e-11	0.00125	0.85	0.65	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	7.56	6.54e-11	0.00125	0.85	0.65	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	7.56	6.54e-11	0.00125	0.85	0.65	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	7.56	6.54e-11	0.00125	0.85	0.65	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	7.56	6.54e-11	0.00125	0.85	0.65	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
SKCM	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	7.56	6.56e-11	0.00125	0.83	0.65	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
SKCM	trans	rs5022636	0.525	rs4520422	ENSG00000180764.13	PIPSL	7.55	7.1e-11	0.00135	0.68	0.65	Gut microbiota (functional units);	chr1:151207467	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	7.55	7.1e-11	0.00135	0.68	0.65	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
SKCM	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	7.54	7.22e-11	0.00137	0.84	0.65	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
SKCM	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-7.54	7.35e-11	0.00139	-0.78	-0.65	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
SKCM	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	7.54	7.41e-11	0.0014	0.88	0.65	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
SKCM	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	7.53	7.57e-11	0.00143	0.85	0.65	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
SKCM	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	7.53	7.71e-11	0.00145	0.82	0.65	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
SKCM	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-7.52	7.93e-11	0.00149	-0.96	-0.65	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
SKCM	trans	rs8081395	0.899	rs2777898	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59738247	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.899	rs8070345	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59739396	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.834	rs2665397	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59749370	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.804	rs2777884	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59753065	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.932	rs2777885	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59753112	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.866	rs2777899	ENSG00000187870.7	RNFT1P3	-7.52	8.1e-11	0.00151	-0.71	-0.65	White blood cell count;	chr17:59755030	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.899	rs2645477	ENSG00000187870.7	RNFT1P3	-7.51	8.14e-11	0.00152	-0.71	-0.65	White blood cell count;	chr17:59768263	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-7.51	8.14e-11	0.00152	-0.71	-0.65	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-7.51	8.19e-11	0.00152	-0.65	-0.65	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	7.51	8.19e-11	0.00152	0.65	0.65	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
SKCM	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	7.51	8.19e-11	0.00152	0.65	0.65	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
SKCM	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-7.51	8.27e-11	0.00154	-0.8	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
SKCM	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	7.51	8.35e-11	0.00155	0.89	0.65	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
SKCM	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	7.51	8.38e-11	0.00156	0.82	0.65	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	7.5	8.53e-11	0.00158	0.95	0.65	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
SKCM	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	7.5	8.6e-11	0.00159	0.82	0.65	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	7.5	8.6e-11	0.00159	0.82	0.65	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	7.49	8.95e-11	0.00165	1.05	0.65	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-7.49	9.09e-11	0.00168	-0.94	-0.65	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-7.49	9.09e-11	0.00168	-0.94	-0.65	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-7.49	9.09e-11	0.00168	-0.94	-0.65	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-7.49	9.09e-11	0.00168	-0.94	-0.65	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
SKCM	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	7.48	9.48e-11	0.00174	0.8	0.65	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
SKCM	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	7.48	9.51e-11	0.00175	0.82	0.65	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
SKCM	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	7.48	9.6e-11	0.00176	0.83	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
SKCM	trans	rs7258465	0.931	rs34053595	ENSG00000267533.1	RP11-815J4.7	7.48	9.66e-11	0.00177	0.81	0.65	Breast cancer;	chr19:18445939	chr18:12067173~12068417:-
SKCM	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-7.48	9.68e-11	0.00177	-1.31	-0.65	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
SKCM	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	7.47	9.72e-11	0.00178	0.82	0.65	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	7.47	9.72e-11	0.00178	0.82	0.65	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
SKCM	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-7.46	1.02e-10	0.00187	-0.64	-0.65	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
SKCM	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	7.46	1.02e-10	0.00187	0.91	0.65	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
SKCM	trans	rs9611565	0.592	rs4822047	ENSG00000268568.1	AC007228.9	-7.46	1.04e-10	0.0019	-1.05	-0.65	Vitiligo;	chr22:41591933	chr19:56672574~56673901:-
SKCM	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-7.46	1.04e-10	0.00191	-1.03	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
SKCM	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	7.45	1.08e-10	0.00197	1	0.64	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	7.45	1.08e-10	0.00197	1	0.64	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	7.45	1.08e-10	0.00197	1	0.64	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
SKCM	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	7.45	1.09e-10	0.00198	0.87	0.64	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
SKCM	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	7.44	1.11e-10	0.00202	0.67	0.64	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
SKCM	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	7.44	1.11e-10	0.00202	0.8	0.64	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-7.44	1.12e-10	0.00203	-0.93	-0.64	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	7.44	1.12e-10	0.00203	0.93	0.64	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
SKCM	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-7.44	1.14e-10	0.00207	-0.8	-0.64	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	7.44	1.14e-10	0.00207	0.8	0.64	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
SKCM	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	7.44	1.15e-10	0.00209	0.84	0.64	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
SKCM	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-7.43	1.16e-10	0.0021	-1.02	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-7.43	1.16e-10	0.0021	-1.02	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
SKCM	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-7.43	1.16e-10	0.0021	-1.02	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
SKCM	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-7.42	1.22e-10	0.0022	-0.79	-0.64	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-7.42	1.24e-10	0.00223	-1	-0.64	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
SKCM	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	7.42	1.25e-10	0.00224	0.84	0.64	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
SKCM	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	7.41	1.28e-10	0.0023	0.79	0.64	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
SKCM	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	7.41	1.28e-10	0.0023	0.84	0.64	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
SKCM	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-7.41	1.29e-10	0.0023	-0.79	-0.64	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
SKCM	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	7.41	1.29e-10	0.00231	0.86	0.64	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
SKCM	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	7.41	1.3e-10	0.00233	0.8	0.64	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
SKCM	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	7.4	1.34e-10	0.0024	0.79	0.64	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
SKCM	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	7.4	1.34e-10	0.0024	1.47	0.64	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
SKCM	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-7.4	1.34e-10	0.0024	-1.16	-0.64	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
SKCM	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-7.4	1.36e-10	0.00242	-0.88	-0.64	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
SKCM	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-7.4	1.36e-10	0.00243	-0.76	-0.64	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	7.39	1.39e-10	0.00248	0.97	0.64	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
SKCM	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	7.39	1.42e-10	0.00251	0.67	0.64	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	7.39	1.42e-10	0.00251	0.67	0.64	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	7.39	1.42e-10	0.00251	0.67	0.64	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
SKCM	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	7.39	1.44e-10	0.00255	0.81	0.64	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
SKCM	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	7.38	1.48e-10	0.0026	1.04	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
SKCM	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	7.38	1.48e-10	0.0026	1.04	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
SKCM	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	7.37	1.52e-10	0.00268	0.8	0.64	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	7.37	1.52e-10	0.00268	0.8	0.64	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-7.37	1.53e-10	0.00269	-0.99	-0.64	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
SKCM	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
SKCM	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	7.36	1.6e-10	0.0028	1.48	0.64	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
SKCM	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	7.36	1.6e-10	0.0028	0.67	0.64	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
SKCM	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	7.36	1.61e-10	0.00281	0.99	0.64	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
SKCM	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	7.36	1.63e-10	0.00283	0.8	0.64	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
SKCM	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	7.36	1.65e-10	0.00286	0.78	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
SKCM	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	7.35	1.67e-10	0.00286	0.99	0.64	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
SKCM	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	7.35	1.67e-10	0.00286	0.81	0.64	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	7.35	1.67e-10	0.00286	0.81	0.64	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	7.35	1.67e-10	0.00286	0.81	0.64	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
SKCM	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	7.35	1.72e-10	0.00294	1.03	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	7.35	1.72e-10	0.00294	1.03	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
SKCM	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	7.35	1.72e-10	0.00294	0.94	0.64	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
SKCM	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-7.34	1.8e-10	0.00306	-0.94	-0.64	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
SKCM	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
SKCM	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
SKCM	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	7.33	1.82e-10	0.00309	0.8	0.64	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
SKCM	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	7.33	1.83e-10	0.0031	0.87	0.64	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
SKCM	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	7.33	1.83e-10	0.0031	0.83	0.64	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	7.33	1.83e-10	0.0031	0.83	0.64	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
SKCM	trans	rs5022636	0.525	rs4971021	ENSG00000180764.13	PIPSL	7.33	1.85e-10	0.00312	0.67	0.64	Gut microbiota (functional units);	chr1:151246152	chr10:93958191~93961540:-
SKCM	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
SKCM	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
SKCM	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-7.33	1.87e-10	0.00315	-1.03	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
SKCM	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	7.33	1.88e-10	0.00317	1.43	0.64	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
SKCM	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	7.31	1.98e-10	0.00333	0.8	0.64	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-7.31	2.04e-10	0.00342	-0.93	-0.64	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
SKCM	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	7.3	2.1e-10	0.00352	0.76	0.64	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
SKCM	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	7.3	2.1e-10	0.00352	0.76	0.64	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
SKCM	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-7.29	2.15e-10	0.0036	-1.42	-0.64	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
SKCM	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	7.29	2.22e-10	0.00371	1.02	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	7.29	2.22e-10	0.00371	1.02	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
SKCM	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
SKCM	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-7.28	2.26e-10	0.00376	-0.77	-0.64	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
SKCM	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	7.28	2.28e-10	0.00379	0.98	0.64	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
SKCM	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-7.28	2.28e-10	0.0038	-0.77	-0.64	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
SKCM	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	7.26	2.49e-10	0.00413	0.77	0.64	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	7.26	2.51e-10	0.00416	0.76	0.64	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
SKCM	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	7.26	2.53e-10	0.00419	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	7.26	2.53e-10	0.00419	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
SKCM	trans	rs7258465	1	rs8106096	ENSG00000267533.1	RP11-815J4.7	7.25	2.57e-10	0.00425	0.83	0.63	Breast cancer;	chr19:18425606	chr18:12067173~12068417:-
SKCM	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-7.25	2.66e-10	0.0044	-0.99	-0.63	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
SKCM	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	7.24	2.69e-10	0.00443	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	7.24	2.69e-10	0.00443	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	7.24	2.69e-10	0.00443	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
SKCM	trans	rs11077773	1	rs11077773	ENSG00000234925.2	ATP5HP4	-7.24	2.69e-10	0.00444	-1.16	-0.63	Information processing speed;	chr17:75063978	chr12:68642519~68642993:-
SKCM	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	7.24	2.76e-10	0.00454	0.86	0.63	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
SKCM	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	7.24	2.77e-10	0.00454	1.01	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	7.24	2.77e-10	0.00454	1.01	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
SKCM	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	7.24	2.77e-10	0.00454	1.01	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
SKCM	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	7.24	2.79e-10	0.00459	0.64	0.63	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
SKCM	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-7.23	2.8e-10	0.0046	-0.9	-0.63	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	7.23	2.81e-10	0.00461	0.97	0.63	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
SKCM	trans	rs5022636	0.891	rs4971027	ENSG00000180764.13	PIPSL	7.23	2.83e-10	0.00464	0.67	0.63	Gut microbiota (functional units);	chr1:151277945	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.79	rs10399679	ENSG00000180764.13	PIPSL	7.23	2.83e-10	0.00464	0.67	0.63	Gut microbiota (functional units);	chr1:151278361	chr10:93958191~93961540:-
SKCM	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
SKCM	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
SKCM	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
SKCM	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	7.23	2.85e-10	0.00466	1.42	0.63	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
SKCM	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	7.22	2.98e-10	0.00487	1.08	0.63	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
SKCM	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	7.22	3.01e-10	0.00491	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	7.22	3.06e-10	0.00498	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	7.22	3.06e-10	0.00498	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	7.22	3.06e-10	0.00498	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	7.22	3.06e-10	0.00498	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	7.22	3.06e-10	0.00498	0.6	0.63	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
SKCM	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	7.21	3.16e-10	0.00513	0.79	0.63	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
SKCM	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	7.2	3.3e-10	0.00533	0.66	0.63	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
SKCM	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	7.18	3.51e-10	0.00564	0.8	0.63	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
SKCM	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-7.18	3.58e-10	0.00573	-0.58	-0.63	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
SKCM	trans	rs8081395	0.509	rs1292045	ENSG00000187870.7	RNFT1P3	7.17	3.68e-10	0.0059	0.64	0.63	White blood cell count;	chr17:59869851	chr17:20743333~20754501:-
SKCM	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	7.17	3.69e-10	0.0059	0.75	0.63	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
SKCM	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	7.17	3.79e-10	0.00605	1.02	0.63	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	7.17	3.79e-10	0.00605	1.02	0.63	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
SKCM	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	7.15	4.03e-10	0.0064	0.8	0.63	Longevity;	chr3:48407742	chr1:27649419~27649610:+
SKCM	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	7.14	4.2e-10	0.00665	0.68	0.63	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
SKCM	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	7.14	4.2e-10	0.00665	0.68	0.63	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
SKCM	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	7.14	4.22e-10	0.00669	0.81	0.63	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
SKCM	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	7.13	4.55e-10	0.00712	0.73	0.63	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
SKCM	trans	rs2627282	0.577	rs921781	ENSG00000239322.1	ATP6V1B1-AS1	7.12	4.65e-10	0.00726	0.95	0.63	Blood pressure measurement (high sodium intervention);	chr8:2914789	chr2:70941817~70948610:-
SKCM	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	7.12	4.68e-10	0.00732	1.49	0.63	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
SKCM	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	7.12	4.7e-10	0.00734	0.95	0.63	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
SKCM	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	7.1	5.14e-10	0.00792	0.82	0.63	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
SKCM	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	7.1	5.15e-10	0.00793	0.97	0.63	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
SKCM	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	7.08	5.5e-10	0.00841	0.96	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
SKCM	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	7.07	5.73e-10	0.00864	0.77	0.63	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	7.07	5.73e-10	0.00864	0.77	0.63	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	7.07	5.73e-10	0.00864	0.77	0.63	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	7.07	5.73e-10	0.00864	0.77	0.63	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
SKCM	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	7.07	5.8e-10	0.00865	0.79	0.62	Longevity;	chr3:48407507	chr1:27649419~27649610:+
SKCM	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	7.07	5.84e-10	0.00865	0.68	0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
SKCM	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	7.07	5.84e-10	0.00865	0.87	0.62	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	7.07	5.84e-10	0.00865	0.87	0.62	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	7.07	5.84e-10	0.00865	0.87	0.62	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	7.07	5.84e-10	0.00865	0.87	0.62	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
SKCM	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-7.07	5.9e-10	0.00872	-1	-0.62	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
SKCM	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-7.06	6.07e-10	0.00891	-0.69	-0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
SKCM	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-7.04	6.61e-10	0.00964	-1.01	-0.62	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
SKCM	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	7.03	6.9e-10	0.01	0.66	0.62	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	7.03	6.9e-10	0.01	0.66	0.62	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
SKCM	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	7.03	6.9e-10	0.01	0.66	0.62	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
SKCM	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	7.03	6.9e-10	0.01	0.66	0.62	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
SKCM	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	7.03	6.92e-10	0.0101	0.79	0.62	Longevity;	chr3:48464565	chr1:27649419~27649610:+
SKCM	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	7.03	7.06e-10	0.0101	0.86	0.62	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
SKCM	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	7.02	7.11e-10	0.0101	0.84	0.62	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
SKCM	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-7.02	7.13e-10	0.0102	-0.78	-0.62	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
SKCM	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	7.02	7.33e-10	0.0104	0.78	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	7.02	7.33e-10	0.0104	0.78	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
SKCM	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	7.02	7.33e-10	0.0104	0.78	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
SKCM	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	7.02	7.35e-10	0.0104	0.84	0.62	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
SKCM	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-7.01	7.49e-10	0.0105	-0.58	-0.62	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	7.01	7.49e-10	0.0105	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
SKCM	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	7.01	7.63e-10	0.0107	0.85	0.62	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
SKCM	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	7.01	7.66e-10	0.0107	0.6	0.62	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
SKCM	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-7	7.71e-10	0.0108	-0.96	-0.62	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
SKCM	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	7	7.77e-10	0.0109	0.84	0.62	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
SKCM	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	7	7.84e-10	0.0109	1.38	0.62	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
SKCM	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	7	7.84e-10	0.0109	1.38	0.62	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
SKCM	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-7	7.9e-10	0.011	-0.79	-0.62	Longevity;	chr3:48445934	chr1:27649419~27649610:+
SKCM	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	6.99	8.13e-10	0.0113	0.58	0.62	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
SKCM	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-6.98	8.44e-10	0.0117	-0.74	-0.62	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.726	rs10459246	ENSG00000121089.4	NACA3P	-6.98	8.44e-10	0.0117	-0.74	-0.62	Platelet distribution width;	chr12:56776034	chr4:164943290~164943937:+
SKCM	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	6.98	8.48e-10	0.0118	0.97	0.62	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
SKCM	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	6.98	8.53e-10	0.0118	0.93	0.62	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	6.98	8.53e-10	0.0118	0.93	0.62	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
SKCM	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	6.98	8.53e-10	0.0118	0.93	0.62	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
SKCM	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	6.98	8.57e-10	0.0119	0.85	0.62	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
SKCM	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	6.98	8.57e-10	0.0119	0.85	0.62	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
SKCM	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-6.98	8.67e-10	0.012	-0.77	-0.62	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
SKCM	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	6.98	8.75e-10	0.0121	0.87	0.62	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
SKCM	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-6.98	8.76e-10	0.0121	-0.79	-0.62	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
SKCM	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	6.97	8.92e-10	0.0123	0.74	0.62	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
SKCM	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	6.97	9.01e-10	0.0124	0.94	0.62	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	6.97	9.01e-10	0.0124	0.94	0.62	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	6.97	9.01e-10	0.0124	0.94	0.62	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
SKCM	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	6.97	9.05e-10	0.0124	0.67	0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
SKCM	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	6.96	9.31e-10	0.0128	0.81	0.62	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	6.96	9.31e-10	0.0128	0.81	0.62	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
SKCM	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-6.96	9.56e-10	0.0131	-1.01	-0.62	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
SKCM	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	6.95	9.64e-10	0.0132	0.73	0.62	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
SKCM	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	6.95	9.64e-10	0.0132	0.73	0.62	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
SKCM	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	6.95	9.64e-10	0.0132	0.73	0.62	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	6.95	9.64e-10	0.0132	0.73	0.62	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
SKCM	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-6.95	9.68e-10	0.0132	-0.8	-0.62	Longevity;	chr3:48436629	chr1:27649419~27649610:+
SKCM	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	6.95	9.86e-10	0.0135	0.8	0.62	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	6.95	9.86e-10	0.0135	0.8	0.62	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	6.95	9.86e-10	0.0135	0.8	0.62	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
SKCM	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	6.95	9.86e-10	0.0135	0.8	0.62	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
SKCM	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	6.95	9.96e-10	0.0136	0.67	0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
SKCM	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-6.95	1e-09	0.0136	-0.81	-0.62	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
SKCM	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	6.94	1e-09	0.0136	0.69	0.62	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
SKCM	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-6.94	1.01e-09	0.0138	-0.99	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-6.94	1.01e-09	0.0138	-0.99	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-6.94	1.01e-09	0.0138	-0.99	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-6.94	1.01e-09	0.0138	-0.99	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
SKCM	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-6.94	1.01e-09	0.0138	-0.99	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
SKCM	trans	rs12483240	0.793	rs17000954	ENSG00000251034.1	RP11-582J16.4	-6.93	1.07e-09	0.0144	-1.47	-0.62	Parasitemia in Tripanosoma cruzi seropositivity;	chr21:25447979	chr8:22540845~22545405:-
SKCM	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	6.93	1.07e-09	0.0145	0.96	0.62	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
SKCM	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-6.93	1.09e-09	0.0147	-0.8	-0.62	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
SKCM	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-6.92	1.11e-09	0.0149	-0.98	-0.62	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-6.92	1.11e-09	0.0149	-0.98	-0.62	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-6.92	1.11e-09	0.0149	-0.98	-0.62	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
SKCM	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	6.92	1.12e-09	0.015	0.67	0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	6.92	1.13e-09	0.0151	0.65	0.62	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
SKCM	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-6.9	1.23e-09	0.0161	-0.77	-0.62	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
SKCM	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-6.9	1.23e-09	0.0161	-0.77	-0.62	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
SKCM	trans	rs7078219	0.714	rs11190137	ENSG00000276408.1	RP11-490B18.5	-6.89	1.3e-09	0.0168	-0.85	-0.61	Dental caries;	chr10:99528187	chr16:75556392~75557059:+
SKCM	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-6.88	1.31e-09	0.017	-0.64	-0.61	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
SKCM	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	6.88	1.33e-09	0.0173	0.58	0.61	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	6.88	1.33e-09	0.0173	0.58	0.61	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
SKCM	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-6.87	1.38e-09	0.0179	-0.93	-0.61	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	6.87	1.38e-09	0.0179	0.93	0.61	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	6.87	1.38e-09	0.0179	0.93	0.61	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	6.87	1.38e-09	0.0179	0.93	0.61	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
SKCM	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-6.85	1.54e-09	0.0197	-0.79	-0.61	Longevity;	chr3:48414217	chr1:27649419~27649610:+
SKCM	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-6.84	1.58e-09	0.0202	-0.76	-0.61	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
SKCM	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-6.84	1.58e-09	0.0202	-0.76	-0.61	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
SKCM	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-6.84	1.6e-09	0.0203	-0.57	-0.61	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
SKCM	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	6.83	1.64e-09	0.0208	0.58	0.61	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
SKCM	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-6.83	1.65e-09	0.0208	-0.8	-0.61	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	6.83	1.65e-09	0.0208	0.8	0.61	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	6.83	1.65e-09	0.0208	0.8	0.61	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	6.83	1.65e-09	0.0208	0.8	0.61	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	6.83	1.65e-09	0.0208	0.8	0.61	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	6.83	1.65e-09	0.0208	0.8	0.61	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	6.83	1.66e-09	0.021	0.82	0.61	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
SKCM	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-6.82	1.73e-09	0.0217	-0.99	-0.61	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
SKCM	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-6.82	1.74e-09	0.0218	-0.76	-0.61	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
SKCM	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-6.81	1.82e-09	0.0227	-0.78	-0.61	Longevity;	chr3:48408490	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-6.81	1.82e-09	0.0227	-0.78	-0.61	Longevity;	chr3:48408549	chr1:27649419~27649610:+
SKCM	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	6.8	1.87e-09	0.0232	0.94	0.61	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
SKCM	trans	rs12145833	0.538	rs4658547	ENSG00000189343.7	RPS2P46	-6.79	2.01e-09	0.0248	-1.16	-0.61	Obesity (early onset extreme);	chr1:243227829	chr17:19445970~19446852:-
SKCM	trans	rs12145833	0.538	rs9803701	ENSG00000189343.7	RPS2P46	-6.79	2.01e-09	0.0248	-1.16	-0.61	Obesity (early onset extreme);	chr1:243228332	chr17:19445970~19446852:-
SKCM	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	6.78	2.03e-09	0.025	0.66	0.61	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	6.78	2.04e-09	0.0252	0.66	0.61	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
SKCM	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	6.78	2.06e-09	0.0254	0.76	0.61	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
SKCM	trans	rs11062517	1	rs11062517	ENSG00000234961.1	RP11-124N14.3	-6.78	2.1e-09	0.0259	-0.61	-0.61	Platelet distribution width;	chr12:3126673	chr10:17233325~17234833:-
SKCM	trans	rs13190036	0.786	rs10068127	ENSG00000217325.2	PRELID1P1	-6.77	2.11e-09	0.0259	-0.96	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr6:126643488~126644390:+
SKCM	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-6.77	2.11e-09	0.0259	-0.96	-0.61	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
SKCM	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	6.77	2.13e-09	0.0261	0.8	0.61	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	6.77	2.13e-09	0.0261	0.8	0.61	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	6.77	2.13e-09	0.0261	0.8	0.61	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	6.77	2.13e-09	0.0261	0.8	0.61	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
SKCM	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-6.76	2.21e-09	0.027	-0.78	-0.61	Longevity;	chr3:48458887	chr1:27649419~27649610:+
SKCM	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	6.75	2.37e-09	0.0286	0.67	0.61	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	6.75	2.37e-09	0.0286	0.67	0.61	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
SKCM	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-6.75	2.38e-09	0.0287	-0.95	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
SKCM	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	6.75	2.38e-09	0.0288	0.66	0.61	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
SKCM	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48419904	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48421052	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48422302	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48429347	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48431794	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48437629	chr1:27649419~27649610:+
SKCM	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48438208	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48442021	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48442035	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48443151	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48443275	chr1:27649419~27649610:+
SKCM	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-6.74	2.47e-09	0.0297	-0.77	-0.61	Longevity;	chr3:48445369	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	6.74	2.47e-09	0.0297	0.77	0.61	Longevity;	chr3:48447994	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	6.74	2.47e-09	0.0297	0.77	0.61	Longevity;	chr3:48453142	chr1:27649419~27649610:+
SKCM	trans	rs11989843	0.666	rs7833734	ENSG00000179611.3	DGKZP1	6.73	2.54e-09	0.0304	0.66	0.61	Obesity-related traits;	chr8:117058576	chr13:43968424~43971199:+
SKCM	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-6.73	2.58e-09	0.0308	-0.87	-0.61	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
SKCM	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-6.72	2.68e-09	0.0319	-0.96	-0.61	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
SKCM	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	6.72	2.73e-09	0.0323	0.8	0.61	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
SKCM	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	6.71	2.74e-09	0.0323	0.79	0.61	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
SKCM	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	6.71	2.78e-09	0.0327	0.84	0.61	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
SKCM	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	6.7	2.95e-09	0.0345	0.68	0.6	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
SKCM	trans	rs1174864	1	rs1000098	ENSG00000231977.1	RP5-963E22.4	6.7	2.96e-09	0.0346	0.77	0.6	IgG glycosylation;	chr7:53098281	chr20:63166797~63180903:-
SKCM	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-6.69	3e-09	0.0349	-0.73	-0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
SKCM	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	6.68	3.11e-09	0.036	0.74	0.6	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
SKCM	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	6.68	3.18e-09	0.0366	0.74	0.6	Longevity;	chr3:48376724	chr1:27649419~27649610:+
SKCM	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	6.68	3.19e-09	0.0368	0.82	0.6	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
SKCM	trans	rs2950393	0.611	rs7138821	ENSG00000121089.4	NACA3P	-6.68	3.24e-09	0.0373	-0.71	-0.6	Platelet distribution width;	chr12:56796206	chr4:164943290~164943937:+
SKCM	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	6.67	3.28e-09	0.0377	0.93	0.6	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
SKCM	trans	rs9525638	0.505	rs2200287	ENSG00000258354.1	MIR3180-1	-6.67	3.28e-09	0.0377	-0.83	-0.6	Cortical thickness;TB-LM or TBLH-BMD (pleiotropy);Total body bone mineral density (age 0-15);Bone mineral density (paediatric, upper limb);Bone mineral density (paediatric, total body less head);	chr13:42594524	chr16:14909887~14911345:-
SKCM	trans	rs10916248	0.569	rs4654002	ENSG00000250659.2	RP11-864I4.3	-6.67	3.32e-09	0.038	-0.66	-0.6	QT interval (drug interaction);	chr1:224075680	chr11:62537312~62542018:+
SKCM	trans	rs10916248	0.569	rs7528514	ENSG00000250659.2	RP11-864I4.3	-6.67	3.32e-09	0.038	-0.66	-0.6	QT interval (drug interaction);	chr1:224077561	chr11:62537312~62542018:+
SKCM	trans	rs13253073	0.883	rs12545602	ENSG00000260318.1	COX6CP1	6.67	3.38e-09	0.0387	1.45	0.6	Glucose homeostasis traits;	chr8:99834612	chr16:11903923~11904137:-
SKCM	trans	rs12367822	0.597	rs2371559	ENSG00000121089.4	NACA3P	-6.66	3.49e-09	0.0397	-0.7	-0.6	Platelet aggregation;	chr12:56805073	chr4:164943290~164943937:+
SKCM	trans	rs237899	1	rs237900	ENSG00000258922.1	CTD-2313J17.1	-6.65	3.6e-09	0.0408	-0.7	-0.6	Depression and alcohol dependence;	chr3:8767010	chr15:92805770~92808567:-
SKCM	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	6.65	3.61e-09	0.0409	0.78	0.6	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
SKCM	trans	rs991967	1	rs1934852	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218421578	chr7:7255154~7277779:+
SKCM	trans	rs991967	1	rs6657275	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218423119	chr7:7255154~7277779:+
SKCM	trans	rs991967	0.955	rs6668651	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218423299	chr7:7255154~7277779:+
SKCM	trans	rs991967	1	rs6671370	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218423702	chr7:7255154~7277779:+
SKCM	trans	rs991967	1	rs12048049	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218423955	chr7:7255154~7277779:+
SKCM	trans	rs991967	0.909	rs4846481	ENSG00000230825.1	AC005532.5	6.65	3.63e-09	0.041	0.68	0.6	Hip circumference adjusted for BMI;Height;	chr1:218425142	chr7:7255154~7277779:+
SKCM	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
SKCM	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	6.65	3.67e-09	0.0413	0.66	0.6	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
SKCM	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-6.64	3.71e-09	0.0417	-0.78	-0.6	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
SKCM	trans	rs13253073	0.765	rs35615286	ENSG00000260318.1	COX6CP1	6.64	3.72e-09	0.0419	1.54	0.6	Glucose homeostasis traits;	chr8:99834866	chr16:11903923~11904137:-
SKCM	trans	rs10916248	0.55	rs7544572	ENSG00000250659.2	RP11-864I4.3	6.64	3.77e-09	0.0424	0.66	0.6	QT interval (drug interaction);	chr1:224077515	chr11:62537312~62542018:+
SKCM	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-6.64	3.81e-09	0.0427	-0.77	-0.6	Longevity;	chr3:48455358	chr1:27649419~27649610:+
SKCM	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-6.64	3.81e-09	0.0427	-0.77	-0.6	Longevity;	chr3:48457056	chr1:27649419~27649610:+
SKCM	trans	rs237899	1	rs237898	ENSG00000258922.1	CTD-2313J17.1	-6.64	3.85e-09	0.0432	-0.69	-0.6	Depression and alcohol dependence;	chr3:8766809	chr15:92805770~92808567:-
SKCM	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	6.64	3.86e-09	0.0432	0.83	0.6	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
SKCM	trans	rs638882	1	rs2155266	ENSG00000260942.1	CAPN10-AS1	6.63	3.99e-09	0.0444	0.38	0.6	Hip geometry;	chr11:115897538	chr2:240582700~240586699:-
SKCM	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	6.63	4.03e-09	0.0447	0.78	0.6	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
SKCM	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	6.61	4.3e-09	0.0475	0.57	0.6	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
SKCM	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48422209	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48423094	chr1:27649419~27649610:+
SKCM	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48426493	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48432839	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48437797	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48440237	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48446507	chr1:27649419~27649610:+
SKCM	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-6.61	4.34e-09	0.0478	-0.77	-0.6	Longevity;	chr3:48452692	chr1:27649419~27649610:+
SKCM	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-6.6	4.42e-09	0.0485	-0.78	-0.6	Longevity;	chr3:48440024	chr1:27649419~27649610:+